var title_f16_9_16528="Meconium pseudocyst";
var content_f16_9_16528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meconium pseudocyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two weeks later, the ascites has resolved. The echogenic cystic area is still visible. After birth, imaging studies identified a meconium pseudocyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen T Chasen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16528=[""].join("\n");
var outline_f16_9_16528=null;
var title_f16_9_16529="CT image of cancellous bone";
var content_f16_9_16529=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    CT image of cancellous bone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 207px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three-dimensional CT images of cancellous bone from a normal individual (left panel) and a patient with osteoporosis (right panel). Please note the trabeculae in the osteoporotic patient are thinner, disconnected, and further apart.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. David Dempster, Helen Hayes Hospital, Columbia University.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16529=[""].join("\n");
var outline_f16_9_16529=null;
var title_f16_9_16530="Fibrous pleural tumor Lateral";
var content_f16_9_16530=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibrous tumor of the pleura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEASQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxvTL+AqMzOFx8p55rUW5iDAi4nA69P615crsv3WI+hxVmO6uMYM820dg5pgeuWV4GkTbdyqM85Y/nXTafPGQAdSZeOrE/414TDLPwDPKf+2rcfrVhJHx800xGMZMjf40XFY+nvAFzBb+ILdpb+CWMyorbpQFAz15PSvVfH9xp2o+CtVtku7SVmjBVUmVjkEdADXwcVVvvZYHsSTXQeH9WmsGJs4IFfs2M7fpRcD0rT0Wx169gQeZmQFieccCvQ9LmWRBtHOOleW+EvNkl3zMXkkO5mPJzXqWlwlFDGmBrpggHoT61E7gJwAOc8j+H0p7uAMZHSoW6nv8ASgBJCNvTg+1Q5GQpXFDsfmA/nTDu3denQigBzMuR0BPt3poZcgECmMduT680wsnBBG4j0oAnZgzAcc8f4YprY3cDaO1Qbhjn8jTw/UHI+vpQAH14wO1IW4yOPpShgVbcvHT8KaNpznOeuTQA3qBke596azAZAGOKcWwCSeeagY5bJB6UAOLkdsntSLtK/MevSmM/ynHX+dIjDPIBPY56UASMFI244x606OQvctH5TBFQN5h+6Sew+lRFhnApd54AGR1H1oAuxHGAR361YjYEnKjNUYXz6Z/nUyy7SD0P0oAvR9SMAr6jvSSopTlQQOc9KhjYc8jj0qRSxU45OPzoAxtStlO48EH2xXmnjrS90RmVfu9T7V67eBWjPBzjGQM1yWtWizW8sbjgjHFAHgskYjfBBPOBVmEEfMQCan1e2aKaRMEFSQfWsw3jQuEW3lkH8RUdB/U0hmoow4PripB14xTFI456+lSryOc0AKFB/KjbjJpxA3AU7gDPHSgCMp6CinnHfFFAHnIqxbqSy4GT/Kq461ctxu+pFIC5CBxnAz+dWSpKqR1HPPeo4B/SrKe2f50AN2njjPpg9K2dDtXnnRVXJOAPU1lRLukAA+btz0r1HwHomCs0iY789hTQHX+ENIEESb+uOTXZRqIzgDHqKp2SIiIqjGOwq2o5LBiMj7vGDz1/pTEPdzgHHHeq7S8kNnAGB2okJ7jg1E3Pc0AG/jb0Xpj1puD/AAjaCaAMt/OntgEfpntQA3aSM9u1ROw4yeO9PdwWwOMe9QS4VsH65NADwoJ3MMD+YpXdV9gP5UzzgR0+buwqjcT8HJxtoAtidWyM446ipUA9iPWsKS82OAhJP861bKbMQJJJPagCd1XkEjH16VEFz0PJ9KGcgt/dHU9qj88cjjHrQAOoXGcbunHSmdSaVpFLHHBPaojJ8xxz7UASgjbx+tKGB4x9PWqzPyOT9KkBzjtQBaUgNxjPU1IrZJBXmq6PUiSKDu5yPWgC7EyknJPp71cQgsNuMn19ay4nz1GMnPB71dibjoAemTQBPPHxnPXg1g38ABcMPwrdkO5Rub/69ZV+PlJ+pH1oA8Z8d2Ih1RpNnyvzXI7VVzxkfWvUviDaB7RZQMlGH615fMMP3pMZZhAwMDH0qwmOAOlVIDlQAB6dasqARQBMoAHp60pAPPemjpT+3SgAwKKTI/i/l/8AWooA82FXbX1GBjrVIdau2/TIU4/r/kUgNGIg/J/EvWpUGAFJOR3J5qGNwFXPTFW7C2kvLqO3jB3N1I7CgDovBmjtqF2shU+UvXPevbdJs0ghREIAXvjrXO+E9JWxs40RecV2llH04GDVCL1vDgBs/wD1qmYDngEHmnHIGFxgd/aoXPGc8e9AEcnLZ789ahwcnvgd6mcHd9f0ppUg4HFADVVm6dMU2RQF6E+vFSn5VGM47d6q3dysZAypbuB+tAFG8mKZfpjge1ZcmsRlzG7Dd2PrVTVr8NJsyC2cccAfjXG3l8PNY7gRk8CgD0C0u2k35bIx19KZcsQC5O0dK5DStYkeZIpGIPXPtW5qF1hQrHKkelAEU98FP7sYyMZ7mtSyvAkcCSPtZhnBNchdyOWwCVGccjrV2ZwkrBiCygKvGelAHW3NypxtzjsM/wA6gFyzNjAC+9c+b8qpLNnGOvNT2tyHG4tgngUAbxk4G5tzdgKkBGO+fSs6GZABj5m9TU8c+Q21N56HtigC3jGc456YqZQABjJNZ5kxjD5HTFWUdXXK49DQBYXBI7Ypw5zmq6tx1+WpQf0oAtqQCCD71ajJPPHXr6VnxueM8/1qzE54XkHrx2oA0Qd0Z7t1+tZ8+HQjH3asxSFQB1pssQm3NASW/u4xg0Acd4stzNpc4PLFCfyrxq9jCykgd+1e86qm+0dGA4B+teIavAUndSOQf5UmBUg7Z6dsd6tKeQapQnacnIq5Gc457d6Bk69OmMe1SDqc8VGvOeT608fhQAv5/gKKNnqB+VFAHmgq3AzD7uf6VUFTxnk4IpAaMRZmGAcnpj/CvTPAmi+VELiVcyMe/b2rjPCWnG/vUkKny1Ne16LahI0UKNoHFNCNrTLfagB5Fb1qhByBkfSqtpCAi4x71pRrj8c0wF+bknpSOucEgk4qVeAAeKjkcDO7A69e9AEBG3heB/Sh2WJS0rDI69qo32qx26kRgMfc1hXuqvKSGbPp9aANW71EFdsalV7+9Yd1dZP3yR0zVZ7glDhmx3FUWlJAyD6igDO10kFgNwOc7ux+lco+5mODgmuu1aKUwxlipjPBA5xWLLZoY2bkHHXFAGbbySLMpHAHrXRyXLPHGHcHdz1rCMSrtdsYBx8x61pWe25cYGCh+8Txj0pALNcGaWGMdQwJOcbqgnvcljglsk7s06KzNxcyuhYKoOPeobmydVJHT/PSmBFLeM5XGWI59K3dJkWVN1zII0Q4wvVj6AVzYjmeQCNOnA3D9a0rESWzD5iJW6MO3rigDphJnKsPKjA4Tqx9zU0MspUBQFiHQZ6/WqdlKhXMSb3b7znk1chYlyCQWGOD0HFAFuJwp3N+QqVGZZMj7p61UaZQ237xXsKsB2MQJ+QdQWoAuwIQcE7gasoh259+lUbKQyZx91etaKM244wRjpQAjKwwe3oatWql+CTxxxUbfMAfuj09asW7bTg8fXpQBYWJivGQccds0oVkBy2D655qVMAAqSSKjcZO5icn0oAzr4JNCyS/6zs3T868Z8W2jwahMjjnPXpmvZdQACMcEMf1ry7xshkcFvvqOD60MDhoxyc9jVqLkiqrZDgHIHbHarMWRjPekMsIAe9TDpx0qFc96lHPJ5oAcpwOAD9aKQdKKAPNBVmzia4mSKMfMxxVWu28B6SZG+1SqCM4WgDu/B2krbW8YC5JFeiaZbEINo4xWPolniJR+ea6qziAXoMCmIu2qDaMfdzg8VejQ4HFV4B07c8U6+vI7WE5xnFAC3lwkZHPA6D+prmtT1XJKqc4647VS1TVPMLl5Nq8+1cfqGteYWjhJA6bj1oA2by+DHIck9ODVeKYyHJ+n1rBtJ284MRuXuCOta8V0I2+VFXI4Hr7UAXoowwJlO3A5GcfrUN0VAGwfu8dc96T7QkgyeG9CaozTSOQVxtVsDPWgBftCGKSPcdx+YFj1rPnu2kgPkoVbI35HWlkjXLtyccmokZtrMsblicUAZ+C0iqwAXPrWnpMMhnMaDIPUCs0xhZSHb6AV0uhmLy13rlw24Y4/OkBNpOnTbZnJ2djnHAp9zZopA2buwA5wK6C/VPLCptCkbiB+tY0l7DCx8rlsYz3pgVEshLIBsAA4POAB/jVG4tfLZmTnPXJ6Vp77h9oAALdcnt2FQywhEYNISo69s0AUNOuNpeNATgA4A/z61rQ7ozm5chyMiMDn8aylk+zMWhBVc8svf2q6k7SLmFfL3dWPLN+NAGiZSiboYY0zxvY5P1pbZRje7M7A/eeoVCCIDcWI5IzVhZRtXKqOOmM0AXbJws2M5Dda0ZmJUY6jtWAl2xGEAwK2I5t+0nGJFwD70AXIucZOc1Lv4CtxVWz5Ryei1aI3IG7j1oAtQPu6fSpypC5z/n0qraZZ9rdzWjFASu3d8360AY9+mFznjt7V5141izCHxyp5r0rUFHk4PBBxXCeLIvMs5cA9Oh70AeWTKBIevzHg/0qSHoCKjuQA4BA4zx60+FgyBlOR24pDLaevWpV9jUMZz1qZT/hQA4D0P6UUo9gfwooA8+0mza/vo4FBIJyxHYV7L4ZsEj8uKNAqKOgrifA+nGO1+0MvzzHgeiivV9BtwiKQOv6U0I6TToSsYwK2IOW46D/ADxVG0wsfoTwPerYkwcZ5POc0AX0cLHu4AA5IrjPEWtxh2KtlVyMVd1rUHaNoocqO7entXGXmnPOhLhuffrQBhajqz3UmN7FfTPWoIW39QAx9eM1stoaBD5ancfQ9KqvpbQEkYI7Z9aAIYw6uR39c9qtfbBtCxfMRz/n1qhK0hYLOjAjpnpVqzVWLAR5GOq0gJHkdpAyk4Y59Kn8vzSzBSQevtT7ey805ZnYjqp4xVpbSW0XOGYHp/hTArwwGW3OMhT95jTZleCLcr8KvPHWrZKPanouDnk4wajW1mvbT5CVj3feI6/QUAc8ZI42dpxkPyPWnWGskXCrBhUVh96oNSsVFw8ccjSYGM9yfSoTos1rZboD50p5255+lIDsorh76QGOSRCRtJBxuFXIbOCF9877wo3EZ6YrFshcp4dgnVSCufMY8Y9s1Z0m5lFvvu13R/wt2PtTA0YrhpH3+SBz970FMkCSkl3Lc/dHAFRrLLLkou0DtnrU8CJGQJSzMf4V6/j6UARTW6uFAA8v0xg1DBbCNXM7BWU/IM9KuXVyI/kY7NuBgHn86WzW1mhkfyyX/vMePzoApG5UbxEDkdfeoY7qV2wsWRjPHf8AGn3TLACkcygk52oB+pquPKiwZLhy2c7Qc0AW1imLMzEqpH97pWvZRSSWsL5OAeorHs2gDKUUsx5y/Nb9tNutTkgYYY9BQBpWhMbttPDDrVsKxAPWqMEySKBn7pyAO9aFu/UY460AS244Lc/T1rVjUAhg/pwOaxmkyuVJ5PIzzV6zf93tbk9OvNAFLUBuMmDnLZx6VyGuxbreT6EfWu4vY/mxxuI6965bWEyjA9hQB4pqK7ZSMdCe1NhzjuKta8m27deeGNVID0zjnmkMtpnAz3qZe3p2qGPsRUw60APU5HB4ooz/AJFFAG34ftAiRRqANqgDjoP/AK1d5psYVF4rndFgxErEc+wrp7P7o46GmI1IjhMnp9KRpMoxzgdz/Sod2AAMc1FcNkBQeBQBXlJJyfyxVeRBwG+nWns5UEShRk8BTnIqjPc7Sdo/xoAW52oByFH1xTY0TIZhu9KbADKcuxOORxWjDbxg8DnrigDM1GwFzB8qjP8ADtrJtrecOYioDL7YrtY0RUxtAJ5BB6VjaxF5UqSELtPDGgCtGZETDOB746VbS/iW3aOTnAyHFZbMJGYLIWIBwMVRKynCRkhT2PB/KgDptHhsLuaM4WV89u1dnb+HlP7wr5aLwF7V5zocBjlEgcq+7tyK9G068lhUK291buTxQBx2u+E0iu3KHy1c5BzxWd5sGkQLDGgluWbazEcDNdp4jK3Nv5gyuzg9eK5qKxsndLrUJ2jtx97jlj7UAQxzrqMM1gEOWUsoHOcdsVyF5etbXQgu5WdUO1Y1PT6128d1Zw3XmWKtHFnCnu3vmvO9XlRLpiq4fcck9aANOwvppUIdtkKHGF4z/Wr0d4FO6NiCOAF7Vysdy8soUfcP93gV0NhaZZS75LdhQBed1nTc4O8856Eio4ZJA8abWEQbG09K1YdP/dByAqL0yO9T2li0j/LG0hPPHNAHO3NriVhvO/d2HSnvBEmN7vuxyvetbU4LkTsscci4HLhOp71jSJJwoicv6vwKAHxzwRN+6zuI+prV0uQyiTe2FPJFYscc/mLthznvtrUsRLGj5TYe4AoA3bSQrcKF6E7a3NgLYBG4dweK5nTTJ5quOSPU11jOjSBwgBKg8etAFeZShwwz3561b05gAUYgDqDTGiEwYnJHYitDTY1UHoMDPA60AR3XIDsuPcZBrnNVX5ZD/M9a7C8Xfa5YgnOQfSuS1k/LL04H5UAeLeI1DX82P7x4x1rNhPzY6ge9a/iIYvZSOuTWRHjPXkfypDLaAZqdORgelQRiplB7cUAP57Z/A0U4YooA77Sl+RORg81twZGDngViacwCAqMA81qo+M4piLkbZPOMVHPIFDEnFIjYXJ61mXdyJJSin5V460AE07M2AMn+QqFYyWy3OKGIABx+FTIwPXGO2exoAmtlx0H4jtWghCDkH1571UgYchcY6VPHcRhgCQx7Ac4oAs72APQDsKp38LT2p3sEReQB1Jqy0h2gqPyFV5omdHZ2zx36UAYouUVj9mA+Xqx7VXWRZpss/wC9JyCq0+LylQqCGx1xUMjp5xAUHsCOlAHW6ctpbadH5jB7hjnoOPQVpW05wFWQbT61wsFykcjqZAu/271p2d8ZkEeWZs4GBx9aAOnuZ1WQKxRkOc+wry3xBrUrX0iHIhRiEH9a9T+wGaOMttViACM9DXK+LfB8sQS4BTYRk4wc/SgDi7XVJLm5SAltzkKoBqnrNs6XkrzfKAxBX6GtjRbH/iZqPLwUO4HvxVDxJBdyX85ZeA2STwKAI9KEUkyDaVHqO1dHGBbsZQu4KcbyOD+FctaXcVomeJH6Z9DVy21O6m4aTAPQtzzQB0kmpSogKq+Sc88cVe0/WcA+ZcPGCcBYeCfxrnpr5hGqyS+Zj16k060KORIUxzgGgDX1XVIMyDzr1nPXM1c/NPC7ZZrnOOu8c/pVvULPdM5ByM8YOabHpMpVXkaNF/vMelAFaNbdmXc1wc9QWH+FdJpNvCI22QNt4+dif51jR2SoymOTzHHcDp+Na1i2I2TfIyr/AAg8ZoA2bR18zauGHQgV0FvgRIHGFPUk4rl7OdTMMhVPqK6lVDwKxQn0xzQBauVjh2uC2GHYdqdZTeXJ8vTtmqTXG8GI7trL37VDZSFpFxnigDobqTKEHj1wOtcjrJwr++e3SumlOV3EE/LwP/r1ymtcq4wcY59aAPJfEQzeSYPesSPHmEgZYAAnHNbGuALeOoOfWstRz160hk8eRz61OvYdKgj645xU6nGKAHUUdepxRQB3llny1LHBKgleuPx71oREHOMfSs21PA5+bH6VeiOF3cfj2piH6hdNHGETIZiPmxwBVJThvqfzqKZzLKT2PGO9PQhcA9T1oAnUgjOAPXFTKo4z2qmJAHAUDnvUySMTgcA9waALsbFeBwCO9TQgbst171VtwTg5zmrSjBAx+tAFyLaVzxxVLV5hHZvzweBj3q5DgDn/AOtWPrc0WViI5zkjNAGPHIyqwwFAPNVJ5djEHkkjA7mtMwB1IjBV2Gd3YU22tYgx3kSyDkgjI+tAGfbW8l5IFYEDBOTxXXaBBHGscrLvfPyL6+5qOxsXkwURSGH3QOtdLa6PJFGrSczddo/hFAFuyfypvtLjcy/MAemfpXJeLNburi7MnmAru+7/AA128dgkdm1zcyIFUHr1xXiHibWGuLx1gBESk4/2uaAO3sJoZLczRRRm5K/NjoB71zHieaOSxZ3OZlGCqjqKf4YknS23MvySRlix6ACs7TpoNQvJYslS2cO3+FAHIwl3kOUxk/KMVfi3A7Aef9mtrUvDb28iPHIBE/Y9R+FTWekeT8zsu7g5PpSGFjbSTIiuMjPBNdt4e0iykCi5nRCoyoYfKT9a5+K1IwFD4HPJ6e9dTpOt2lhD5EjRNtGTvTdzTESX2i2ygtbyQSqRuOG6VzV7buM7VMiKPuqeB71oa3qsNyweSKMhOFMYwfxArm5Z0eYvGzwgn+E0APeZgMeUwX6cVasZVW3kZiDkduPwrOLISv8Ap8gPdcZx+ta1oGWFdkySZ5+ZBmgC5puWlXzMqrHlv8K70xIjRKjptCDgcfnXDacp89TLKCM8AV2QbgHaW4GO+PagCHUF24dD9apw7hIDt5PPtVuRS6kfdwehqxp9upcFmJOcnHFAFyQkWeAMcf3a5LV2Ox8dea9CkCBQnAXHINefeImWNp0QEhSQPpQB5Hrj776X6461mR9sdquao4e5f0LYxiqkQ5HrjFIZZj9OanHX/wCvUEYx3qcduaAHDJHeijJ7/rRQB2dp1LbzjpjHAq1cShYCRzkDmqdkTjJHHb/H2p17LjHJwPT1piIUl29acrFsE8Cq6MXJJ61OhAc80AWocuRubA9fWrSALhR2/GqyYABOfx7VOpOKALcWQPftVlDjB6mqsX3B2+tWFkjXG75vpQA+a4EMLOR0Fc+ryXc5Z1KKeg9a0rqRZnAUDAOAKcI0iBKlWY/3R0oAzkikSQISwZjyRW1Y6QsXzTE464z1qCEBJtygllHcdK2rISv/AKVcAFieMjHAoAsaZOlrKXCYU8YHXNa93qMEdoWXe2evODXJ6tqkcEx2MDNjIPpXPR6mz3W+Z/3R69z9BQBp63rt3PK0DSeTYlSB83JrzeWeD7cFaEvhsZ7Yrv8AxAbSSW3e3XnZ90HgD3rjhYz3V8fIUKc/eHQUMDuLW2kk0F2gRC6xkKAOCT2IrjtCt5LfWlS7jKhTnHbNaVpd3ul3sFt5shQcOQc5z2rs4dPSbTvtc6IxB4I6kUAUrphKCvkh+M46YrnJ51ilYzyDHQKeTXU6V5d+TBbkSyKCzD0FctrOmlrqQuU6/wAORgUANfVDK6wRqzKewHFPkVUhka6gZJJMBQp7etWNOtJ7VIrmyh+0Ko9P8Kl1iWHUVPztZykcxy5A+oJ5oA5qc7HLbztP3Vx/OoSTK2GOAB+Aqw1q6MVEkb8YOCKkXTLmQ5WI7QMkmkBUQKgBGTngGtay8wbWRtv1qO3sZdwDbh7YrXgtOPLYFjj1pgaukQhrgFsbvUeldnaID8qoSCMfMaxfCljuugQoURjLMRkiuilVTAzoCSAQf6UAUrnAk+VFwfen2VwI2+6vXAyKqXUpMETkgEtx9Khgb96CzdDQB0F7d5Usw2lRznpXnniK43RTOT1ycV1mpSEwgg8fXrXBeI3xayknHFAHm94wZ23Y5JPNNjHPQZ+lMl+ZiQAealhAA59O5pDJ4wep/OplGWPTp1J6VGn4VIuQOgoAfux6CigbRxn9KKAOqs5F8okD5SSxOc1Wu5PMkwMjPapA22MdT8oHNQAFpgcLsI7jnNMRJEdq8ZyTnNWIWG7cBkdvSogFXOenSnqS+Dnav60AXg24HjnvU0ROBnr6VVjOSAc4Hb1qZZFDfe57n+lAFvcy9ePanYQHJzu64qoZmkwE6Dg471NAPmDE5PcZ6UAWUIbG1OB1OKt20GOcAZ9etRxyA4CIApGasLMEKs5wBzx1oAvQ26R5LKqgck96yNY1kujRW4BVRgnpj6VBd3zzRShDgfnmsKSYrIUUEuR68CgBJgCeScYzhu/41HAAz7sfKpznt9KglDySAKTu7j0rVS0EcQVyPM6nPSgBlvDud5JF2xY4z6U23mjtw+Gwei/41nahfGdzGrhY4vvEDrWHLqJMzFCdq8Ak0AbVxcuhdtw8zOQM/rW3HrtzH4bVUyrYyQR1Ga4uG8FxI8kzMGGAoXpXaW0UFxo6lnDOBkAD9KAKWhagYLgSW5VZW5POevvV+/V76QuGVQcFlHH5ViW1jIkvm4ZYWJUcdKniNwZgEV9o6+hoAmtJ7nT5pLeC4UqvzAKc1MdRnvIs39ssnOCcd/rUUVmWDSwbzt4bjNTW84ScdG/2W6UANSxsWHmBHjbsd1WrWK5iIMN4EAHSQcUy4jilAPnBWPIXGOPSqj3DQgqSCB/CT0FAHSBJHhRZ1ibvvj4qEbI5do3/AEbt71gR6nEjEkHYBgDPFTR6i0sobCsD3JyR9KAPR/DUiRW0zPnDjAxVx5444JEXlSOPrWR4f3zWwD9WxzVi5SSOXbjKkYPPegDOuPMkDAcgcioVc7lzwR1Bq1CmNxYHnsaS0iEk+GXJB9P5UAGotiNF5+7kc1wfiuXbZvkHJ4r0PVbZiWVSPRf/AK9eW+NZCibWJBBOaAOL+bceBz3BqzH1yKrIvz5xj8KtRjPSkMsKOP8A61SDIORUacnHWpRgHIoAcM4Hyk/SikPXI5z9KKAOgjOQeR+FMZ9i8EcjimEhAzHOcYzngjt/+uqhfe/zfhxQItrIzdPyq5HuKhj0FU4TjI457EUs8xI2AnA7A0wLn2rr5ZHHBNKHDDJJOaoREgjGc+1XkinY4SJtvfPWgC1GW28d+nap4tiHrk+g7VDBZ3mOUAHuaf8AYbs/wjHrQBckvcRAKMYOD7VUe6V85f5TwT609NMuShV3G3OQMfzp6aBdSSZWROexFADIn3qyKMBl696rJasynKnPTOegrah8P3isCAjE/wB1qfJp17a7iLOTn0GaAMmO18mRXUhDnPI4rM1m/wBxb58sTgEnFSa5fzWwIlikRiOhHSuC1TWPOkwjAN3xQBf1C9VW2q/U5P8A9est7g4ZVwN3U+tUTIxlLbu+KlUgttHQ96kZfs3JUkn8a7XweBKzfP8AKuCQa4qyjZxtUEntXa+GLmPT7C5bYHml+TP93FNAdc15bWMsayFZIznrjqap6jdyNeK1om9GAIAHP5VgQXUbQvDcMSxbcrMc80SsXZNuAAckDgfWmI72x/s+e1KzRS2suMOpQ4+tc7quk+TITC8Uin7pzjNU7fXJYYjvdnxwQelQtqkF4v78Ec/wdRQBmXPnxMfNRlPuMCoJJ3lH7wEMO9bP2aeRf9AvY50Iz5UnGPzqC6hMa/6RYlHP8SN8v5UAYj/LjPDHtV7R2f7UgPJZsAAUNah5cDBz2HWus8I+G/PuEkJIIyTxnFAHU6bFlUVHwUAzmptTkjys0THZux171O2nSW2JFffGR1HUViT7mtXQcHdu5oAcLza42A81b0mXfdqJI1CZ5YHGKpW8XAb5S3Tce1aVgojbIGcAk5P60AWNYdROVH3V79zXi/jqbzLsheRkkCvUNWuWEUrdGxivHPFcu/UCO/pQwMiDnIx17iridATmqsCYA45I9KuR9evP0pDJkFSAZzwaYijipF6dPxFAC/8AAuntRTwD9fxxRQBoXLblJ/lVdWxz/SpTkR49+9IUB+7z6UCHq7kbVOWJ/GtGwsM/NL1POKTT7TbzjLHqa2LePb3zmmA+3too1yEAq4mB24qDdtyAKA5PFAF1Wx6VKsmFzms9X+Y88ClMh/KgDSE5J4H1JqQHzONzKfUHFUIGPpzV2J++c/WgCdI50JaORmx0BNQz6rPADmVlI7satxygLnPHSs/WoYL22ZWz0zuXrQBw/ivxY7ymCPa4PViuc1yT3tlOuZ7KJ89dowazvFNve2OqS/aA0kf8JA7e9Zcdy/O45BH+RSGbyx6XOxZRNb54wrZxU0OjyXDH7DLFOckBAcOfwNYcDAv83PPY1t6U4SVGXhuuRxQBcNjdadtjuoWhcjoRxV7T8KSxJCgc5710Gl64bmRbfVgs0DfL8w5UfWk17QoLh0l0OT93j/Vk0COfWVZCwJxglt3rWrp10htnxnLjHPNYTCSxvSlzGyk8FT3FadpHayTKsNwI93BSU4xQBFcSyJIc9D+WKd5geNldCreoqze2NzBGTLGXToHTkYrKjZhJtbPfrQBbgkaEkqSDnjFbVteiSMj5t2MYPTNYMcTK45PI4BFacSYTChfU5oA27WCO4lU71QHqdvWvRfDUEVpp0mzzCXGNw44rzzSYw0isjggkHA7V6Lp5KQrGyb1PO30NMCW7ulbbbqSFzk5OCawpkzu6EHIxV/UTHHdEupVzyCDms87HPyuCR+BoAghkx8u0gZq2mVUsfTFNiXcdpUBh3qW8ha3TD98nPagDn9Zm3qVzwBXkmuyeZqD5wcGvUNZcBJM8f0rynUP3moSEZxntQwEhHp+NWo+Krxcjv681aUE0hkop4Jyaao9KkXj60AKDjvxRQTjpkfSigRolS8I2jr3qzZwk4LcHtUVtgwqnUdM1eiI2ryeaYFyJgqgdu+asI+By2KpxkfhUy88N3/SgCRpN3uBRvOeoxjmo9oC5L7RnGTUixdi3P0oAeG5xzUqkUxYFOQxzUsduqLgHI6CgCWI5GBwatRvlRjOf51AkKds47GrUUakc5/OgBwYttAJ68471JLH+5P8AOnJEi9sj1q1EkRB3DI+tAHAeJ9NWcbioLAYziuAv9ByxaNcH0HSvoM2Vm/8ArIw3PJp66FprEHyE574osB82rp0sQBbk9OOv61pW37uMcHdjAFfQ40DRnGXsoZG9SlLN4Z0OVB/xL4BjvjBpWGeEWrkuCoYkdSAa3LCSVWVl38dB0Br0+fwxZhcQxjZ/dxVWfR4ECkRIrfSmIybGzttSgD3UCyM3B3LyPpWHrvhFVZ3sgSB0UHn6YruLe1SKLKjDE1Hell+6BnpkCgDy2OK7tCuyUs4JDIrkMB9DTnmwxS9tmY9nUbCf6V0OtaS13dGUc47g8ipNFiuYWCXDM8Q+7vGaAKNlawT4kR96qOVcYYH09Kiuo3kxsUhRXUSW0JkIjiRX65C4FWE0sSsrlOB1BoAyfCtvKLsGT7oGfT6V3CXRSzZs4YcdKoWtrHECYQN3p6024uCLDBADbs0ARajOzpE5I34weeTVViXKk8ZHGO1Vp5S4I9egp1szdM8A9KAOg0f95dpHIMkjOcVa1RlbzEI6Z/A1X0JSZGkkX5FFV9VnEaSsoC9gPT2oA4rxDMVikOcDnqa8xmO6eRif4uuK7bxNc4hfmuGiIZix+U0gLsfUc1ZU9Mniq0VWU6j3oGSipB9KjQZPPOKeh656UAOXpySeepopMZ/+vRQBqWrHyx6nt3q4mfwxVG2Hyr6GrqdPp0piLKYyP51MrdM+veq68+n51MnzY64oAnV+g5PepI2PA56dahUZ4qcenU4oAmQ/X3p/mAAGoh+XNOOSMnn0zQBYDkDIz+NSCU55Bqsh4yCcmpcjFAFuKYlutWonbPQ5Pc1mxEDB4zVhJGBzxx3oA0kl6A81YhnII54znrWUspzzzmplkwBzk0AbRujux0I6UpuCOc4B5yKyVkz/AEp3ncjOcUAawuCeAeeuTTHlV8hgOlZvmnjH5inGTAGcZ9KALkkSyKCuFJHbpVC6R1xvX5euQamim4A9vWpBKDwwGPfpQBiSgDnHPrnmqzgsSTkZ6Y71tXNpFIN6cY446VnTL5AYOPlHcUAS2aiSLIIDKMelXDdxxLtGXx1wKyUvAuWJGDwMdqkjUTHK55oA3E+6kiEgHoDxisyeQESDGQXq1HOEjaMt82MLzWOk22QpJkDpnHegAMRV9xJK980+zUs54A9KuFQwDcFe3vU0UQibeo4bt6GgDQtx5NsST83v0rnPEV0dpGe+TW/czKsW3jgcmuM1+YnOSD2oA4fxPOTG2WHIrnrcEj3+n+fetHxHIXO1eucHmqEJPTrk80hlyMcCrC/Tg1BHx71YU8c/pQBIvYGnKOh7+nrTV6DJpyn356UAKD/f69h7UUZx0/lmigDRtuEBB4xV2Ngen0561Rt8bB1FXIyCcnr70CLKHgc/gami5PHI9agTpipY8AUwLA6dvepFJOcnjpioR2IAxTx14FAEytg8mpVI981Ap5GelPJIz/hQBMrdsVIGPcmoOvPcU9Tz1oAsg4xinhs5OOlV1JA9DUi/c9+tAFgNz6U5HqHPJ574xShh60AWd+c04PkYJx/Wq4bpTgw9KALQcAY5xSmTJPtVYHkY7U4sG7gUATiTpz7VIsmAcnrVMHoTjP8AOnA45zz2z2oAuB2HfP41HKPMDAgMCckdajDDB5pUORg8nvQBmXOns5LR565xUlmJIo9rcP1xWqhz78U2WDzlwCQR3FAFC8LC5XB5AyPeq8mXRpGxnPIqzqA2S8jtwaqh8fKwG1uDQBNaXGwhCcpnOP61vWQBYZ5jPOfSuXHyMCc4ra0mR2Vuc7RkZoAk1NypbP4Y7Vwuvzg5GMDP4V2WsvtjBH5ivPtemGW4IoA4vWH33Kg4xnNOgHfPtUF03mXXUHHbFWbcDGBj6UhlmMZ+tTp+VQIy5C55Pb1qdc8UAP5IwOM9DT88U0cgZpfbigB+/B5FFCsFGDRQBoW2BEvQ59quxjqefeqVt/ql9fYVdQ4x27CmhEydCT+dTIM4J5qEDqM4qRScdTj2oAn9iORUgPHU1EMgAc04E5Az+NAEy+pGD604nAG0kUwfjj27VIBxjJz70AKrLux3PIH86kXjn3zUfQdTT1FAEi/jTlJx/SmKSetOJ4NAEgbjrg09W64znrUS+oHTrSrkA5oAmBwSKcJBwQOvH0qE5Hr/ADpcnOOTQBZDjgH8qA3HPWoEyOCcYpzMeOMY9e1AEgb/AAxTi+O/41ECc8DpTgcH1HegCZWPXP0z3pynDfj+FQhjjnvTg3v1oAuRtwKmXocEnntVWEg8Y+lWAeAM80AJcwmaHa3Yde4rmpjJDcbJR07+tdWDmqer2IuLbcoG8cj/AAoAw4yWzkZ9u1b2iDbHOxHGMCuejBXrwRxXTWgEWmKB95znFAGbr82I1Bxwua811ubcX5Ofc12/iK4JLAMMdOK851eXlyTQwMTrNK2epq9FnAOOvaqFsDg459Aa0YvujB6CkMnjxkHAJ5FTLwOOv8qiXI+npUvYe9ADuB2460q5K5PemjPGMdfSn/pQA4EjoD+VFIWbPTP4CigDStSWjB5OOKuxjt1qjanMft0xV5OAOBTQiYenOR2FSx4yMkg1GvIqRB68fWgCYYxjP609GyMjkEdajxk8jIPbFSgYJPf3oAlQkjrxTg2SeuKiXcc9j0pT155oAkBGMfpTh1HU47UwDPTmnD0I/KgB4Oc9sccjrT88j1pqjoe1BJ7EelAD1PIz0p2cEbRTFH8QHFO47880AOJ5yD1oU5GDSAZ9TQM55wBQBIpxg9PrTg3Ixg44qNWPbPSlzzzjFAEm8Y46eo6UofLd8UzPqOKM9cHr27CgCVSSKdGef/rVCnPU8enepFODigC1Fy1WV6YPFU0+nWrCtnOcZ7GgCzG3OMc1cXDrjPv0qiCABz71chz1JI96AMK8stl/n+A8kAdDVy4k8uFcZ4GRV/Uox8jAD8KxdVkGMZyF6mgDlNdl4bBw3euD1ZyY356112uyHnB4rh9XfMgXtSYEdmuV69s1ei4UcdBVO1JBAHfsaux9ACc+9AydeOPxqVex/SoU6ZFTKcdaAHflilBo6r3pBheKADAPUUUnPbP4UUAatqTsHGBir0YwvOM+lULQgRKWx071cjmRuA2BTEWlJ/SpkOT6+tUwwPSn7sAdf8KAL2Rxj8KN+7AB+X1qCFwwxnOOtPiVh/EScdTQBNv2nHWnK2SWPFMGc5NPQYPHH9aAJGBxTlJIGMHNNPQ9enanKOvXFAEmcY6YHWj72D603gDPT6Um7GDjn6UASj26UpGAOR83PHP51HuDDg5z6GlAyetAEgYg8YzSbsD60hGBjv7d6Uce3tQA4E98U7OOc8H2pgIyf6U7Pp+lAD1OR1PFO+tRkngjnNOyMg9eOwoAevHrkd809evB/WoUPqPepV5b8PSgCwg4BHJqUHnjrjHNQL0PHJ/Onoeec0AWwc1etslQf51Rj6ZPNXIjwFwCaAFunPlDiub1FxlyeT61vXjkQu2cmuU1OUBC2f8A69AHKa04LEZyK4nUWLXPUY611WqyZZuv1rjpmDXTn3pMZds+oPb09P8A61XlHNUoAdowcfWrif1oAnXoOKkA57fjUS8Ee9PWgCQdzRkk+1NBzS9uf1oAcO/OKKQc/wD66KAJzKVgQHIB71PauWAPaoIVWWEcdqniG1cf/roEaMR6A1YU5GMZ+lUoBhgT06GtK3A27scflTAIV8tskdfSrQUHmkAwBUidOQfxGaAAfex/KnY+Y9Dk8ij7xx7+vWgYGc/yoAeTgAjmnqevbHrUIIJGeaeGAztzQBJj6YpCefTIpnLHtntTgpB5OaAHIoVQBhQOgFKRyMcU3g8YFO+7zxn2oAcOBk9MflQOlISS3Wlzge9AC+/encFT7038aVjyOOaAFBGRn8KNw5CkfX0pqkE805hjpkZoAVCBkZqUEcdj71CM5HODTgx3jk5oAurgnqOalQc8Hg1WTOBwetToOuaALUZA6YxmrNuMtx+gqojdRjpVqFm5ZhkDigCHU3Agxxz6Vx2qsCuP8muo1NwUbngVyOssBkYIwOKAOQ1iUKsh5xXJRkGVivGT3/z710evSBLdzwT6d65aBvxxxUjNi1I2Esc8f55q8n5e1Zlu4PJHPXmr8TZXp09eaYFhTnFSIT3qAHjIPHSn7uOeT6UATAigGow3uc04HPTknvQA4NjoDiimYJ64zRQBYs+Iif7vb1rRh5AOOpoooEWYeT9HArRThBwOuKKKYEiyHcg45qwD8n/AqKKAFztJ79ev0pkjnB4HQGiigB/VRn6UbjuUe9FFADwdvI70Z/MmiigBYzkc89adIcNRRQAxZGWUoMYFIWOB3oooAlRjuYdgcVN2NFFADF6detM8xsj6GiigCVOhOeakU45780UUAWYjgfhTwx3AUUUAWYxlyD25q2nCcUUUAZt/8sTY/WuM1hyZGB5wAfzJoooA4XxS5FuQMcjJrnImO0/TP60UVIzSjcqDwDjAye9XoCVAA6DAxRRQBYyRTlY89KKKYDlY0u4/nRRQACQ46CiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest lateral view shows the mass projecting into the retrosternal region and mimicking an anterior mediastinal mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lateral chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16530=[""].join("\n");
var outline_f16_9_16530=null;
var title_f16_9_16531="J curve diastolic HTN";
var content_f16_9_16531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73430%7ENEPH%2F80901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73430%7ENEPH%2F80901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Lack of true J-shaped curve in diastolic pressure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 441px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Age- and sex-adjusted mortality rates (per 1000 patient years, bars show the 95 percent confidence intervals) according to achieved diastolic pressure in active treatment and control groups in a meta-analysis of seven randomized clinical trials of hypertensive patients. The number of events is shown below each bar. Among treated patients, cardiovascular mortality initially falls at achieved diastolic pressures below 106 mmHg and then rises again at low diastolic pressures (upper right panel). However, a similar relationship is seen with noncardiovascular mortality (bottom right panel) and in the control groups (left panels). Thus, the increase in mortality at low systolic pressures probably reflects underlying poor health rather than an adverse effect of antihypertensive therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Boutitie, F, Gueyffier, F, Pocock, S, et al, Ann Intern Med 2002; 136:438.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Lack of true J-shaped curve in systolic pressure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 449px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Age- and sex-adjusted mortality rates (per 1000 patient years, bars show the 95 percent confidence intervals) according to achieved systolic pressure in active treatment and control groups in a meta-analysis of seven randomized clinical trials of hypertensive patients. The number of events is shown below each bar. Among treated patients, cardiovascular mortality initially falls at achieved systolic pressures below 180 mmHg and then rises again at low systolic pressures (upper right panel). However, a similar relationship is seen with noncardiovascular mortality (bottom right panel) and in the control groups (left panels). Thus, the increase in mortality at low diastolic pressures probably reflects underlying poor health rather than an adverse effect of antihypertensive therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Boutitie, F, Gueyffier, F, Pocock, S, et al, Ann Intern Med 2002; 136:438.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16531=[""].join("\n");
var outline_f16_9_16531=null;
var title_f16_9_16532="Famciclovir: Patient drug information";
var content_f16_9_16532=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Famciclovir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     see \"Famciclovir: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/32/4613?source=see_link\">",
"     see \"Famciclovir: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Famvir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Famciclovir&reg;;",
"     </li>",
"     <li>",
"      Ava-Famciclovir;",
"     </li>",
"     <li>",
"      CO Famciclovir;",
"     </li>",
"     <li>",
"      Famvir&reg;;",
"     </li>",
"     <li>",
"      PMS-Famciclovir;",
"     </li>",
"     <li>",
"      Sandoz-Famciclovir",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691508",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat herpes infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cold sores.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702101",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to famciclovir or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a lactose-free diet, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for an infection that came back, start this drug as soon as you can.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3761602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for shingles, start it as soon as you can; no later than 3 days after the rash shows up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12461 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16532=[""].join("\n");
var outline_f16_9_16532=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169842\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169843\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011790\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011789\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011794\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011795\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011797\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011792\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011793\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011798\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011799\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=related_link\">",
"      Famciclovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/32/4613?source=related_link\">",
"      Famciclovir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_9_16533="Coronary artery territories";
var content_f16_9_16533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Coronary artery territories",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 329px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFJAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqC6vLW02G7uYYN52r5rhdx9BnrQBPRSAhgCCCDyCKWgAooooAKKKKACiiigAooooAKKKKACiiigAooqG7urezhMt3PFBEOryuFX8zQBNRTY5EljV4nV0YZDKcg/Q06gAooooAKKKKACiiigAooooAKKKKACiiigAooJwMnpVe1vbW7MgtLmCcxna/lSBtp9DjpQBYooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMHxvq1zo3h2afTkjk1GaSK0tFkzs86WRY0LY/hBcMfYGvOvHKaP8PLLTbrUPCx8U3mo3cVpdavqDwsxeQ7fmLbmHtGiBAOMr39E8daVdav4cli0xkXUoJYby08w4UywyLIqsewYptJ9GNee+Ons/iTpllYJ4l07w5NYXUV3dWGpWm66injOQrAzINnUZAIbqrYoA6SbTo/A2vaXNoafZ9A1K6Wyu9PT/U28rg+VNCvSPL4RlXCneDgEHNHx78T/wDhFvHVh4b+y6Qn2qxN79u1XVvsMCYdl2Z8p+Tt4qympHxpqmi2em3EV/p2mXCXepapbRlLaaaMHZFDlm3HzMOcMwUKASSeNK98F/avinp3jL7ft+x6c9h9j8nO/cxbfv3cdem38aAIrv4l+GdL8qHWdUtorsW8Nxc/Yllu4LdZMbWeZI9qoSw2s+zIIOBmpNR+JnhHTodclu9XVItEeFL9lt5XEJm/1eNqndn1XOO+K53xd8Jn1rWPE91p+u/YLXxNDBDqkD2fnMRFgAwvvXYSowcq45J9MY/iX4FHUovE9ppfiIWGma8lkJYZbHz3ia2AClX8xeCAcgjv17EA721+JHhO68X/APCL2+rq+vCVofsnkSht6oXYZK7cbQTnOO3XirmteM9D0bV00q7uLmXU2i8/7JZWU93Ksecb2SFGKrnjJxVHwT4L/wCEY8Q+KtU+3/av7dukufK8nZ5G1SNudx3deuBVbUvBV+nj248WeHNYtrG+u7NLK5hvbE3UTqpyrKFljZW7dSPagDn/AAt8XLaXxB4ksPFUkFhDZ62dJsJY7Wba+c7RK/zKrHHfaODxxXZ3HjnQbTXrfR724u7S9uZzbW/2qwuIYp5R/DHK6CNye21jntmuF1D4MG9g1yNtfCtqmvx64SLLiMoSfKx5nOc/e4+lVm+Bzv4vttbm8QRTvb66NZWSbTt90yhgwtzP5v8AqxjjCjBJODwAAdjB8VfB09xFBDqkryS3ElpFixuMSTx/eiVvLwz8jCg5ORjOa53Xfi9ap4l8EJoEkN9oGtvepdTC0ne4QwKpCpGAHDbiQVKE+gpul/Bv7A+ht/bvmf2Zr02t/wDHnjzfMx+6+/xjH3uc+lUtN+Cl5pN/od/pniaBbzSb+/vozPphkRzcqg2lRMp+UKec857Y5AO3PxN8InS9P1CLVjcW9+sjWy21rNNK4j/1h8pELgLg5JUY71VvPi74Fs59Phn8QQiTUIEubXZDK4ljeQxqQVUjO4EFeowcgAGuQg+AlhaW+gvDqNreahpvn+cdV01bu2uzKxZt0G9duCeMNx710nhX4Zf2F430/wARf2jaE2ukNpZs7TTltYiWnaYuiq2EHzY24J7liSaAPR6KKKAM7xJq0Og+HtT1e5UvDY20ly6qeWCKW2j3OMD61ws3hi7trW11XVdE03xJ4jnBku7jVboRW1gNu4pFlJNiA/KNq5OMse9dx4m0mPXvDmqaRM5jjvrWS2MgGSm9Su4e4zkfSvJ/HAl8f+GrfwvrXiuPwfrMBxqlpNENt8AMZjJdN8LHnKk9cMARgACeFtX06XwZbfELwfp39iW6TldV0qEj7PcRK+yR1CgLvUZdZFALbdp68dn8WvGmo+AfDNxr8Gj2mpadahPPD37QShnkVAFUROGGWBJLD6Gucs1ivPDdt4B0G50zUYt6wXdzpFs0NrY2gILoxMsmZnAZQN27L7iBjJ7D4p+D/wDhPPAuo+HPt32D7YYj9o8nzdmyRX+7uXOduOvegCJ/HdhpEzWXi+ay0rVUspNSaC3kmuYxbJnLiUxICeD8gG70zmhfib4PaJJf7biWJtOGrb3ikVRal9gckrgEt8oU4YnjFZfxS+GEHjy90G5bUmsH05nSbZB5huoH274idw2ghevOMniudt/gLpY0jxfp11q08sGtsotSkIQ6fEszTJGvzEOA7c9MgdqAPSPDHjDQ/E011Do928lzbKjTQT28tvKiuMoxSRVbaRyGxg1HN400OPxBLokdxc3WpQsizxWdlPciAv8Ad8140ZY89fmI456Vl+DfA9xo3inU/Ees6smpave20Nnugtfs0SRRgYwhdyWJGSd2PQCmaX4J1DQvGGt6zoGs2sVprVxHc3tneWLTkMowfLkWVNuRn7wbB7dqAMH4TfFu28T6Zp0fiWS3stb1C7uLe1ihtpkhmEZ6LI25d+Oo3Z5HHIrq1+Ifhr+0Xsbi7u7O8WCS6EN7p1zatJHGCXZBJGu/ABPy5PFcVonwU/syy8L2/wDwkLv/AGJqVxqG9LTY0vm4+UfOdhGPvc/Ss3RfgE+nalYXk3iK3nmtba9tmnGmFZ7r7RG6B5pDMS7Jv44HCgcdaAO4i+LfguWPfHqtww+x/b1H9nXOXtxnMqDy8sowckZxg5xg1hah8XLay+IttYvJBJ4Tm8PDWhewWs002TIVzhMkJtGTlOOckVBZfBb7N/Zn/E/3fYvDs+gf8eeN/mb/AN7/AKzjG/7vOcdRVWD4KX9i1k+meKYIZIfDzeHpGl0wybo2dmaRcTLtb5sAHcBjvQB3OpfEzwjp0UEs+rh4prRb4Nb28s4S3Y4WV/LRvLQk4y2BTV+J/g5vFEXh1NbifWJXiSO3WGRt5kj8xCrBdpBUg5BwMjJBIrjP+FE6fZ3tldaVdabM0Omx6c8Wt6Smoxts6SqpdNj/AIke1dX4G+Hw8K+Lde1pdQS4XVLeztxbx2iwLD9niEeRtO3BxnaFUL0FAHd0UUUAefahaN4x1jXftsT32iaO32WHShIEjv7kRq7mU5wyjeqBW+UEMSDxjkvDs2ieLPGF54b/AOEZ0jSNU02yF0mreHL5ZjZSb9nktIsUZWQEHMfzKQDkEV1Wo3j+ENY16G+u/wCzdK1t/tNlqzRB4bK6aNY2SXPyqCUWRS2AxZhnOM4sTaXpPjMeMNe8U2Gu66dP/s2ysNFtgjzLv34WISyM7E98hQDk46gA6az8W3lj8ONa1jVYEutT0GO7S6RD5a3Elvu+ZTg7Q4VW6HbuxzirmneONMb4d6b4v1ySPSrG6tYrlw7mTyzIAQgIALHJwMDJ9Kp2fhS71H4ca3pOqyrZ6lr8d29yyDzVtnuN2FAyN2xSq9RnbnvWDcfCzU9Q+H9n4S1XxFZvZafHB9hntdMaKaOSEjY77p3VxgEFQFznqKAOjm+J/hG30q71C51V4ILO5S0uUmtJ45oZX+4rxMgkXPYlccHmnN8TPCSWF/dy6qYksLpbK4jltpkmSZvuxiJkDsTzjCnODjoa5DWvgxJrceu3OpeIEbWdZv7S8uLiGx2QqluMJGkRkJHBOWLn6VU8X/CSY3eu61Y3l5eajea1aazaQWttFm3lgDqAwlmRZFIc5+ZDxxmgD03wr4u0bxV9vGiXMsz2E32e6jltpYHhkxnayyKpz+HFVZvHegW+uw6Pdz3trfzyPFAtzp1zCk7p94RyPGEkPptJzkYzkVzXwT8Ma5oZ8V6l4mgjtrzW9Ve9WBSuVQjgkK7qpJJ+UO2PU1hW/wAD5YfFllrjeIoJ57TVX1RZZ9N33Uu7GIpJvNyyLgYAUYyeORgA7m3+JPhe9jtf7P1Nbie7iuJYIvImVgIMiTzBsLRAEY+cD2BqrpPxP0C70vR5p7nzL3U7drqG10y2ur1jGrFS4VYRJtyCNzIvOayNE+FV1pWq3WqL4i83UNUhuotXdrEBLvzWLIUXf+62Zx1bcOuKxb74GfafC+h6MNX09JdKtvs8eqDTZVvVzIzkpItwoUYbAVlcD5j3wAD2qKQSxJIoYK4DAMpU8+oPIPsadUFjbm0sre3M0s5hjWPzZm3O+Bjcx7k9SanoAKKKKACiiigAooNNV1YAqcgjI+lACkgDJoGKZIdqk9hVKzuQJzaPw+0tHx1UEAj6jI/MUrjsaAIOfahiFBJOAOpNZ9tc5vL5P+ecqrjP/TNT/X/PNN1a58mxuJMkeXGXz0xjnjv/AJ96LhY0lYEkA8g4NKSB14rLsLoSxSSKRhpJOfZXKA5z0+Wlvrhhbzgf3GGCM84x2/lRcOVmnxRUULiSJJEOVYBgfUGpBTELRRRQAUUUUAFFFFABRRRQAUUUUAFVL7TLC/Km+srW5K8KZolfH0yKt0UANjRI0VI1VEUYVVGAB7CnUUUAFFGKKACiiigAooJpkkixozuQqKMlicAD1oAfRXNS+NNIMnl2D3GpPnbmyhaWMH3l/wBWPxbvTD4ytICW1Gxv7C3BwbiZUeNfdjGzbAO7MAB3NRzxva4ro6iimRyLIiujBlYZBU5BFOBzVjFooooAKr31laX0YjvraC5jU7gs0YcA+uDVigigCK2t4bWFYbaKOGJR8qRqFUfQCpaMUUAFFJmoL28t7G1kubyaOC3jGWkkYKqj3JoAsUVzH/CZWbHdBY6pPD/z1S2KjHrtbDEe4BrS0nX9O1WR4rO4P2lBue3lRoplHHJjYBscjnGKlSi9EwNWigHNFUAUUUUAFFFFABRRSEUADKGUqwBUjBBGQRVSx0vT7BmawsbW2ZhhjDCqEj3wKuUE0AFFJnmqt5qVlZMq3l5bW7McKJZVQk+gyaALdFMjlSVFeN1dGGQynINPBoAKKKKACiiigAooooAKKKQnmgBTSKQygqcgjIpGOASegqjpcpaxtgck+UgJ9flHPWgC8xwMk9KwZbl7LVzATmK4Bmizz8wyHXvzyGHT+LqFrYuH2RkDBY9B1/Tr/OuU8WLK+lSXFqpe7sm+2Qr1ZtgO5RjnLJuT0+bvxSY4vU6I3YeM4wCP85/z/wDrxNXE4hL2IxewHzIFOcFlH3T6Bh8p+vriksrpXkBil3wuoZGHcEEg/iCP09RU91DuD7gACAOnbjr+XUdPwrPmbOtUkVPDF894t5fPbzW/2q5Z1inQrIqgKgDA+u0n8utXr1lljeOTcyMCu0EgkFccYPXp0+tU0LLJxuHPIzjkn9P/AK3cfeZJKZU6q3C56HOOT3+nX170ubUpUUtixpnlWVnHbwOQkYCgk7iec5JOM5zn8fpUklwCx3EenUkYIJOOpI/z2rKaQhWznGMEk8fnnjqf8KZJMfmLFAzZPOCDy3GPz/TtzS5ivZG/4N1Fb3RUhJxc2RNrOh4KunGfow2sPZhW8OleWTS3el6n/a+lIXuAgjntC+Fu4hkhQx4Dr821vqDwcj0PQdWs9b02O+0+XfC5IIYFWRhwUZTyrA8EGtYu5x1KbgzRoooqjMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACjNBNUtX1Oz0jT577U7mK1s4F3yTSthVH+e3egB2p39rplhPe38yQWsCF5JHPCj/PbvXm2rRa54nvEuL17W20s4MGl3EDyZ7hpgrruYjGF5VfcjcPKvGHxEuPiL410XSLEPa6AL+ErC/DXGHBLyAf7PRenOTz933YAZAPGRyM4wP09awx6qYfli93qZyl2MK5i8QRWUjQ3+ltKkbFFFgygkDIH+u47VnWNxqt7HE0+rRot3EstvJDbIFfK5AYtuPfn17ds9DZ2B8Ravc2s5ddJs9q3KoSn2qZlDeWcH7iqwJH8W8A9GBd4o8L2elaabnRrRLeyh5urG3TCNF3eNBwsi/e4HzAEHkgjGjR93mkaUOS/vrR/wBaFL4eX02kah/wj99cM6Shmtg4UeW4+Zo0wANhX5lH8O1h6CvSlzjmvJrqA3YtkeZVu4GW407UANwLKcqGI6g5wR3BI6nJ9G8O6qusaVFdBPKlJKTQkgmKRThlJHoQee4we9daknojevBRl7uz/rQ1KKBRVGAUUUUAFFFITQBR1rU7fSdPku7reVXCrGgy8jE4VFHck8f4DmvO7m28QapqX2/U59MXYQ1vbPE8sdqM9R8ygvkEFz9BgEiti/uP7Y8QzXALGz08vbQDna03Ilk6dj+7Hph/WmeTPq2pnTbKR4I0XfeXKY3Rq33UTj77YJB/hUZ4JXPFVqSnL2cCJPWyOcn1S+h8R2uk3XiDSIpZoGfYkGx96lAFCvK3UPxx2Par114euLwxNNrepLNC4kjeGOBHjbnkHy8j3weRwcgkHu4/DWjR6ebJdMtGtmzuSSMPvJ6sxOSzHuTyfWuZubWTQNRisZZXl0+5LCymmYu0T4J8lmPJ4yVYnJAIPIBaKlCVNc0fyE00bvhXWpb5ZrHUNo1S0x5pUbRMh+7Ko7A4II7MGHTBPQDpXAX6z288Gp6erve2ZJMajJnjOPMiPuQoIz/Eqnpmu30+7gv7GC7tJFlt50EkbqchlIyDXVQqe0jcqLuWaKKK2KCiiigAooooAKqapqFtpljLd3snlwRjk9SSTgADuSSAAOpOKtE8159PdjxJqi6gTu0q1YixUkFZHHBuMdD3Ce2SPvDGVSqqceZibsVtXu/E+vsrW06aNphBxBhjcSj1eRGGzgH5UOR/e7Vz8VnewQSyaDa6XeTRSJHM1vo8jlvmG8+YZcMygkkZLEjoSa6yC0fX9RlsYy0WnWxC3ssbbWdsAiFSOnGCxHIBA6sSvc20ENtbxwW0UcMMahUjRQqqB0AA6CsIU5VVzVGQlzbnkWl6Vdmc3ei6vb6bOkm2RbPT2gyy9VmhaQgnpncoODkEdR6J4Z146iZbK/jjt9VgUNJEjZSRCSBIh7qSDweQeD2JzfGNmtlqFlrEKhRLItneYH31c7Y2PqyuVUe0jegrL1yY2At9ZjJWTTmMrkD70Jx5yYH+zlgP7yr7Ckpyo1OVu6Y7uLseig5opFII46UtdpYUUUUAFFFFABRRQaTAqarIItNu5DnCQu3HspqhZyKPlOABkDocYA/z/h0qbxLIYtCvCOrJsH1Y7f61k2spWVwCTg8Hnkf5B/DHuKBqNzTu5zgoeAcEgn9D7nAHpz9M58EgF3GDhsuB29Vz/wChdOe1T3bbQSSQAepPof8APP8Ak8/ql8un2V5eSAYt4mmZSOyYOMHHQgj8fXNG7KUb7FTw7IF0TS9hyiQCJTnghflH0OAOeeorp/MV48hjyPp+Ht19a5LSYmsdJ020lfdLbW0cUjE8EqME9MfePtgEVqRSnqc7u2evX1/H8c965+az0PTVO8UaDbMqdmCOAPcdP6fhjNVJ5AibQ+7A45JxgD34GD/+sgVG84AJHG7gZG3Pb19D+v41lTXRZgEzg7emQR6dO/HSk2WoWLc8w3fN244HAH+QOPc1BJOcYbcD/Fz7N3+oOfx98U8OQSflGMcenOemeoz+Q54FMJJfacgj+EDkHnIH0OfxPtmqUXYpQZM021j29gSozyOg6Z/n344ht9Tbwzqn9swEtpk5CajEoz8oAAnAAzuUDn1XIPKrhrLltu5QR2HQZByOMccfgKkjQNDJE4VvMB98k4z069fb7uO5FaQTvZk1KKmrM9XjYOiuhDIwypByCPWniuF+Fd6/9lXOizuWfTHCQknObdsmIf8AAcMn/bOu5XpVnjyi4tpi0UUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFITilprHmgCvqF7b6fZT3l9NHBawIZJJZDhVUckmvlbxf4m134xeMYNG0COSPS0ctbwsdq4GM3Ex9geB23ADJPOz8dfG914q1+Lwf4aDXFvHcLHKIj/x83IbAT02oR343c/w17B8J/AVr4G8PiHKzapc4e8uMdW7Ip67VycevJ71200sNBVZfE9l283+hL10MEeA9H8E+BxZ2UEc+p3lxbwSXkifvJHaVMkHnaqgEgDpjPJya6UHjGQM9+uO34dR69K5z46+IrvQI/Dx0+0+1z/aJZ/L8suNqxlM4GD1mHcV5pL8TfFN3FJbrpCI0ysiv9jkjCs2RuyXPfHUdu+Djzq+ExGJftYq673X+ZE97Hvnw+ix4Us7kgK18XvjgYP752kAPuFYD8K6GQKeGGc+oqHT7WOxsLa0gAEMEaxIPRVAA/QVYI5qlpoa9DyL7H/Ytzqek3Q8zS4Jg0Yx/qIXyY2H+yOY/rHn1zb8D+IILXxi+mreR3kGox5WaJw6+dGvGSOAzRg5B5/dCpvHGlxXvjhZzb29zJDp8Z8qdA6MPMk7HjPPXHc1l6iXh0l7jSk3xwOs0UJzut54yGUY5wpKhT04ahS3t/T/AM/z9TvV6tK2n/B/z/BnsANOFU9MvYdQ062vbVi0FzEs0ZxjKsAR+hq2p4qjgFooooAK534g+IU8K+DtV1h8FraEmJT/ABSH5UH4sRXRV89ftT+JOdJ8OQSf9P1yB14JWMfnvOPZemRW2HpOtUUF1FJ2Vzl/BvxfudPt7fT9a0wXaJiMTWhCysSdpJRvvMW5JBGT719I+D9Nk07RY/tSBL+5Y3N0Bz+9YDIz6KMKPZRXzb+zv4Nj8Q+KJNWv0BsNIZJEQ4IkuDkr7YXBbjqSvbivq1RgVeNoYejWaoK3f1JgurFAxWfrumxavpc9lOWQSDKyJw0bjlXX3BAI+laFIRzXKyzgdKnmuLcpfIqX0Dm3uEXOBIOuO+0gArn+Eg8Zq/4Qu/sWp3OjOf3cga9tASM7SwEqY6/K7Bv+2gA4FZ3jLSQvii0uPtd1b2moxmGWOB/LEk6DcmWHzAmMOPlI4jGc8Vn3WmWmiomr6XYol1YuJy6p+8mjUESIzkZclCwGT97ae1cEbUKtu5n8LPUAc0tMidZYkkjYOjgMrKcgg9CKeK7zQKKKKYBTW4+tOprHB/CgDzX44eKJdF8Nf2fp7sl/f4jaResMRYKzfUlgo+pI+7XE+GfGetXd2dHgsbS4n+1nTreSMmMLtUkSOnI2qoJONpwvArl/iDrkuv8AiLxJcu3+jRy2kVqM/wDLISfKw9mOX/4HXpfwO8ONFea5r12oAlvJYrReyjIEjenJUL2I2sO9d1XCUY4fmqq8uh1SowjSUprVnp2iaZBpGmQWVsWZYwdzt96Rycs7epYkk+5rQHAoApa4DlMPxrbtdeE9XjiUmcWzyRYOD5ijcn/jwBrBHk39kBhXguI8EEggoyg447HPNdwwDAg8ivI/Duj3NxodnFf6rfukEf2YwW7CBAYvkOSg3k/Kcndj2A4rjxUVo2RM9B8DTvceDtFklJMps4g5PUsFAJ/MGt0V5/8ACvxNol1ph0Kzvk/tHT5poXtZCRJtWRsEbuXGMfMM+9d+DXYr9S0LRRRTAKKKKACg9aKQ0AYfjIH+xMKOWubZOfeeMf1rEEvl3TN6sxHIx/FxyM92H+PStzxeSNHTbyftlp27faI8/pXOSH/Sn6YJOcc4wcY9Dx/M9qRrTWho3Eu6JgrHO09umB6cYxx+Y9a5Xxg5fT1tVBxe3cNsAxx+7aUb/wDyGr5Ht+W8T8mGxgjJycjGAPr6evb8ee1YtJ4i8OxY3bZ5p3OOu2B1PPcZkB/H8x3SuawjqkX0bfeMeDl+qnOMdfbuB/hitEQtHGCwxgdCcdO/J9uvr69Kw7GULdDJxngFsDOeg/I/h0rpnXFvGyA59Dx2z2Ht17fy5bI9OT5bGFqEvzOu7kYBOM+57enbuD7VmIwAkmcZjHA3Hr7f1/8A11Y1YjziwIKtjbyOnH+J/PvXPa5IzWdvbRll+1zJAW5zsJ+bByMfKGOaun7zHJqCcmWZJ9U1BHn0nSb+9tIyR50KKUyDggbmBfng7Qeh5yMVQW8mKh1Zjt4wykHI4IYMAwOevfPviuzf7XLAkSX91DDEAsccMnkrGoAAA2YwBxXEatotkNQlV45rhtwctLK7sxJyTyeTnH159q1dt7nJRrVJytY0LfUXAUO2VB75GeM5/LH8/QnZs7hmIOGBPdj05zzn8fxPvxwUmjacvyjT7L8Yl9+c+nf04HbBq9ZaJpjAYsLRMnAIjCn064+n59+9Qaudic+34nf+ClMPipGAH762eNgO+CGB9+hxx/EfWvSl6V4RBotjBd2xhj8jzX25jYqehxyDge/au/0bRrWQg/a9QBzwBeTKFA7cMMcH8M9+9NHlYuElUu1Y7miqFppsVtgrJdsw7yXMj5/BmNXl6UjlFooooAKKKKACiiigAooooAKKKKACvPPjh4uk8JeC5XsZdmp3zfZbYg/MhIJaQd8qoOPcrXoRNfNXxtE3jX4yaP4Vt5NscCpbnvsaQeZKw9/LVP8Avk9+m+HgpzXNstWKWxv/ALNfgeO00seK7+IG5ulMdiG58qHoXHuxB54O3/eNe69KgsbWGysoLS0jWK3gjWKNFHCqowAPwFTHjrWdaq6s3NglY8J+N+rwp41t7c+KZPD8lrYKQ0UMkjSCR33j5PQRoea5jwlO2q+KdIs4fHd1rRe8hZ7IwzIHVGDtktxgKrevbpya0/HY8Q6h441240vQNE1Gy+0CFJr6OJ3GyNEZRucEDcH7d6v/AAtsdak8e2Da3oeiackMUtyj2MMQcsF8sglGbj96OuMnHXFdS5FR3V/WN/8A0m/4mW8j3wd6DQKG+lcBseb+KNk3j+VI7jyryLToGi54OZJtynvyAKgBe4kkntUEeoRgJcWxHyyj09xk8H/Jh8T3trD4l1+fUkkS1gWKJZ4wSyskXmYHv+849araHeXOq2Vo19GthrcQdcnBBdHKuhPfDKQfz9qmSe7/AK/4H4o9Gj8C/rT9V36o6/4Z3SS6FcWcalBYXckATGNikiRFx7LIo/CuwXpXn3gm+H/CW6hbOnkS3Nqszw/9NI22s+e+VkiGe4UV6CvSrRw1I8s2rWFoopD1pkCMwGScADvXw18QNfbxN401fVid8U858kDOPKX5Y/8Ax1R+L19c/FnVn0X4ceIL2J9kq2rRxtnG1nwinPblhzXxNjb0G0D5R26ZH+fqfTj2smpJylUfTQyqvofQH7KWqQq+v6QzDz28u8Tp86gbGPv/AAH/AIFX0MvSvh34d+I38KeNNN1fJEEUuy4UnG6F9wf0zgHdj+8Pbj7giYMgZSGU8gg5zXLmdH2eIb6PUqDuh9BooNeeWc54+gL+Gbq5jGZbHbep6/uzuYD/AHlDL/wKs5WDLujwQRkdDn2/TPr+ldjIiujK4BVhgg9xXnvhsNFpMVtIw32TPaMWPXyWKbunGdgOa4cXHaSImup0HgKXGiNYHOdNna0GTn92MNFz3/dtHn3zXSjpXG+GZPs/iu9gHCXdpHOoz1eNijnHrh4hn0ArsR0rppS5oplR1QtFFFajCuU+KOsvoPgTV76A4ufJMUJHaR/lU/gTn8K6uvI/j9qeyzstNSUo7Q3F6dj7T8ihFB9j5je3y1pShzzUS6cHOSijx0WM+p3N5Y2AHn3P9nRRAjKgnaATnsOp9MV9X6Jp8WlaTaWNv/q7eNYwT1bA5Y+5PJ9zXhfwYs5dQ+IE8kyqYLCzhuCfLAPmtHtUEgDIAaTAPTFfQS9K6sfVcp8vY3xdTmnbsLR3oorhOUSvPtIGyTU4SBuh1C44wOjyNIOvsy//AFq9Crza91Kw0rxJ4h/tK+tLNWvI5F8+VUBBt4Aep5yQelcuKi3DQiex5Lr/AMKNZnim8T+Fbh57r7bcyS2ytsniZJ3G6Jh16ZxwfQnPHY/CL4vyX15H4c8afuNWD+TDdSL5QlcceXIpxtkz06ZyOAevf/DS9gvLDVhaSLJbxahJ5brnDB0SQkZHI3O3PT3NcZ+0J4Ag1jQLjxFpsITVrCPzZ9mF+0QqOc/7SjkHrgEemPTo1lVhGlW+T6r/ADQJW1R7KDmlrzj4FeMJfFng1RqE3m6rYOLe4Y8NIMZSQj3Xr7hq9HrCUXCTi+hYUUUVIBSGlooAwfGhxoseRkfbrIYP/X1FXNTybbp2JH385yc8Z47ev/6q6Lx0wTQULdPt1lz6f6VF/nmuRvZWW5dsnJJOMYz7eo6fzPY0jaka8WVjBGeABke+eg/P67gOAa5bV5BF4j8NykqA9xNbZH+1A7d+2Yxx/wDrrVGp+VD5YUEZxng9+mc8f4Z965fxddr/AGP9vjO1tOuIrsk8lEVxvPP/AEzMn+eo1pobRdpJl+NvKuG6B1PY4x+B+npXaQyNPp5CeWMddxPTHB4+n6flxWpkx35kQAqxDA9uecfqO/YV0vh67SWDyHHJGORtzkdMe/HH0FckXZ2PTqxbhfsZmvJtcAgqwG32GP8A6x/zmuS1SVY/7MlfIEN2u7aOm5WQDPP8TAdP0rutatgfOGM5b5sjJOcZ/SuE1e2aexuYAdjkbo3OMLIpVlOfqM//AF6qEuWRUo+0pux30EiPajOCeSMd8jn17Z/IeprnNXjaXUZB1BUZPbvzxx/k54Iq9oV8LrTLSYhlMiKWBJJVsYwfcZxVTUJVS/uXYAAKAC2DtGM9fzrep3PPw1lPUwbiERtj5ckc5Y4PODk+hIB68Yzz0pLOYRtwwGMHPT2/DHODj1POTUF9cGR8gEZ7c5HPI/L+XbpVRZcBmZgqqCWPGFAA+nvWcL3PR9rCOp1QlR3slJ2nzU6fXn/P+Ir0DQyQ2UZTg4zjjufy5B/qK8StLzVNVltpLOW3treUqUE0Bldl/vcMoGQenJ569a6+wufEGlOGS/t5rcD5vs9iTIoA5wnmfNyRwCDzxnoel2PMxdT2jukezDkZpw6VjeHZLy5tIbp9UsdQs5kDpJBatHuz3yZG/LFbG4A4PXrUHAOooopgFFFFABRRRQAUUUUAFBopDQAhr50+EDDxB8e/FGsSBXEAuWibuMyiNP8AyGtfREzbI3YDJCk9K+dP2Ux5+s+JbiQkuIIAfq7yE/j8oH4V0UV+7qS8l+JL3R7jpXiFb3xJq2kG3MZstuyXfuEvyqW4x8u0uo75yDW71NcJoJEvxAuriLmGX7btPsps4j/4/FIPw9q2LXX57jxxeaN5cItILbeJAT5hlGwsD227ZY8d859q5ij5y8aXHgY+L9eGu2/iCbUhf3CyPbCHyv8AWPjG5s4AGOfTPpXb/s+L4cuPEuqXHhe21OBIbTZOb7ZktI4xtKE/88jnOOnvx4p8SGDfELxMVywOo3AyOv8ArD/+r67K9o/ZQswth4kvtgBkmhtwcf3FZjj2/eflivaxNDkwkZuT1tpfT7jKPxHueo3senWUtzKrMqYARMbnYkBVGSBkkgDJA56iqQuNbPP9nacoPZr58j64hrm/iqzTWenWaEhvO+17QeWMeAg6jP72SI/UCu6HNeKanmt3pWq/8Jm1xrVva2+hXVzDcyyRTeaDKiKsaElVIy6oc4x8oX+KsrWNU07TvEOt6Rqknkxi68+3ZfmcGRBJkADOC7OOhyQRzXrlxDHPDJDOiyRSKUdGGQykYII9DXlNzMbbXLmO8R5rB7TyHdyWbENzPHvPrgeXk9eR1qWtNFr/AF+JvQbc1Yj0bWnHjHQPtGn3cUjPJam8kh8pZImRiBtch8mRY+x69a9eXpXkOuynTNPSS4KzWtrPDeW9wOSojcOVJx/dUjI7fp66gwKcNtP6/rsGIjaV11+7/geg6kNLQabMDy79o64EHw1lRkDrNeW8ZUkgHDhsZBBH3exr5Vt47W8kijt454LiUqqrERKrMduFCnBGSw5Ln+VfTX7UT7fh7Zgcb9RjXrj/AJZyn+lfNPhy4W18SaRdMwCwXsEpOOABIp7f09PTFe9lsbYeclujKfxI3viH8PdY8Cm1/tgwS210MJc25JjD8ExtkDBwDjIAI9McfUXw81y8l8C+H3utK1F5TYw7pFVMPhBhuXzyOeQPwrr7i3huYvKuoo5o+CUkUMpx0ODWZoQjhvtUs7XH2WCVSoH3Y3ZQWQeg6Nj/AG68uvjJ4iMY1N11LUUnoaFhfxXqyeWHR422yRyKVZDjOCD7Ec9Ktjmuc1jU7bQtdtJ73elvqKra+YFyqSLuZd3oCGbntt545HRDmuUoDXm2oajaaR4o1u1uDKGklju44ooZJCVeJVzhAT99HP416VXEayMeN7vP3W063/HEk+f5isMSl7N3JlsZmnatHP4u0N4IL5Fd5bZpLi2eFSGiZ8fOAckxIen+Fekr09K4G8BXUNGYY3pfIOBnqGVuwxwf1rvQevFGGd4BDYdRRQa6ChCa+cvjPdvc/EXUoyRsttJe3C568K5J/wC/uK+jDXy/8RZDc+ONfkyPmt7xPX7myPnHptz+dduX29rfsjqwcb1U+x6d8CbER6dqmoY5uGtoM4xkRwIc/nIw79K9TFcH4Yz4N8C6LZPbmXUZVV5IN2Dvdgz5OOxcIPUlF4yK7xelctafPUlLzMKk+eTkKTiisHxrcyRaDPDbyNFNdK0KyKcFBsZnIPYhEfB9cVr2IxZW49I1H6CsyCc1wWoQRx+OtVcxoZXtLaUMRzgmVTz1/wCWY/Ou9rjfE6eR4uspMHbd2Usb8cExOrKPriWQ8+hrHEpum7Ey2F8JSeX4m1yDtLFb3Wf7zHfG35CNPzrq5o1mieORQyOpVlI4IPUVxumMR44sef8AWaddBueflkgwffq3PvXa+nWig700EdUfN37Pjt4f+KniPw4XIgKzRKM9XgmKrx/us5r6Ur5l8Knyf2obpYz8rXt3uB7gwuT+uf0r6ar0cX8al3SCOwUUUVylBQaKa1AHJfEC63LpumRkmS4mFw49I4iGz/32Yhj3Poa5h/8AW/vCDnHBGARn69OR/LvU8twNS1fU9VYho2kNtAT/AAxREr+IL+YwPow9KrZIPBK8k459fp69fYe5o2OiCshrJlCSWzgYIx+Ht1P+eRWbq2lQ31nOiSSQmVCrGL+6wwVweOhIxg8e/XVXJOAD27Z7gf0x1/xoSIOu1ScfK3X9ccev+eDVxdtAauc7PFqEGmWkMjW955CbWlBMbsAuBlTuB9c5AOegzV3w3rkSal9imV4J2QuqyoMMgwDgjKnHHGc08RCLzTLnyxyAM9eB+WG9vpxiuKgvDceLnuY0leGyVoVKgYZ225AbOAFAOT6k91OMalGKTlHc7aFeTahJ6HsGqSCSLhmXPUAbhzgYx3/kP5cZqojmZhCQjEFWAbJAwPfryfXHNWo9RuJ4QHCQJ0bB3s3rz2GB2HYc+tRrd5MBGIbPqTn1P+f04IiNLXmma+109nT+8qXOoRaey2w5h6ZX1Pr9eR+PvmmPdTvI2LC6eNj2Ucg5GMfr+Hp1g1HT9yzW9x8wI2kg5x1/wJz17jnNVPCuhf2u13Yvq08GuWxLlJV3JLCchXXkHHG05JwQM8EE1Vqtq0B4ehRpvmr6f1/Xc17UWN1L5Rm8icnAimUo3c4GTgt0OAfU9eaPEXh1/wCwr+GMAtJC8QUDG0Nwf1Jqpq+i+JtKt2OoW6anZg/M8eZNvHfgOOM9iBVbS/E4+z+Sl0PKOB5F3+8jBBHCt1XqTjheDx64wr8rtI6p5X7WPtMNLm+f9fikdDaaQUuYpDtVFfcD2HPb65x+h5xWt0YMeV+U5xx249jz36epHFYVj4nSMqmqRhEwpE8D+YuODzjnv798ituK4tbqIS2U0M8YIG6NsgDGMcYIGD/j3rojOMvhf9eh5dfDVaH8SNvy+8boeq32lazNo1tL5Vrfq11BLgZikUqJVAIwM7lfkHkucGvQPD9jHA0lw7yzXUgw008hdyOPl9FGecKAOenc+VeIG+y21tqe4o2mTpOWHaPBWTP0RnPPPyjA6E+jeHtVSRRFbxy3MmMExL8i8f3zheMDgEkenWrscc1Y6sdKKaM06kZBRRRQAUUUUAFFFFABSHrS0hpMBsihlKsMqRg180/AG5n0Sz8XRQIRqHmRQebJGRDb+X5m+SVsBVVd27Gct0Ge3vniG4uZLmy0nT5jBc3e95JlALQwJjey543EsijOcbs4OMVzfgHwhpf9kG8LXc0N3ez3wiluGaKQtKTHIy9GO0Ifmz0BrSM2oOPewupq+A9L+zWf26SOSMTRJDbRy/6xbdclS/o7lmdvTcAeVycu4b+zfiJJcOQvnSKrMeB5c8SRqff97aov/bQV6Biua8a6IdUtY57eET3UAZTCX2efE2N8Yb+FvlVlbjDopyBmsxnxBdmcXE7Xu4XfmOZi/DGTLbiSe+Qevt6c/U/7OcUOlfCuS+unSGCW7uLh5X+VVVDsJJ9B5Z/Kvnv4l6VNovjTU4pRdhJm+0q1xB5Ujh8liR0Yhw2WU4PJHbHvngSMW3g/w9pV68V61tbx3Mei2LeZLLKx8wNcMcKiqzZ2nCggZZsAV7WYVlPDU+XqZwVmzpCk2ua/YS3cbRSXLi4jgcfNb2cLh1LDs8kvlEj0XHVDn0AVjeH9MntWuL7UnSTVLwqZjGcpGqj5Ykzg7VyeTySWPGcDZ6V4poZvia7msfDmq3dp/wAfMFpLLFxu+dUJHHfkCvNmWez07QbuB3vJIrzUNPl805aVWleQMx/vERA57lvfn1ieMSxPG4yjgqRjqDXkOvwX+iaZNZhoUuIpIXUXzeXDdvCV8uaKXlVdlRUeNsdyPV01dFQlyyTDVzEnhzUvIAl0qa3kV0PJtm2nPHXHcjtwe/Pq+kyPLplpJKCJHiRmB9SBmvHb3U7HWtGhn0u6SKTVZk0ySF/70jBTx/eUMW//AF17WgAXA6ClHXXr/X9X6m2IlGTTX9ev+fUdQaKQ1TOc8d/akz/wr6xwcD+048n/ALZS18wWiST3lvDAN08siIgB53FgB+OSBnnr+LfXnx90aXWfhnqX2WNpbiyKXiKD1CH5/r8hevn/AOBWiQ6x4/sbi6mjjsdPb7SXkcASyLyignq2SrEegPrXt4HERpYWd3/TMpK8kfU/jbU5tJ8M3d1aukVwCkSSOu4IXdU3Y743Z/Crvh6HydEslKlXaISSAnJLt8zEn1LEn8a4zxNdx+LtX0/RdNkWew3NJczKco64KNgjqoVnG4ceYyYPytj0ReleIamV4n0aLXdGuLKXYrMMxO6bgj9iR3HYjuCQeDWN8Pdae5tZ9H1ANHqemHyZFdixdB0bJ+9joT34bgOK6+uP8Y+HriW7h1zQiYtXthg7AMzp6HJAJHoSAw4JB2sjA6/PFcTqx3eN74jnZp9svbq0k+R+WDWj4d8W2mpiKC622moMSgic4WRh1CEgEkd0IDjuBxnKkP8AxVGuliQ2+HnP8HlLt/8AHt3H/wBeufEtqmyZbDXXzvEOg245xcNOwBz8iRSDd0yPmaMVH4u8XXmm6hOtludbWRIhBHEr+c5EZYuxI2rmaFBt5DPk5HFVFmum12/vY57ax06ygFm+oSsC0TsVaRUTnc+FgAzwDnhsYqdtLEOkSX7W80ET3NnFbRT5MwQXSO0kmed8jsWbPOAucHIDw8eWCCGx6BbypPBHLCwaORQ6sOhBGQakJrF8FAp4T0qE/egt1t2z6xjYf1Wto1sUUtV1G30uye5u2IjXAAUFmdicBVUclicAAdTXgt14Q8Rav8SYxHbQ28ayyXd0xmRxFFJKJRGxAYCQ424IIPONy816ZdT3Ot6xbyWkvlmR5YtPfhhFEmFnutp4LEkRoeQN4PRiK7DS9OttNtBb2ceyPJLEkszserMx5Zj3JyTVwnKF+XqVGcobGTpXhzybz7fqd099f8YZuEXHTC+2TjoBkkBcmuh6UooNQSYPiqJ51sYowC8sksa5GcE28uD+n61p6TMtxpdnMn3JIUcfQqDUOu28k+ns1soa6gZZ4VzjcynO3PbcMqT6NWNZa7badpM4z5kcJD2wJ27oZAWQkn7qqA6knoIycUAdSTXn/jrxFpTCweO5Jms7xHOInKmNsxO27GNqiTcTnHy9a0LzU/EGoWM0MXh+SOG4jKCdLtQ6q3BYK4UhscgHHOPw0bPw/bP4cXT9Qt4i8yb7jZ2lI+ZlPbB4HoAB0FTJcyswaMnw4pvPFtxcrzFp9sbYsB8vmyMrsvTqqon/AH3XYyyLDG0khCxoCzMTwB3Nct8PilrYXmlrFFC1lcOPKijCKAxOWAAGFMgkI9sVwX7Q/j6DStGk8MaZMr6nqCbLrYcmCA8EH/acZAHXBJ9M3h6Lk1TjqStEcd8DVPib40av4gC4gj+03a99plfagz/us/8A3zX05XnHwN8FyeEPCCm/j8vVr9hPdKTkx8fLH+AJz7lq9HrfEVFOo+XZafcNKyCiiisBhWP4uv5NM8OahdQHFwsJWH3lb5UH4sVFbFcp8Qn3WmlWZOEur+JWw204QNKOfrGB+NALc5tLZdP0+2tI/wDVwxJGobHQYHPv/n0zVXpkHJyMYwT+f4n6Y6cnN69Yr1G0lgRgbfT0/wA8dD0rPVtwXnghcbiefQd/VenIPPOaa7nUh424UAAjOQCAOMle+BnnGOOmKkT50HO4DnIwfx5zgYP6VEhAXcGHA4Y447Y49vz+lcz8SfE//COaBi3fbqF2dkBzyg4DNgnjA7+pz6k6UqbqTUI9SZOybZy/xF8dR2txNpWnKsksZ2zOCQoYZymcZPXHGOenUVzmlarq19PH5TADORBCoWNVzyCB26dfb046H4DeDYdRun1/Wog9pFmK2Ei7kaXA3MQeuOgznn1I56zUdLi0zWNX06EARDbf2pU8eXITuA+jCTj029D068TXoYa9KMFJrd76hhqcq0171rlrw/mRgJW555JJ6Z6j8eR/Lvf1t5dL8uWGI+XnG9TyTjpx689vX2xh6XPtuFyRywHPI6f4HHXHvXoDeReaGUuHBDKDw2OCMnk/Unj2/HwudzPdlBUrSscraKusWEj7l+0xHhVBJKnoR/L8Pz5fVbaeK5gvLSQW2oWjF4ZT8wHGCrDoyEfKRnp34Fa0Vy+kX5kQj9zIYplHQr1H5gg9xxTtblgl2zxNlHBB7DPA+vc8flWd7G3Ippp6o9A8Ga/H4g0c3Aj+z3UTiC6g35MMmASM8ZU5Ug8ZU/UVR8XeE9G1G3aW5sYRcyMsZljJjkBZgvJXBPXv7fWuM8B3bWni+JV3CO/tnjcE4DNEQ6HH+60vr688V6ZqhD2KK+CxliPIABww/T5RwP8ACuhr3bngVnKhUai7WOMIs9Cujpvh7RoprxYgZJGbaFBJwrPhiSQDx+uTWJq1ne2Mpu7+1azLuSskRIQE/wAIIJIHXGevpXZaeYh4h1J/PikDsqkL1jYKo2HvyMkHA9OxrWu3KW7ggHcpDDAIOQM5BAz3/LBqMNP2WsUbYLFSpNzl73NvfU4KxvVumew1EI5lHl5YACUYO5SOgOCfqM9MVteArez08QaZrFpaySowht7iSJT9pQA7c8Z3hRgg8/KSPWuf17T4IJ8W8WyElT5aEgIR/dPVfUc8Y4xxTdO1iezRI7yP7VCWG3zfvEg9MnhsY74PGc9K9Fw51eP3G1fDQr+/h+vTr8u57wgCqAoAA4AHanCsDwrc2N1YGTTrqeaMkboZnLNC2ORhvmA9s49OK3lGBWJ5EouLs9xaKKKYgooooAKKKKACkPWlpDQBwmqyzXWvarBaO0V1eSw6OkwP+pRYTPI4/wBrbKQP9oL2BrtrO3itLSG3t0CQwoI0QdFUDAH5Vw87C11y4uHAAtdfid+xKT2iQq303yAZ/wBk13q9KLALSMKWg0AeY+ONG03XvHOmnVbOK7SxltEiWUZUtI0xdSOjcRxnB/rXotjZWtjbiCyt4baFTxHEgRR+ArirfbN43eMnDjV5JW46iOxjVVz/ANtd35/Wu+FHkACiiigAIzTSBTqQ0AefeN7W2TWL6+EMIubfTo5xKEG8+XcBwC3X+Ad69BTpXCeMcT6vf2wYbpbO1tME957lk+uMKxPsK7telIBaDRRTApavu/sq98v7/kvt+u01wPgjwjpU2kXMUEb2kPnoZIbcKsUn7mNlJQggHBHzLhvftXpLqGBBAIIwQa4j4cubPdp8p/ePbRPljy0sIFtMP+A+TF/33QgOo0nR7LSo2Sxh2F8b3Zi7uQMDc7Es3Axya0QKBRSAKQjNLRTAwtc8MWGrM8jgwXEgCySRqrCUDoJEYFHA7bgcdsVgx+Apba6ln07Vo7BpIvKf7Pp8SBsZ2sR93cNxwcdDgg4GO7opOKas0BzPhzwhZ6PFb+dNLfzwZMUlwBiMk5ZlUDAZiSSxyxycnGAJ/F7qtjYwFwrTaha7ckD7kqyt1P8AdjY/hW/XC+M521TU00+2LYjzab1OMXE6lTtP96OAyuf95fpTA3/BSn/hE9Kc7g01ukxDdQXG8j/x6r+rytBpd5Mh2tHC7g+hCk1ZiRY41SMBUQbQB2Aqj4hhkuNB1KCDmaW2kROcfMVIH60AYPg6Bft+QoCWml2drGCOU4Zmx9QY/wDvkV1wrlvC9xG2rzeUR5N7p9rdwEfxDDK2D7AR/wDfQrqhSAKKKKYCEZry7x5bXem6/aNbwq+mslxOVUnczMpDpgA5AZvMPfDSEA7ePUqp6pp1tqdt5F5HvQEMrAlWRh0ZWHKsPUHNKwFbRNb0/W7cS6fcpIdoZoww3JnpkA/kRwexPWtPrzXmmteHrnSrmOaC4eKYuBb6imEBlY4CXCj5QzHAEqqMkgOCOH67whrv9t6axnjMF/buYbmFgQVcEg/hkHpkcEZOMkA4r4zaRrEenzan4Yvbixu5F2SNBIULHgYJ7bgqrxzuVAPvNVD4VfB+30O7i17xHdR6prBbzogjF4YmJ3B9x5kf0Y9PrzXrl7aw3tpNbXKb4ZVKsvTj69j71k+FbK+0yzks71o3hiYiB1OCVyewGAOhAHTJUDCgnSNWUYuK0v8A1uK2puAYpaKKgYUUUUAFcZ41dm8Q6HAOgiubjg4IKeWuQe3EhOa7OuI8YjPjHRycYWxuj9Png/zxzQVHcxblgXVW+ZTyQo47f4+nXv2NRtzBueMHtnBIOD9D/XBzVy9UhuMrjJA6jpkH0PTjt/KquNpyqkAEkZHTpjP5Yx1+nSnE6BQq7852gHIPTaMk9T6HtjvjpyfnT4ha5/bniW5uIGzZwkw2w5xsU9evcgt+IH8Jr1/4m6udH8JXRhZkuLrFrGecjPX6nbu9eee5rj/gx4JtvEVprN7qQ/0fZ9ihJwcSOOXB9VypB9816uB5KFOWJn6I5qt5SUEe7+AG0lfCOlReH5kl01IljQryW/vbsfxE7ifc+9YnxLtfsdpp3iGFR/xL5THdEcA28pAckD0bY/8AuqTXJfD/AMKRXWnXNvb3t74f8UaY/wBlvWtZPkmP/LOR4z8rhlI54yck57934P1Qa5otxpfiKazfVYpJ7G+t1YDzACVLbOu11IPpz715NemuZtO+vzNqc3BqSPPn/c3JjB4ONvHXPQ+vv+Z9zvWfiExWoibdjtg9ev8A9f8Azmua8Q6RN4YuotMvXlmgwRZ3JGd8QPCE92XgH1ABx2GWZRyfMUDHTrxg+/Pb8+uea8/2bT0PoqVWNWKaNa4u1/tzGf3N2DEw6AMMsp44zjd+X5UXeTBgbewXKntkc8/kBx9OnfNv5o2iS2hkBvZZEaIld20qyEtjg4wMde4HGRXQeF/D2seItRuUg+xrYRvsmvA7MA2PuhNo3MBkkbsDPJya0VMmdWNK8paI0/CEJvfF+neUgC2ImnlYYIBKFAufUmQHGOgIHTFej3kgknij3FQpLtk4yTkBfyyfpt7YpND8PWnh63+z2xZ5Wx5k743yntn0GMgDGB9Sc5d2kl3byahali0EgkjXGdwwOPf5CF7fxe9VUvKPKjwcVV9tNyRm+HrV5rS8lRibw3MkrEg7iS+4+hyrbSM4Py44ya6BNSgnRoyJY5kwGRYy+3GcD5QSAM5+YA+3ph28n9leKHk3gW04EjYP3lIHzD3GDn2AP97HW6vpltqmnGR4I5ZQhYZUfMpHzJ9DyMZx09Aandc0TKMtPdOI8VWyGykkSRGKMoK9x83BK9f0/rWRpVxCFeC4U+S/RpBkde/0x175/K7fNbWWhtIbCGJmICCHIhIyQdy8DPyMNwAPA56FpY4o0kSz1GF4BJ80fmHmEnGV3DqOc57gjIzkDrpVbwtJHpUqidHkkt3oRRtdeGroalpsheBSQ6sSQFzjDdMr056rjvyR6z4d1q21zTlurbK4O1426o2M49+CDn0NeZG31Cw3QRIk8JOQGA79QckAc5GOlTeCb6LSNcjMTMun3jCBw4P7tjjbnnj5iR0H3j6Vd+Zb3FWXt4c0viXXv5M9copopwqDygooopgFFFFABQaKKAOS8XWkNvdm9u8rpl7B9g1CQNtMK5Jimz22szAntvB6KavaBq0vmLpOslY9YhXDHG1LpR/y1j9QepXqp4PGCd2SNZEZJFDowwysMgj3rktR8KOluINPNvc2CkMmn34JSMjp5Moy8WO33gP4QKAOuzUN5dwWVtJcXc0cMEY3PJIwVVHqSa4hI9Ztl8pV8VQbeAkM1ndIfpJMC/b+PH0qS10vUZbiK5m0Z7ueI7kk1vUhuQ56rHEjxqf9pcGgCO1Lrrmn65MjQQalqciosqlWWN7ZUQsP4SzW6kA8/OoPPTvQa5TVLq7msJrTxDos6WzqC1zpsxuBGQchgAFkDAgEFUOCAag0fxHesvkRGy19Y8KZ7G6jjnPvLC5UK3rhuvRR0CA7OisA+ILhM+f4f1mLH+zDJn/viRqX/hJFZtsek6y79h9kK5/4E2F/WmBvVT1bUbfS7GW7vHKxJgYUZZ2JwqqByzEkAAckkCuZ1TxfPbbUazttNkfGP7UvI1c/7kURdpG/2cqT61TtbXVdXvI7tVmadchNQvrfyY7YHg/Z7Vvm3Hkb5OeerD5aQD9AtbnUPEZlvlCzW8pvrtAQwjnePZDBkcHy4iS3bc6sOtd0OlUtH0yDSrFbW1DbQWZ3dtzyOxyzse7Ekkmr1ABRRRTACK4nWrKew1vfaPFFJPMLmxkk4Tzyu2W3YgcLIq7h1+bJwSFz21V9QsrfULSS1vIllgkGGRvrkEehBAII5BANAFbRtVg1W0MsIdJI2Mc0Egw8Mg6ow9R69CMEEgg1oA1xeoaHqtldLdWUs15IiiNLiORUuggPCOG/dzryfvFWHOCSc1FH4svLJxHqP9nZzjN20mnSMfRUkVkc+6yYNIDuqK5+DxGZEEkmj6pHEekiLHOp46jynYn8qk/4SexHBt9XB/7BN1/8bouBuUnesT/hJrI8LbauT6f2VdD9THis/VvFM9oi/wCgJZbziOTUrlIvM642RoXdz/s4Umi4Gv4g1M6daKtsizahct5VpATjzJCO/wDsgAsx7KD9Kw/Btgk0y3+8z28AZLedhg3MrHM1yR/tEbV7BQcfKwFVNP0S91y6e61dpFtpk2StKnlSzRnnyljzmGE/xAku+AGIAwe5jRY41RFCqowFAwAPSmA4dKD1paQjmgDg5YrnSL6Czt4ybixaSbTQMAXVo2DJag54dONo7hIzzh8dnpt9b6jZRXVlIJYJBkEdQe4IPIIPBB5BGDUer6Zb6pZm3ud4wQ8ckbbXicdHVuzD/wCscjiuPuJbzQbuS4vJ4rCZz810yn7BengBpQP9RLwBuzg8ff4VQDvh0ornoPEUkcKNqGlX0SsARLaL9sifP90x5cj3ZFqT/hKdLBwzXit/daxnU/TBTr7UAbtIxxWGfE9mVPkWmqzMBkBdOnUH/gTqF/M1iXni+8uJza6ZaRpcg7WjyLuZD6FIj5a/V5VA70mBveL57aLw9ex3ieaLmJraOAfend1IWNR3J/TqcAE1zvhOxubnxNLrNrPAbIwpazyKp/0yVFw8qnuu7aoP/TM44OafZeFr3UpvtGvzvtZdrqZA8zqeqF1AWJT0KxjnAy55B7aGNIYkiiRY40AVUUYCgdAB6UAOxxQBilopgAGKKKKACiiigAriPGR2eMNDbpusrxc4zzug4+mM129cX8R49k2hXfQR3TQu2cYV4n/9mVP0oHHcyLs7lAUKWxtx156en+fp0z5mVVJQAjB4I4I2sR9Rhf1+tW7+RT8xO3uMdBx9R6+ueuT1zQPDfN1zyM56HnP48++M92FCOnc8h+N18X1Ww08MB5MbStnj5mOAT7/IDntu/GvaPhToyaP8NdKhdMSXERuZF7nzBuA9eFKj/gPevAPiFHJqXxHuLI5O+WG2UZPOVUdfXLn8+/UfVxaOKzj8nAiAGxegwAMdvw+pI+vfmHuUKVJdrnPT1k5HBeNyfD/ifRvFUe+O2VvsGqSKMhrdz8rtjsp5ycc+1WJrzwn4zumttL1O1bXYQJYby1GLiJl6FWI+YDPK88dfUdXv3RlXwyFSDuxhh39cjnGOe3UVU1vw1oet2sUGo6dERA26IxgxvGcE/KVwR05HqPxrg542XNuuv9f5mjTuRQaPqF9Zyaf4pl0/VLRl24W0eJ8jBBJLnBGewGD6c5525+FmjyFxDe6rboxyAlwrbPxZCx/EnvVu203VvB17KdKjvdb8Oyp81kbgNcWrjnMZdvmQ85TOQRxWj4V8WjxM8jWej6nFbRymF5p/KUwuPvLJH5hdfpjuOOlS6b+Jar+unQqFXl20MbTPhBodrmSXUNVuUb70bzLH5g6YLqu/2+93+lehaRY2umWMdlptvFbWduuyOOFNioPoPryfUn0pIpCjY5I7D8j/ACxUy7k7jPAGPqen69MelTPbyCTb3ZQ1hCtnOpYLuXYM8dSF9+5H58VX0GPZolsxVV8wNOQR90yEuRjkcFiOvPXjqK3i3UFso7KFkLi5kBEYON6rjJ9wAQ3b7nvxaCPJ4cQI20mBTnHGMKSD6ZB/X88Yt3Mr6nL3iw3SwvErr9il6Et/q2dlTk9xtU+xBB6Guh0SSS1u5NPuARxuifHGMdPboeOcFTjjGcmeFV0bEC4DWjg7wSTIhJOfVtznPqee5rTnje/0qC6tctPD8ykdxkZwPwBx3HHAJpRVk0iI6HGsx1XxM1laTmC0LymCR498buMPtwODyMhTj5UHXBx117pM+u6UDqENvDqEajmCQlHx0IYrkd8ZBxuxyDzkeB7pIbU2d8IxGZTLBKOVLHqMn+LuOncdenbb1jbIxx904zjr3/Pr6/XFVVyvTZbHdWSUvc2Wx5zZ6nLp8jWGqpJ5aEIkvoM98A8/e465DY3Dq7W7ZBYyXaP/AKFLiK5KMCFDfdk46YOAfp9a39fQXWryR2kKSsYA8y8kHHDZH8RIKcHqMcggGsRFis1BV86feN5M8D8+WT6HHQggZ9+R0w41L6bMulU5nbZ/memeH7ie60Symu9v2lol83Z03gYbHtkGtEVxvhO4m07U/wCxbqQyK8HnxSHjLDG8fiSD/wB9V2K9K2i76nDOPLKwtFFFUQFFFFABRRRQAUUUUAJj3oxS0UAJiqOoaRp2pYOoWFpdEcDz4VfH5ir9FFgMEeEtGT/j2tXsx022c8lsv5Rsoo/4RPSm4mW8uFPVLi+nmU/VXcit6igCjpukadpaMum2FraK33hBEsefrgc1dAwKWigAFFFFABRRRQAUUUUAGKayhgQQCCMEY606igDGl8L6HJKZf7JskmPBljhVH/76XBpv/CM6f/DJqSD0j1K5QfkJK26KAMQeGNOxhzfSj0lv55B/485zVvTtF03TGZtPsLS1dhhnhiVGb6kDJ6CtCilYBMUtFFMAooo70AFIVB68j0paKAMSTwroTyPINKs4pXO5pIYxEzHOckrgmm/8IppHIMEzA8ENdSsD+Bat2igDCPhDw83MujWEzdczQLIfzbPt+QrYt7eK2iWK3iSKJRhURQoH4CpaKAExS0UUAFFFFABRRRQAUUUUAFYvjDT5NT8PXdvbqGuQBNAp4zJGwdBntllA/GtqmsKGB5NFNHe2cdxB80ToGXIxxt7jtkHHJ9uKZ82VByxJ7njsPzP8zV/xRpj+HdUlukB/sW9kLFh0tJm6g88I5OQezEg8MoFMhTk7VVeeDkD3yMnjnB6Y49qLs6Iu54j46RdP+J8FyxVY2ltrjJ4wqsqnr0xg/p9K+pHRAphfAZvXgHOcn+f6+1fNfxws2+2aZecgyRvAxJycgjH4/Pj6gdq908GayNe8Kabeb1Z57cFtw6noR74YEf5568cnOjSqLtYzp6ScTejt8tjOHxk4IPOf165/E561Gh8s7GwB2B4wOwH8vy/BrXGPvLtwB6EDgn+p/KleUFiV4IJ25HGRkZxnpjbx/UGuCN3uWydGIwFOOR7Z6f4j8/asaeyurPxNFq+mR7o7uNbe/j3BCQCNkoycErkgg87TjsBWiJOB9M4IPQH2HOBkH8Mezops4Dd8e4yR3wT6n8s+9O1r2Fa+5ZUkkMe+Dyfxxn9Pw/OeJl8vGQFUBj0GOnUfp7cdKoS3EUCGSRtiZwGPcnIAHc5x79PaqMmuIkNy8Sk+RGZCBgkYGc9ePr6fSnyOaskNtbFLxbbXk17Dfh4rfTbCCZp55PvHKnKqOw7liegq7JcS2vh/SrXbGby4gihVZW2gttHGcE9c9s8HggYrL8PSXGt6HBHPcoFnQsyvHuEi4JAxjn8/bvUN3pU+o+I4LTVtQuYIoXW4gYyg+ftzyDk4AOTzyfTpUyp2bVzNvrYu2fm2tldQ3s6NdadcMHbG0GJ+fwztD4Oe4FM0uRkjutJku7e1ycCV3w3lEHbt7E4+XceM54NSWOk2Z13Vo3R5ynlHMzZyWXp1x1U9uDWcsEQ1SxURpJFCsqMrID8nmARjB6YAb16d6iNoyVgheLTRo3WlDTr6GLSmhgguYwI/MGVdhwFJ5AB65wTlzjOTVjSr8sZ7S7tTaXyEs0YOQR/eXB6Hg+/1yBrto9hPYzR28EduZNpDoPuuM4PB7E9PQ1jXXm3ujx3hyb20k25x95SQcEn04y3sexxWcnbS5UZNMsacLW1ubiaNI0nuGBkfcSW2gAc57Dp0AHP0y/EdlAXcIFEdznbgYCSZ9B3DEepG9zVq5IaNJY3IikUMvH8JGQDz6Be3rnOM1malE91bGJZmjl6pKF3FT9T9cY49qfJd80Td910I5NSeOTw1qfQ29wIJs9lYbDn6Ak16svSvCPG13FZQPpMaM91PJFLlSBgn75X14JPFe26TcG70y0uSNpmiSTHpuUH+tdSi1G4YqnJRjNrct0UUUHGFFIzBVLMQFAySTgAVyEXjc6kXfwzoGra3ZqSPtsHkw28mOD5bSyJ5nPG5QVP96gDsKKwfDviiy1u5uLMRXVhqlsoeewvY/LmRScBgASroTxuQsueM5reoAKKKKACiiigAooooAKKKKACiiigAooooAKKK5W68YpJqNzY6BpGo65PbP5dxJaeWkELjqhlkdVLDuq7iDwcUAdVRXOaL4str/Uxpd/ZX2j6uyGRLS+RQZVHUxujNHJjuFYkdwK6OgAooooAKKKKACiiigAooooAKO9FFABRRRQAUVieI/EtloTW8M0dzd6hdbvs1jZx+ZPNjqQvACjIyzEKMjJGRWVN42k00CbxH4c1jR7Dq17L5M8UX/XTyZHKD1YjaO7UAdhRTY3SWNZI2V0YBlZTkEHoQadQAUUUUAFFFFABRRRQAUUUUAFFFFAEN1BFdW8sFzGksEqlHjdQysD1BHcV5vrnhu/0AvNpcc1/pQywiGZJ7b2GeZE546uP9ocD06kI5oGm1sfOfxA06LxN4SkOnss8luxmh2HO7GQyg+pXtg8gjk8CP9n7W92kX+lvIN9tILiIHnG7OR+Y7Hv3zXtuveENM1aWS5USWWoOObu1IVm9N4IKv/wACBx2xXz1YaVceBfjU2l3kiLa3zfuphEVjkWT7vGePn+TqQMemK7qU1VoToS9UF/fUj2ySdJS7RSBlGVzwcHoAc+mfyOKUScgEAknp0HXPX0weCf7xrkdc0zULVjNYrdKpAIktzwVx0cA8jn36571zE3iXWbY7Li7aM9MTwIhxx6jI4x2rGlhHV/hyX3mkqvL8SZ6qJAwx97I6jvx2/M/ic/XD1jxdp+nOyK5uLjklU+4nf5m6cFjwCTnPBwCfOrjX9T1FXR72eZMYdYVHAyBg+WM468HjAHrik8M3emRTmTUIftPzZXZgrCDgjMY6n8T0GADweqOB5VzTd/Jf1+SMpVrvTRd2dvp1xqXiac3EqyW1iej8qWX+7H6A4GXPXqM9Rt+J7iDSvB+orABEhhMa7R1ZzjJ9Tzk9yfSpba4jkiWWF0dHUOjDG08EjGPTJ59/TisPxa8d3qGk6ZIVELym5nLHgRRqCQ3sRnnvgfhw39pNJqyXQ2lHliddpWjRp4W020k+W4trVFDqeUcLknP1x1//AFWhBb6tpULXqbyF3LI2dyN657HP9T3qtpPiXRrpxFDqVq0pPyp5gDH6A9eM+tT3H+jW8I27VaZAqr8vBYZHHvnI+vvXPK922tSbojdE0yN44Q0txO5Z2kyzuSD1xycDHAwfX0PPSTSx3aFoyrpIlvMrNkhCx8tie+TkfXjtmtbT55bzUbO8f/VXRLQqVwRGA2O/OQ+Rx7ewqeLl+z3huI8fvYFGABg7ZI9pB9AG9fx4rC95c3YT7nZWkYSONR8xA4HXI/n/APr78VzXh6eKB7vRbxFE0SsChyfPjOPmzxkHPuDle+QN6wkJjTcfmG0559P8AT+J9awfGVlLPbJqVizxajZAyqVXd5iD7yH1yM4x3PoSKJLXUu2pWt7O7t5Lq0bZLZKd9vICdxDFso6gdiMg9CTjA4rO1C+sNJcvfzb5xjbBEQzsSCQTjoPc8cj0NWNYvtQubWxj0hfIkvYy8l0ykpbJhd3Ofv7iAAP6VneRpHhuwnv2V7iaJS7Tz/PI7EjGDjgsSM4Hvz30hotTqpqNk5HKvaSap4xtrnVYRvug7iA/eSPb8hI6jlAD0ztB74r6DgjSKFI41CxqAqqOgA6CvG9J06e01vSLzVMm9v5v34bpGWOFT04HHU9MdhXsydK6G7pEY2fM4pbIdRRRSOI5L4oHd4VFo7tHb399Z2Fw6kjEM1xHHIM9tysUz23V51+0T4j1jSPD9xpHhxdV0eztLIXMmpWNnOEyDtjt45Y12xj+JiSuAAo+8a9i1/SbXXdGu9Mvw5trlCjFG2svcMp7MCAQexArlJT4li06XSPEPh208UWbL5f2iGWJBcr286CXCq3AztLAnkAdAAZguFuvDXw58Qo051QTWlv5syOssyTIEmVt4DEH/Wc9TGre9ct8Wpdevfi/a6No19dRwt4cmuRANZuNPiSUSOBMTFncy8cEYPcivRdE0PU77V7LU/EMFnYW2moV0zSbNy6QErsMkjYUM4QlVVQFUM3LZyNnW/Cvh7XrhLjXNB0nUp408tJLyzjmZVyTgFgSBkk496APB7P4xapafDvQX0a8Op60uiy6hdR3+nF3dIXdGleX7TGFUmNgMCRjwcEnFbutfFzxDZ2Ghazc6ZFpHhi+02C7m1VtPk1GNJ5cfu2CSxmNRyMncSSvHNes6j4S8N6klsuo+H9Iu1to/JgE9lHIIk/urlflX2HFRP4K8KvcW9w/hrRGnt1SOGQ2ERaJV4VVO3IA7AdKAPMbT4peLdW8U6umi6FYyaHpOsjTbvz5YonWLO0y+a9wpDE42r5TA9N2eK9urHuvC+gXerpqt3oelT6ohBW8ltI2mUjoQ5G4Y7c1sUAFFFFABRRRQAUUUUAFFFFAHPfEO/udK8BeIr+xYpdW2nzyxuP4GWNiG/Dr+Fcb478J6idM8H6R4K1SHT7Wwm3y2Z1Waxa/gVRuQSQgsSc5Ldt2a9PuIYrm3lguI1khlUo6MMhlIwQR6EV5xP4ZvbCxg0fVfDmneNNCtCfsBuvKNzbJjCxusw2PgcCQMGIHIJ5IBhWWtWXiL4KS67Y217Z3Wl3ZuLcXl/JevHcwyAfJPIxZ1blO2QzDFQ/tBXfiRfGPw90/wnq11YXl3LeMI4pmSK4eNI3RJVBAZSRjnIwxrs7PQdS1t9Ph1XTbPQvDmnypNDpNs6u80iMGTzdoCIisAwRd2SASQBg9fd6Xp97e2d5eWNrcXdmWa2nlhV3gLDDFGIyuQBnGM4oA+aG8T+NNL1/4jXPii5nW8i0Jb9NJW9lFvZFpVCojRSKQQmMuhUkk80/4qeONW8SeAfFuiRrY2lhpWj6ZcXPnJJLPdPP5T/u3MnyqpIBLByT3ycj6Nu/D+jXs93PeaRp1xNdxCC5kltkdpoxyEckZZeOh4qrqHg/wzqTxPqPh3Rrt4ohBG09jFIUjHRBleFHp0oAteFv+RY0j/rzh/wDQBWnTYo0hiSOJFSNFCqijAUDoAOwp1ABRRRQAUUUUAFFFFABRRRQB5qb2axtPiZ4mtoln1qxMsECNltkcFsskcY9iztIQOpkrlPgx4luJNX0LTtfF7f6nruif2mt+dZmuonUsNyvbMFjhIIwNgPQjPJr0fWNF1XT/ABDNr/hc20sl0ipqGnXLmNLrYMJIkgB2SBfl5BDDAOMA1j6fpuqW73CeFfBOkeFbm6GLjUpPs5Kjn5ljhyZWB5AcqOcnPQgD/DOr2vhLwD4innbOlaBdXqQKD0hjYssQP+znyx/ugdq8a+E/xB8T6Le6ufEt/qF9NrGhz63p6ajFcLFFPEJJPKj8zG5CmGzGduAAD3r6M0/wrpNr4Xj8Pz2kV/poH72O9RZhOxbezyAjDMXJYnHU5pfEPhXRtf037HqFhbMEt5ba3mEKGS1WRNjGJiDsOMdPQUAeNaf8afEFpbaZd6zYabfw6j4fn1lINPhkikt3izw5aR8odp+bAx7450tB+IfjnUNCu9TvLLQLCxl0Y6pY31yyLHvUqWjaNLp3ZMNjzPkIOMoOlejeCPAnh/wZpUVno2n26yLCIJLt4Y/tFwo/56uqjd+NTReB/CcUd1HF4X0JEuhtuFXT4gJhndhxt+bkA89xmgDnvhN421LxydVvbqCzsLG3aKKKxKt9rjZoldmlJbAUljtAXkDOa9Dqlb6Tp1tqM9/bWFpDfTosctzHCqySKowqswGSABwD0q7QAUUUUAFFFFABRRRQAUUUUAFeR/tE+FF1rw7aazGr+fpDl5WiUF/IYjeR67cB/oGHevXKjmRJEZJAGRhtZWGQQexpxk4vmQHiPgn4g2Vvpktn4vvI7PVLLbulflbtD9yWMgEtkc8ZznPO412um32m6/ZC90e7hurd8pviOQDtwQe4xgcfp687L4N0XSbyz0vWbC3u7aOQ/wBl3NxHu/dk5EDNjkpzhWzlQCM4bbgeKfBl1YRXOqeA7m5064dQbmxtZPLW5UEZKZ+6+MYwMen+1Mo0pysrxb9Lf5o3Tdr7nftZMeVBYEYBH+f8jH1rm/E2hx6jBJtSNNQjB8qUjnPXax6lTgZB6cdwKqeE7eHU9LtdT0nxBr4V2w8dxOszIwJyjK6kA9OnqMe/WTr9o24BIC8AAZ6HAx+XT1Hc5MKcqU7p6o0aUo67M8z0HxHcaUj2ItHnJkIjR32FHLYKE4IHPIz6ntius0HS5ftF1e6w8b3d0nlEL92KM/wA++eR0+vJOJ4801F8u9RFzIfKkA5D8Hafc8Fc98j0ptj4wt7XS4EuPPuLvBQcFS/OBycE8YzjJ5r0qsZV4KtRW+/kzlg1CXJN7bHQ+CbGzvNLu9G1Szglu9PlMLsUAZlJJV9w5BIBx9Pz6nTtImjmja6v5Li2t1xCrqFYcAAse54AzjvXMeClu5dUv9W1ERxNdqiJCpDbVA6sQOeAOB79K6vVtR+w6RcyqQZNh8oZAJfAAX3/AJV5taVqll/TNlG8dinqLXE+rXX2VlhWziEnKgc5YgZPA+63/jvTNQ+I5zf6bbXITYWieRx2VkdGI/Q8/wD16ZBpt680tqbhGimZJbh1OWULGo2Y9S4Y9ABx6YOrrlsJNLWOCESeUMpFj76gEFRnuVyPqfrXM09bEOLszR064WS3XYykqMED2xj+v4H8KoeJ7yTTvDuo3UcQZkhPROx4J/AZPccemM8nYeJrXSpUtr6ZfO2gBi4LSqOj4ByMrgnIAGcV1kOpwy2zupR42U5U8jpzx35x9eaudnsXFXV0UIIktNItY4JBLFHGMOnzKx7kY7HORz0IxjHOLqdst21uJXYLFOsxUdHK9Mn/AHire+33q3aW8emaUtijq0UUkhTriKMuWROf7oIX0wPyrXDyKrmJQzhTsQkruIGMZwcc4ycce9aQVrGuyE1HzHvNHaPa0iXke1DnDfMvJwewBH416snSvHtHuNS/4TLRbW5gtvlkLDyWYrtKNnII427c5+npivYE6Vt0RGIulFPsOooooOYKKKKACiiigAoFFFABRTZGVFLOQqgElicACuW1HxlZea1toIXWL4HaVt5P3MR7+bKAVTHpy3oppNqKuwOrorz+R/Et2d11rUdgpwRHYWqgrz0Lzb89DyFX8KrnR5GA8/XNdlfOdxvni9O0e0dMeneud4umnYnmR6RRXl2ppd6Npl1f2viHWY0t4nl8uSRLgPgZx+9Rj6Dgg8jkU6x8aa/pdrZya5Y2mq20qqr3OmZidXPBHlOxB5zzvB9FzWlOqqmqNIQlU+FXPT6Ky9E1nTtbs/tGmXAmQHa6lSjxt/ddGAZW9iAa016VqSLRRRQAUUUUAFFFFABRRRQAUVn6zq9jpEUb6hOI/MbbGgUu8jeiouWY454B4rn5PF15Ng6foF2ykZWS8mjgVvwBZwfqo/wiU4x3YXsdhRXGf8JF4hAydE0rvwNVfn6f6PzzUD/EG2sbyG017Tb2ylmVpFkhAuYioKgnKfOOXUcoOvsaUasZu0WC1dkd1RVDStUsdWtPtGmXkF3ASRvicMAe4OOhHcHkVeXpWgC0UUUAFJS0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVr+zttQtJbW9hjntpRh45FyrVxmpaDqOjkyaS0uo2XJa2kcGeMY/hY/fHThiG6ncxwK7ykNKSTVmNSa2PDJ9Lu5NTvNV8E6pBYXlw4N7YXURMUkg7lcbkfHUYBPGfShPH8+i+ZbeMNEu7W7XISa0jM0FxwPuknvz1PGeSOK9a1rw7YarKs8qNBeqMJd25CSgZzgnow/wBlgV9q5u60/WdIT95GNRtlX/X2ykSgD+9FnJ7D5CScD5RRzLacbr8fv6mqmns7M4JfHugeInbR9dstQ0g3W0wS3iCMMMgqc5POQOvyn16Cquu+Dl0+xu7qC6JkSMuWZAWZQOct6gZ/EDjqD2l5/ZPiGzls76GG6hDFXilUExtyORwUYBh6H5RXE6vHd+GLGTT7qV7rwxIyC2u3bc9kCw/dSt1Cjna547Gt6FaUXy0W4+V9H6dRVaaavJXKU+jNY6XbalazOjGNJZQAEeIEdcjsCfT15wAK34vEMmrnSYRlL1XPnK0ZKhgB8xycEHAI56Hrmt2wEd3ZLJb+W8O3AZGDpwOeQcY5rlrS0j0bxa8CxJHBdIREMAY9AD2wcjH+0g7c6Or7dONRXlHVf5MlQVNpx2Z6FpVy0MbfaWR55pDIxXOMk4wO5AUY5wePxrViuklRdpIOMkH6L+eM/r9a5GOZjySTu5we/oP6n259zoWl0FfIYhRzkd+uDnP1/OvNnTe6OiyIfEmhxyxFxCkkTYARsqVbd8oyO248HqhJIO3IGBNLL4b8m5WSeXRbkKyzNx5RYAhXwML168DOfw7XVZC+lzvkHZhyR22kEnPTpjpxx9DVO2Ii0+MOu9OYnU85KswP8iO3GfXjGN07EpWlZFQOlxbxyoQEcBge2Ov06Y9uardT8vOc/mAO+PUY7nj8pDBZ2cUkFhDHBExLGOMYUEgZIXovr0A5981HGPnaSThOrMc4xjnBz/nj0rrgmyy/4JRr/wAaX14oY29lbC13Y+UyFi3B74GQePSvSFORWR4W0qLSNISCKLy3kdp5uSSZHO5iSeSecfgK2BVt6nPVnzyuFFFFBmFFFFABRRSGgBssixxs8jKiKCzMxwAB3Jrxfx78eNL0p5LTwvCmq3Sjm6ckWycgZBHMnc8YGASGriviH4o1r4m+OG8KeGZSdJSVogiMQk+zIeWRh/AOcdQcDGWIA9C0b4TeEvBWhXGq61b/ANtXdlA9zLLdLuT5VYnbF931xkMeldapU6KUq+rfRfqybt7HmPgubXvir4llm8V3091odjh5rUHZbvIRlY9gwrDqTkE8Dn5q9g0cDR5Y9GlwIFUiycjG5AP9WT/fUAnnqozyQxqXwtp72OkxpcBBeTkz3RQcGV23MBjIwPugc4VQB0FNuNPk8W3EmlwO8Gn2zqbu8iYq6yAhhHCw+6w6lv4c4HzE7fFrVfrVZ8qsvLp/X4keRLc6xDFetZWcF1f6ioG+1s03Og/22JCR57byM570oTxUyho/DtqiY4V9SCyDjj5VQrn/AIF3612uj6XZaRYpZ6bbR21uhJCIOpPUk9ST3J5NXa2jhoLfUtQSPG/F2pXqjT7fVNKvNKtxcpPcXF3sa2xHhlUyozKuZAnLbRgH1q9DLFLbSXdonm2cgX7Va9dh45X16A8enXjI9SuGiSGRp2RYgp3lzhQO+c15lr2h22kxf8JL4LkjksFBN3Z2rCSJ4+rPEBnBHJKrwwzgbuu0KUYxsv6/rp2OvDVI0/dfX+v6fQoPDPYXsGpaTOi3QwsFxn5bhOf3E/qvOFbGUPI7qfTPDOswa9o8F/bq8YfKyRP9+GRTh42/2lYEH6V59BNDLbPd2kayWUmPtFqoztJAO5fUYx9eMe1nwFL/AGT4tubBJxLp2rW/2u1OfuyxbUkX6lWT/v2aa8/6/wCD+e6NcVSVufr/AF9z/B7o9NopB0pao4QooooAKDRVXUruCwsri8vJBFa28bTSyN0RFBLE/QA0AZni/wAUaT4S0l9R1u6WGIZCIOZJWxnai9z+g6nAya8dsPiX4m+IXiSbS/DWzQdJhjaS4u/KE1wq8qoy3yKWPbB4U88VyVhaah8Y/Fupa1rN09j4c08M0hzn7PEPmWNe2/ALFu3UjkA+qfD/AECz0TQQbSyFo14ftMkeSzpuHyozEnJVcAk9wT3qsW4Yaly7zf3L/P8AIhyZc8O28BeZpkY6wuIrp5ZGmkPoQ7fN5Z5KgcdsAggXLzWLG0uBBNNvuXAYW0EbTSlc9fLQFiOfSq40u48S6uGsbmaztbRmhub6HG6b+9Am4HuQS+PlPA5LEdzpGk2Ok27RadbRwIx3OV+9I395mPLH3JJrzoYZ1PemxKLerOFPiG0jQvdW+qWqgczXOm3ESL/tFmTav4kd+lYun38GpX2pasRHd6NcOLKOSJgwVIcgtx6uz8+igjtXsVcxrng+xvppLvTyNM1NxzcwIMS+0sfCyD68jsRW8cPGDujak1TlzPU4xrM2F8txDdNaXL4EGoxAZcdkmXgSL9fqpU8jvvC+tnVoZ4buEW2p2jBLqANkAnO11JHKNgkHrwQcEEV5/Zzva/arDVYEVIGEV1DkkQkjKuh6tG3BB6g5B5BFSi4l8P67pN8zLJaNKtq9wD9+CQgBW9djsrA9hvxwTWibvr/w/wDwe6+46q1JT9+P/D/8Huvmj1iimjpThWhxhRRRQAUhqOeVIYnlmdY4kUs7u2AoHUk9hXzB8RPH2t/EPWJdE8LC4i0QSrAzIpXztzbQ8p4whOML6dckYXSnSdS72S3bE3Y+gLzxfpiyy2+mSDVL2M7XitGDLG3pI+dqfQndjoprKln1y7x9o1b7Fu6JYwpgZ7bpA2T7/L06DpXKaPpMfw+05FtS0uijDXJPLQScAygd0bjKg8cEZyRXX2GmanqyCUyzaTZtjb8gN1IB0yHBWMdOCC3rtOc+dKdSrL93t3Ju3oip9iuCCzaxqrPgZb7UQAfoML9eKmil1uyw1rqxuwckRX8KsCB2DIEI7jJ39OhrV/4RKzV/MhvNVilHRheyOP8AvlyV7DqO1ZF/ZapoUZmnf+1dOQEvKkQW4iXk5ZF4kA7ldrAAYVqUqdeOqlf5/wCYe8jb0bxIl5dJYahbtYakwJWFnDpLjOfLfA3YAJIIVgOSoHNdAK8f1DUZdbsbaSCEWekyOrpfHDTKRgq8arnyznkM2SMcp3r0fwnqMmo6Vm6Km8t3MFxtGAXXGGA7BlKsB2DCumlKTXvI05JJJyW5tUUUVqIKKKKACiig0AFFFFABRRiigAooooAKKKKAMvVtC0zVmVr+zjllQYWYZWRBnorrhh+BrAn8Hzwk/wBmarIEII8q9iE64wRtDAq3OerFq7Oik1cak1seSy+A3srlriDSXt5m5abRb0wlsdCyEoDxnjDdaL6OyNotprE13nIIk1CHyG79G2opPTlfXvXrWBSMoYEMAQeCCOtTy63NPavqeMQ6ddQtG9lqiyWpAPl3MYk3DHHzAjI9Ow/Kr/lyR9N2c9c46EDqfX69T3BrvbzwtolyzM2mwRyOSWktwYXbPqyYJ/Os+XwZBnNpqF/AuchC6yKP++hu/wDHqvf4ilVj2OegvnTMcils5GOT0x1HpjH6cjvni5eBngQMyMdyqoLEjkfKOpYAcqOu3cOSwrpZPCepKgC31ncL02PbmMenUM3v271XuPDWsNGVa102ZWxuVrl+ec85j7Vm6SbuhucXszChcTruQh0J/hGRnn07g9R/PIrX8LWv2/WWjABgtNsk8mc5fPyR+p6At7Ko5ycWbPwVPPKsuoSJbMOvkP57sPTfIuR6dPyrsNI0200mz+zWEIhh3Fyo7k9TVK63REqnYuClFFFUZBRRRQAUUUUAFcJ8a/Ej+Gfh/f3Nu5jvLnFpAykgqz5ywI5BVA7D3Aru68W/aqLjwTo5B+QaopbP/XGX+mRWtCKnUjF7XE9iP9mHw5HZ+FrnXpYx9pv5DDE2B8sMZwQPT5wwP+6vpXoPxHcf8I9FanGLy9tYGB6FTMpcH6qGFV/g1AIPhd4bRRjdaLIeO7EsfxyTVX40X76R4Ri1dIfPXT72Cd4923cpbYecH+/6VOIlKrOTW7BaItkgLmTGB/Cwzxjv+Q+lXfhmv/FA6FN1kurVLuRv7zyjzGb8WYn8a8BuvjhduGFtodvCTzveYycfQKvqPy+mfePhPci6+Gvhp1OdlhFEen3kUIR+amsYYKthVerG1/67kQdzrKDRSHrVs0OPuLeHxP4vvLS+jE2k6KIl8hjlJbt1EmXX+LYhjKg8ZkJxkAizf2sOleI9KuLGNIV1KZrS6ijXCSYhkkWQgfxDy9ue4Yg5wMNv9M1bTNcu9V8Ppb3SXwU3djcymIM6qFWWNwrYbaFUqRghV5GDmWxsNU1DUrXUdfW2tvshZraytZWlCuylTI8hC7m2syhQoA3HlsjCA4xLOLT9e1Ww0sC1ls5gLWLja0LRxuU/3QzMAOwwBwBitLIINX0HVbRmgji1WKO4tWGNjTBoPyzKDjjOB6YC3l9bah4v8Rmd4wIrlLZJY5MyW5jiXBYA/KCzP16jHPQCj4xQzWtrDNmPUzqFkkbR/duV+1xYIxx2zj29uF1/r+rfij0Y3dH5ev8AS/Feh7WDTh0poHSnCmjzhaKKKYBXkX7TOuDTPAK6erlZNTnWJsdREnzufpwqn2bHevXa8B/axj/0Hw3K6kxLJcK2PdVOPyUn8D61th481RJiex1tjoUPhn4MW2mLkSXqW8N05OWZ7mSOOTnHYPgZ7KK09YufsOk31zzut4JJBzx8q5xz/nqKt/E5pF8DTT2TQboJrW4Rpm2xBUnjYs5A4UAEk9hz2ryXVfFmt6jZ3FoPEHgeKCeMxOFuZAQrAg9eO568flXHWoVMRPmRE7JpHvHha0Wx8N6ZbJyI7dATx8zbQSxx3JyT7mtUVj+Ebtb7wro10rAiazhkBBz1QHrWwORWu2hoFcd8RdUuIIrDSNOuWtb3U3dftCkAxRIMuVJ/iJKIO435HSuxrlvG/hptcFrc2bQpqNoHWPzs7JEfG5GI5XO1SGGcFRwRkEKhbmXNscTYabDa3Ut5YwumopGIrqGSV389M8H5icnknJyeevPzF/Gs2iXsFu27TbuJ4huGWtnKkcj0B5/l70tev77w5eaVB4ojsrOSdZDBfwXDzFPL28SKYx8pMgBOepHHNaGmapaagJL3Sbi0kkjx9rSKVXjkUDlgQcepBP8AI8w46a/1/XR7rZnop05Raja39f0n02Z6R4c1Aat4f0zUQAPtdtFPj03oG/rWmtcv8MraS0+HXhmCcbZE063DA54PlrxzXUKMCrPMFoNFIaYHn3x7vZ7H4W6w1qxVpfLgYjrseRVYfiCR+Ncp4I0a20n4e+BlCR+dqN6LuVwQN5NvO6Z6ZAG3jt1wOa6T9oWJ5fhTq2wE7HgdsZyAJk9Oax/C+pQ6h8O/h1Ooz5Uxtic9HS1uIzn64J/EetXVbWFdu/6Evc6OGEXvjDSLacboI4J73YenmRtCqZ9dpkJGe4U8YFd6tcNE/wBn8YaLNISFmFxarkEfMyrJ3PXEJ/Mfj3K9K5MN/DSCOwtNbr0p1NY810Mo8vvLNtF8Ravb2Ue6xKx3JtccBJMghR0xujkOPfGMYxp+Afs9pr9/BaSbrW8to7iIehRmV8nJzw0Q/Cs2/umv/GmrXlhITLbrHZLCchbhIyxc/UO7L9Uq/wCDIYbrxbLfWalI4rN0mU9nkkUgY7f6ls/UVCvzf1+P6NHZU5nSvL+vX9GehCikFLVnGFFFFABQaKQ0mByPxN8fab8O9DttU1m1v7mC4uls0SyjV33srsOGZRjCHvnJHFecf8NM+Fv+he8W/wDgFF/8dpP2wDjwB4f7/wDE/t+2f+WU1fN+3nB69u/YY5/4EP8AOc+nl+BjiouUnaxE5OOx9Jf8NM+F8/8AIu+Lef8Apyi/+O16N8MvH2m/ETQ7rVdHtr+2gt7prN472NUfeqox4VmGMOO+cg8V8TAA9Oc4OMfT/Ef/AF+d30j+x6c/D/XyDx/b9x2x/wAsoaePwMMLFOLvcUJuW57vRXkPxf1C4tfFtmnk+I7uzj0O9umttFv5LZlkSWALMwSRCwUMwwA5+b7p5w7QHuPEOvaNoviHxDcyxReH7W7ifTb6S1GpTsXWaYSRMrMF2J8oIH7zJHTHmGh65RXhXxA8Q3NhPp1j4X1jXdRj0K0OqPNaLPe/bZPOHl288kKFdpSO4B3kD7pJ4Jr23TryDUdPtb20cSW1zEs0TjoyMAQfyIoAsVwvxL+JemfD+50i31HTtX1CfVPO8iLTYFlb92FLZBdT/GOmeh6V3VeCftGZ/wCFh/DPAyc6l/6Kiq6ceaSj3KiuaSRc/wCGjdA27v8AhFvGe3YZM/2dHjYDgt/regPU0N+0ZoK+Zu8K+MwIwC+dOj+UHoT+94zXkkQAsI88Z0afnkDHmN3/AM9+lGpf8eur4yT9kssdCf4R/Mj9PevW/suD+0zunglG7TPqjwF4rsvG/haw8QaVFcw2N55nlpcoFkGyRkOQrEdVPfpXRV5R+y5/yQzwz/28/wDpTLWJ8YdUvrTxfrSwPr6pBoNrLbz2Oovb21hO9xcL9onRZBuQbULHZJ8qcgCvGPPPcqK8zVB4j8b6rpmt69fQw2GnW0trDYX8lkJlkVjJdbomVnG4bQMlVx0ywNcr4q8XS6d4ms7nTNV1y90fwzFaCeSGKaeC/WYAzvPLGhiJSBo5AXI5ORjrQB7tRXM+O9du9G0zTzpf2QXWoX0NjFPdAtDCZCfnYKQWGBgAMMkqMiuUsfGniO+1S10W3OjfbzqN7p816YJDA3kxpIsiRiTP8e1kLn5lYbhQB6jRXDfEW7uY7nwrpc+oy6fp+p3xt768tnMDHELukSuDmPe6gZB3dgcmsXxig8KaYtz4Y13U73WLbUIlt9KudSkuxcSSDBtm3sWwy5cFydhXcMAEEA9TorlPhfP9t8F2N9Jqc+pXN5uuLiaUkFJWY74ghP7sIcoEHTb65J6ugAooooAK8s/aS05r74aTToMmwuornGM5BzGf0kP4c16nVPVrG31TTrqwvoxLaXUTQzRnjcjAgjI6cGrpz5JKS6CZw3wD1eLVPhjpUaOGmsQ1nKuRlCh+UHH+wUP410vjzRj4g8H6tpaf664t2ER6YkHKH/voCvn2OLxF8DPFM9w0EmoeGrptjSA/JIuSRuIHySjnrw2SB2x7h4M+InhvxaqR6bqCJekc2c/ySg85AB4bGD90kVrXg1L2sNU9biT6M+K3TYxXBVgeFPGDkY6/8A/zmvpP9mjxhBc6PJ4YupCt3bO89qHOfMiY7mA9wxJx6N7GuA+P3gmfw94on1izhY6VqUhlDgZEUxwWQ+mSNw9iR2yPOdCNzDqMVzZXMlo9oRObkceSFI+b65AAH8ROMckV7tWMMdhVJPVfmZK8JH2v4x1G5s7Swt7CXyLrUbyOySfaG8kMGZnAPBYKjYzkbsZBHFVl8B+H5AX1Gy/tO7YfPeXx82Zj6hv4fbaABjjFeRaP8XtH8UaKuleMnudJvo2WaDVLRcqkiHKPgA7W7EYZT82cA4rubbxZZ6pbfZW+I/h6LPyvJbRJBclenHmysoPvsP4V87Vo1KTtNWNk09jq/h/eTXfhqMXU7XEtrc3NkZ3bc0ognkiDk9yQgJPrmmfEDxGnhnw9Pdpse+l/c2cLf8tZmB2gj+6MFmPZVJ7Vy+o/ELwh4K0yy0jRrmHUZ1UJDbWk4lxkj5pZMnblmGScsS2QDzXkuu69qHiTxTp+oas6iaK6uLeKGPJihRY+i56knksevHQbQN8NhZVpLsb0qLq69DmbeKOSOGeaKOWd9NuLqWV0DSNNvJLs2Mliec57mvRfhLYanrXi7RxPeXUuj6bZpqEqTSecDO2UjG59zD+NsbsfIOOhrzu1ZFsrJSTzo00agdSS5AVR1JJIAA7kfj9MfCbwxL4Y8I20V7j+0rhVluf9g7QFjHbCqAOOp3HvXbmKpRgopK/6HVi+WC5UjtB05pRRRXjnnhRRRTAK8w/aJ0KTWvhzcTW6M82myrehVHJVQyv+SsW/4DXp9MlRZFKOqsjAhgwyCPQ1UJuElJdAep5D8HvFNr468BXPhrU5QNQt7VrOYBgWlgKbBIPUgEA++D/EK8sOjPDJJD/wrNrl7eRoXlju59ruj7WK4HQlePatz4m/DXUvA+qL4p8EPOllC3mNHESZLPnt/ejwSCDnA6/Lk1z2oeLdG8YLFf65NeaRq8Kf6U9gxWK8G3AcA8LIOMqThh0JICn0oRSbq0n7r31d0/NRa+8ylroz2L4O6/dW9kNC1jRrnRokcjTxOSyspyTFvPVgd2M9R0zjJ9A8S69p/hrRp9U1ifyLSHAJClixJwFVRyST2r5F1m40ez06K503U9dnupHxCl6wVQAf9aApJOGA29PmXvggweIviJr/AIl8Kw6Jrk8d3HFMs63DLtlJCMApI4YfOOSMnjqcZSy6dWXNDa/p+buwVSy1PXW/aJsv7VEY0Gb+zPMwZzcjzdmfvCPbjOOdu7nI5r26XULSLTm1Ca4ijsVi88zu21BHjO4k9BjmvgR92HKY3YJBAPcN/Vh+vJ4z6tF4p1XxHpeiwX06rpkazQRWMQ/dbYUCozd3PAOTwD0A5rbF5YozjGl13ubYeEq7sif4ieIpfE+vaxqQ3CwOkstijD7sO/7xHq5G7B7bQelJ4a0IeIfFtxpW1l+1R2itIuQUiChpcEcgFQVyD1cZ65rAjjMmmKiDLvoQAGOrb84/PB/CvoX4ReEpNHtZdY1K3EOpX0aIsRHzQxKBgHPILYBI7YUdQaeJlDD0PZx3/q7PRruNGnyI9DRVVFRVCqowAOABTxSAcUteIeaFFFFMClq1hbarpl1p99GJLW5iaKVOmVIwee31r5xtJ7v4Z6neeEdfGdMnuFvtMvj8qiRWGMnsrYCPj7u4nGDk/TdYHjLwtpXi3SjYa1bebFndHIvEkTf3kbsf0PQgjitKc0k4T1i/6uJo5llt9e0ZJYJHQEq8UqYV4ZFPB6cMrLznPIIOQTUnhj4jafdzTWGtypaXtsdjXYVhZ3BHBaOQ8DnsTweAWxmvMNY+G/jnwpa3lt4a1F9S0K5G2WOMD7SiAYyqEgbscfK3zA/w4GOeke80yCKO9+IWq6aVQAQXGmXUJj6fLt4xwMY6decVlh8JGDa5/TRv8k/uIbcT6il1XToLQXU1/aR22M+a8yhP++s4rznx98U7KwtltfD8V7f3MxUPc20DMkEZPzOpOA74ztHIz1PY+LQzWqSiWD4kziQ5AdNPmDZPPUeoxWtpS6prLeXoXxA1fUZyMrFbafcHJPuWCgdsscDOSRXX9XhD3py09JL/ANtYnNvZHolncWEOiw77k/2dEhktr1Q29CCcqwxnf1BB5JyDz19D8E6bcWOjCfUVC6net9pugP4XIACf8BUKvuQT3rj/AIcfDu/0qR9Q8VarPqV5JKs6WztmON1GEd+u6QDA44GBjO1SPUF6VyuKi7J3OqpWdRJNW/r8PyFooooMgooooAKKKDQB5j+0B4Y0zxV4Q0+01jxPY+GYYNRjuY7y8CFHdY5AIwHdBkhiep+6eK8LHwr8Mgf8lv8ADf18q2z/AOlH1/OvY/2kLeG603wJb3cUc1vL4tsI5IpVDI6lZQVYHggjgg1bXwH4QwM+FNAAGDn+zYT0/wCA+nPas5YyeH92Lav2diW0eI/8Kr8MkY/4Xh4bx6eVbf8AyR/nJr3T9n7wxpnhXwhf2mj+KLLxPDPqMlzJeWgQIrtHGDGdruMgKD1/iHHrB/wgfhAZH/CKeH846f2dD+HVfr+Xeqv7OFvDaad47traGOG3h8W38ccUaBFRQsQChRwAAAAB0pxxs8T7sm3bu7gmuh6w1pbNepeNbwm8SNoVnKDzFRiCyhuoUlVJHQlR6Vl3nhLw5e2EVleeH9IuLKJ2ljt5bKN40djlmClcAkkknvUFxrdzH8QrDQljh+yXGl3N6zkHzA8csCKAc4xiVs8ZyBz64Wr+Nr2y+IttpUVvatoCSwWN7ctnzY7udHaJRzjb8sYORnMyY71ZR2WnaTp2mI6abYWlmrhQ4t4VjDYGBnAGcDgVNY2ltYWcNpY28NtawqEihhQIiKOgVRwB7CvNrrxf4ntdM8ReIc6NNo2i39zDNZC1lS4a3hbDus3mlS+0EhfLAJ4yK9PRg6KynKsMg+1AC15B8evDGna7qHhm9vvHOm+EbrTxdfZ3vUifz/MEattEkiD5QBnr94dOK9frw349WFjqfxO+GVnq0cEllKuqh1nQOmRBGVJBBHBAPPp260XtqVHdHnw8B6QE2D47eGwvktb4Fvaf6tiSR/r/AFJ560S+A9HlWdZPjt4bYTJHHJ/o1p8yx/cH+v7V37eCfDhlWJvC+gpqES/Kh0+IR3K564K9ev8A+rov/CG+E8vdQ+FdGki+7dWrWEW+LqMrxkH8h1/C/rNX+Z/f/W/Q7HRqtfH+P9b/APAO8+DOh2Phv4b6NpOla1ba5Z2/neXqFttEc26Z2ONrMOCxX7x5X8K69rG0a6luWtYDcSxCCSUxje8YJIQnqVBZjjp8x9a8w/Zd5+Bvhjnp9q/9KZa7W31u5k+IV/oLJD9kt9Ltr5XAO8vJLOjAnONuIlxxnJPPpmjhJr3wh4avrK0s77w9o9zaWi7beCayidIR6IpXCj6Veg0jTYLKezg0+zis7gETQJCqxyAqFO5QMHKgDnsMVx1p42vZfiTJpMlvbDw68smnW92Awle+jiSV1JJxs2mRRgZ3RNWZZeMvE6aAfFF8dGn0SPUZ7WezhtpYriKJLt7cSLIZWV2G0MV2LnkA9MsD0e80ywvtNbTr2ytbjT2QRtbSxK8RUdFKEYwMDjHaorHRNKsIrOOw0yxto7PcLZYbdEEG772wAfLnvjGap+JvEUOgmwi+xXuoX1/MYba0s1QySEKWY5dlRQFUklmH5kCsey+IdhqNzZWum6Zq13eXUMs32dI41aExTCGVJC7hVZWJzzg7TgklQQDq9RsLPU7KWz1K1gu7SUbZILiMSI49CpBBqjpvhnQdLNudM0TS7P7OzPD9ntI4/LZhhiu0DBI4OOorM8U61qkfiHSfD/h8Wcd/ewzXUlzeRtLHBBEUVjsVlLsWlQAbhjk+1Yninxbr3gTToNW8Vrpl7pKyvBcPp0LxSAsP3LhXcgBmBRlycFlbdgHAB31pZ2tn532O2hg86VppfKjC+ZI33nbHVj3J5qes7w6+qS6LaSa8lrHqbpvmjtcmOMnkICSd2BgFu5BIAzitGgAooooAKKKKAIriGK4heC4jSWKRSro6hlYdwQeCK8f8a/AjQ9V8y58OSHRrw/MsQXfbls5+71T/AICcD+7XstFXTqSpu8HYGrnzDqWifFTw5pdxpl3aHxFojgo0Lj7bGQOm0ZEwxxjGMY9s14ze3klqJLG8hFkBKZGjYFW6YG7cAQAMAZ9ST14/QSs7WdE0vWofJ1jTbK/ix9y6gWQD/voGuqljXTlzcqv8/wAr2J5bnwQDkbjjBweOp6nP6/XLD8ArkFSM9SQAD29wfT+XqMfXuo/BPwLdKfJ0p7Enk/ZLiRFH/ACSo/KsSf8AZ88Mu+6PU9aj46b4WH6xe9epHOaTXvRZm6bPmfSiE1jTgMKGuUXAIAIyT/PH6Hqa9DtQ82u2ltbQy3F2+pXhS3hTfI3ygfdHQc8k4A9epr1+w+AvhK0nimkl1a6aJw6iS4VcEHI+4qn9a9D8PeG9H8PRSLo2nwWplJaWRRmSUk5y7nLMfck1y1szi23TX3nbQrOjTcEtbnn3wx+GH9kDT9T8TCKbVLWPbb26nelucltxJ+8/P0Xtk/NXrCdMU4UV5U5yqS5pO7Mpyc3zSCiiipJCiiigAooooAQ15b41+CvhrxDNJc2SvpF453M1soMTnnO6P3yfuletep0VUJypvmg7MLHyjrfwB8VWLM+k3FhqcXA2eYYXYc9mG0cEj739McfqHw88YWPy3fhzUy2OfKgM49+Y9w7k8/z6fb1Fd1LM69NWVn8v8iXBM+Dx4X8QPIUGgawWzjaLGXIz3+7yOT09+nGPQvBHgnxZdQWsK6BeW4glmzJej7Ou2SMDJ3fORuznCn6V9XUU6uaVqltErf13LpSdFtwPOvAPw0sfDkdnc6k6ajqsEKQpIY9qQhSSNgPJOT9488ZAXpXoa8CnUVwSlKb5pO7CTcndhRRRUiCiiigAooooAKa6K6lXUMp6gjIp1FAGa2h6U0hdtLsS56sbdM/nir8UaRIEiRUQdFUAAU+igAooooAKKKKACiiigApD1paDzQB5j8edD13WtG8NSeGNL/tS90vXrbUntvtKQbo4lkz87kAclR3POcVz51z4mf8ARKTjGP8AkYbX/wCJ+n+TV39pe+1G08L+G4tL1XUNLe88QW1pLPY3DQSeW6SgjcvbocHjIFec/wDCOatnjx7475yR/wATl+emO3v1qlg/rGtr2OvD4Cri05QWx3X9ufEwf80pPpz4itT/AOy/St74C6FrmiaN4lk8TaX/AGXeapr1zqSWxuI5yscix4+dCQcEMO3TOBmvJ18PaoTx498eHoONZfjp/s++PqR1r0b9ma91G88L+JY9V1W/1V7LX7m0iuL25aeTy0SLA3EnjqeOMk0Swf1fW1gxOAq4VJ1Fud7r/hX+1dds9YtdZ1PSb+2tpbRZLIQMGjkZGYMJYpB1jXkY6VjSfCrw3cWd39uhN5rFzMbhtbmhg+3LJkFWSQRgLt2jACgDHTrW94h8Tw6RqNnpsFhf6pqt0jyx2dise8RpgNIzSOiIoLAfMwyTgZNZT/ETTLMZ1yy1PRc2kt4o1CFU3iNiska7Wbc4+U4H3gwKlucScgyX4dWk8l5Hc61rMulXl619PpZeFYJJGbcVYrEJChPVS+D0Oa7eq2m3TXun2109rcWjTRrIbe4CiSLIztYKSAR3wTVmgAryH42aD4jvvF/gnWvDfh0a/HpIvhc2xvIrb/XRoi/M5/3jwD93tmvXq8C/ac1O8s/EXgazh8S6t4esLsX/ANquNOlkVjsSIplUI3c8e240KLk7IL21IvO+Jhtmgf4ZMVU5gceILUPEcdiBz/n2xIb34o+bFcJ8M9l0oKs66/agSKccFfXAHIxXmhmhUnd8YPG4wOcm5/E/f/zkUedBnB+MXjde3JuOvGf4/r/nGeh4Spu0/wDwGX+Rf1ud7N/kfRHwE8P6n4V+FGh6Nr1t9l1K28/zYfMV9u6eRx8ykg/KwPB71s6v4Ra+8Sya5Y6/q+k3klpHZSCzW2ZHjR5HXImhfBzK3II7Vzf7OGo32r/Brw9fareXN9ey/aPMuLmVpZHxcSgZZiScAAfQCtvxT48tvD2q3llJo+rXosbBdTu57RYSlvAzSLuIeRXYjynJCqxwPwrnIK1r8LfDNrBaPDagavb3a3v9siKIX0svm+YxeUJyGJKsMY2kgY4w6y+HNnb+VBPrOs3ekxXkl8mlzPCLfzWmM3zbIld1EjFgrMw6cHAq9qPjS3h1H7BpOlaprl2lsl3KmnpEBDE+dhZpZEXLYOFBLYBOMUy68eabaa14f0u5tdRiutZjEieZBtFtkfIs+TlCxBUDB+YEcUAaPibw7DrxsJftt7p99YTGa2u7NkEkZKlWGHVkYFWIIZT+YBqn4d8E6ZoGoWl7Zy3j3FvazWxaaQMZjNMJpJHOMly4zkYHJ46Y39Rv7TTLKW81K6t7OzhGZJ7iQRxoM4yWJAH41QbxR4fXTodQbXNKFhMrvFcm7j8qRU+8VbOCB3I6UAQ+JvDNvrtxYXYvL3TtSsWY217ZOokjDAB1w6sjK2BkMpHA9KoL4Fs557aTW9S1PXFgMzCLUXjeNnlXYzlVRRkLuUAYUBmwMnNa+ra/aabLoqSiSUatdizt3hwy7jFJKGJz93bG3IzyRx3FDxf4y03wrd6Rb6klyz6lOIUaFAywjcimSQkjagaSME843DigDU8O6Smh6La6ZDc3VzDbL5ccl04eTZn5VLYGcDABPOAMknmtGuS1bxslhrWoadBoGt6j/Z8cUt1PZJC6xrICV+UyCRjhTwqGuk02+ttT062vrCZJ7S5iWaGVOjowyCPqDQBZooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPE/wBqq6gsfCvhO7u3MdvB4ltJZXAJ2qscxJ456A9K8z/4Wd4POf8AicLzjg203/xHqfr+ufrjApMD0relXlS0id+EzCphIuNNLXv/AMOfJP8Aws/wfn/kMcDOM2034fwccZHp09K9L/ZTuob7wp4su7V/Mt5/Et3LG+CNytHCQcEAjg+le2YHpQBilVryqqzQsXmFTFpRmlp2/wCHOS8Q6PrMfiu08Q+HP7PuJ1tGsbmzvpXhSSPeHVlkVHKspzwVIIbtgGsLxL4O8ReMksR4iutMsTp6teWn9ns8my/Dnynbeo3JGuOON5ZshQAK9KorE4StphvG062OqJbpfmNfPW3YtGHx82wsASuc4yAas0UUAFfOn7VepjRvFfw8v2mtYBCNR/eXUTSxjMcQ5UKxPXA4ODg19F0U07NMGr6HxOPiVCudus+FhjkY0iX0P/TD/dpf+FlwgjGteFgARjGkS56n/phxX2vgelGB6Vv9Y/uR+5EciPKv2W/+SFeGf+3n/wBKpaueO/hxN4q8SanqBvzbRy6Xb2kCrNJsaWOaaQrPCCEliYSKCrZ/ixjqfSaK5yzgYdI8XaZrN1q+mW+gzz6nbQre2U13LFHDcRqVDxSiJiyFSAVKKeBg9axtZ+HGv6//AG5qWo6+LTWrpbb7LDZKhtVa2VXh3GSJpVHn+Y5CMOGA5Ner0UAcv420TUNc0fTTaCy/tGxvIL4QXDt5EzJnKMwUkDkkNtOCFOK53QfAupQ+INP1jVf7N8wale6lcW0LM8cLTRoiCIsg3EbNzMQvzMxAr0qigDlPH2j6rqjeHbrQ47Ga50rUxfNFeXDwJInkTRkB1jcg5lB+72Nc1rXgHWvGV/ql54l1FdGE+n/2bBa6RMl0vlli8jO81uGBZvL+4FI2DnOMeoUUAebado3jrTtRvr6CPw7Pe6jZWcM9xNeTYhmiRld1jEP7xSWJALp712fhLRIvDfhnTNGt5HmjsYEhEjjBcgcsR2ycnHvWtRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical distributions of the right coronary artery (RCA), the left anterior descending artery (LAD), and the circumflex artery (CX). The arterial distribution varies between patients. Some segments have variable coronary perfusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16533=[""].join("\n");
var outline_f16_9_16533=null;
var title_f16_9_16534="Timolol (systemic): Pediatric drug information";
var content_f16_9_16534=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Timolol (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27287?source=see_link\">",
"    see \"Timolol (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/60/22469?source=see_link\">",
"    see \"Timolol (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9600170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9600176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Timol&reg;;",
"     </li>",
"     <li>",
"      Nu-Timolol;",
"     </li>",
"     <li>",
"      Teva-Timolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10536764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimigraine Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta-Adrenergic Blocker",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10536897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27287?source=see_link\">",
"      see \"Timolol (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children: No information regarding pediatric dose is currently available in literature",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hypertension: Initial: 10 mg twice daily, increase gradually every 7 days, usual dosage: 20-40 mg/day in 2 divided doses; maximum dose: 60 mg/day; usual dosage range (JNC 7): 20-40 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prevention of MI: 10 mg twice daily initiated within 1-4 weeks after infarction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Migraine headache: Initial: 10 mg twice daily, increase to maximum of 30 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9600285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate: 5 mg, 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9600178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10536904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10536765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, alone or in combination with other agents (FDA approved in adults); reduction of cardiovascular mortality and risk of reinfarction in stable post-MI patients (FDA approved in adults); prevention of migraine headaches (FDA approved in adults); treatment of angina",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9600173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Timolol may be confused with atenolol, Tylenol&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9600201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris, arrhythmia, bradycardia, cardiac failure, cardiac arrest, cerebral vascular accident, cerebral ischemia, edema, hypotension, heart block, palpitation, Raynaud's phenomenon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, confusion, depression, dizziness, disorientation, fatigue, hallucinations, insomnia, memory loss, nervousness, nightmares, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, angioedema, pseudopemphigoid, psoriasiform rash, psoriasis exacerbation, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia masked, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dyspepsia, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, retoperitoneal fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Claudication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myasthenia gravis exacerbation, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blepharitis, conjunctivitis, cystoid macular edema, decreased corneal sensitivity, diplopia, dry eyes, foreign body sensation, keratitis, ocular discharge, ocular pain, ptosis, refractive changes, tearing, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, cough, dyspnea, nasal congestion, pulmonary edema, respiratory failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, cold hands/feet, Peyronie's disease, systemic lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10536766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to timolol or any component; uncompensated CHF, cardiogenic shock, bradycardia or heart block, bronchial asthma, severe chronic obstructive pulmonary disease or history of asthma, CHF or bradycardia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10536885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Similar to other beta-blockers; use with caution in patients with decreased renal or hepatic function (dosage adjustment required); use with caution in patients with diabetes mellitus, may block hypoglycemia-induced tachycardia and blood pressure changes. Use with caution in patients with myasthenia gravis or myasthenic symptoms; may potentiate muscle weakness.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10536864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exacerbation of angina, arrhythmias, and in some cases MI may occur following abrupt discontinuation of beta-blockers",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; avoid abrupt discontinuation, wean slowly, monitor for signs and symptoms of ischemia. Timolol decreases the ability of the heart to respond to reflex adrenergic stimuli and may increase the risk of general anesthesia and surgical procedures; beta-blockers should generally be avoided in patients with bronchospastic disease; if administered, use the lowest possible dose and monitor patients carefully. Patients receiving beta-blockers, who have a history of anaphylactic reactions, may be more reactive to a repeated allergen challenge and may not be responsive to the usual epinephrine doses used to treat an allergic reaction. Beta-blockers may block hypoglycemia-induced tachycardia and blood pressure changes; use with caution in patients with diabetes mellitus. May mask signs of thyrotoxicosis (exacerbation of symptoms of hyperthyroidism, including thyroid storm, may occur following abrupt discontinuation). Use caution with anesthetic agents that decrease myocardial function. Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9600203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9600204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9600180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9600181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies timolol as pregnancy category C. Timolol crosses the placenta and decreased fetal heart rate has been observed following maternal use of oral and ophthalmic timolol during pregnancy. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother; however, timolol is currently not recommended for the initial treatment of hypertension in pregnancy. If timolol is required for the treatment of glaucoma during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease exposure to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10536905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure; liver enzymes, BUN, serum creatinine with long-term oral use",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10536889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors; reduces blood pressure by blocking adrenergic receptors and decreasing sympathetic outflow; produces negative chronotropic and negative inotropic activity",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10536890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypotensive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Within 15-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 30-150 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 4 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10536891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Distribution: Distributes into human breast milk",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Protein binding: &lt;10%",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Metabolism: Extensively in the liver, extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Bioavailability: ~60%",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Half-life: Adults: 2-4 hours; prolonged with reduced renal function",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Elimination: Urinary excretion (15% to 20% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Dialysis: Not readily dialyzable",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, \"Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,\"",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16534/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16534/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gold MH, Holy AK, and Roenigk HH Jr, \"Beta-Blocking Drugs and Psoriasis. A Review of Cutaneous Side Effects and Retrospective Analysis of Their Effects on Psoriasis,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1988, 19(5 Pt 1):837-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16534/abstract-text/2903871/pubmed\" id=\"2903871\" target=\"_blank\">",
"        2903871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, \"Psoriasis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(18):1899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16534/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16055 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16534=[""].join("\n");
var outline_f16_9_16534=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600170\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600176\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536764\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536897\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600285\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600178\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536904\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536765\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600173\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600201\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536766\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536885\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536864\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600203\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600204\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600180\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600181\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536905\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536889\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536890\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536891\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16055\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16055|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/60/28615?source=related_link\">",
"      Timolol (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30932?source=related_link\">",
"      Timolol (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25014?source=related_link\">",
"      Timolol (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27287?source=related_link\">",
"      Timolol (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/60/22469?source=related_link\">",
"      Timolol (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_9_16535="Postterm pregnancy";
var content_f16_9_16535=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postterm pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/9/16535/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/9/16535/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/9/16535/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/9/16535/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/9/16535/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/9/16535/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/9/16535/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timely onset of labor and delivery is an important determinant of perinatal outcome. Both preterm and postterm births are associated with higher rates of perinatal morbidity and mortality than pregnancies delivering at term.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postterm pregnancy refers to a pregnancy that has",
"    <span class=\"nowrap\">",
"     &ge;42",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    weeks of gestation or &ge;294 days from the first day of the last menstrual period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/1\">",
"     1",
"    </a>",
"    ]. Accurate pregnancy dating is critical to the diagnosis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, approximately 27 percent of pregnancies deliver in the 40",
"    <sup>",
"     th",
"    </sup>",
"    and 41",
"    <sup>",
"     st",
"    </sup>",
"    week and 5.5 percent deliver at &ge;42 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/2\">",
"     2",
"    </a>",
"    ]. A study of postterm birth rates in 13 European countries observed a wide range across the continent: from 0.4 percent in Austria and Belgium to 8.1 percent in Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/3\">",
"     3",
"    </a>",
"    ]. The authors attributed the variation to differences in prenatal assessment of gestational age and obstetric practices.",
"   </p>",
"   <p>",
"    The prevalence of postterm pregnancy in a population is affected by several factors. One of the most important factors is whether routine early ultrasound assessment of gestational age is performed. Among pregnancies dated by first trimester ultrasound examination, the prevalence of delivery &ge;42 weeks is about 2 percent (versus 6 to 12 percent by last menstrual period [LMP]) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/4-7\">",
"     4-7",
"    </a>",
"    ] and the prevalence of delivery &ge;41 weeks ranges from 5 to 11 percent (versus 13 to 22 percent by LMP) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/6,8-10\">",
"     6,8-10",
"    </a>",
"    ]. In a meta-analysis that compared the rate of labor induction for postterm pregnancy in women who underwent sonographic estimation of their delivery date (EDD) in early pregnancy with the rate in women whose EDD was calculated from their LMP, early routine ultrasound examination reduced the rate of intervention for postterm pregnancy (OR 0.68, 95% CI 0.57-0.82) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors that affect the prevalence of postterm pregnancy in a population include the rate of spontaneous preterm birth, the prevalence of primigravid women (who are more likely to deliver postterm), and the prevalence of women with pregnancy complications (who are less likely to deliver postterm). Local practice patterns, such as the rate of scheduled cesarean delivery and elective labor induction, will also affect the prevalence of postterm birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of postterm pregnancies have no known etiology. One third to one half of the variation in postterm birth in a population can be attributed to maternal or fetal genetic influence on the initiation of parturition [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/11\">",
"     11",
"    </a>",
"    ]. In rare cases, postterm pregnancy can be attributed to known defects in fetal production of hormones involved in parturition. In the past, anencephaly was a cause of postterm pregnancy in the absence of polyhydramnios, but these pregnancies are now routinely detected antepartum and terminated or induced. X-linked ichthyosis (MIM 308100), which is associated with placental sulfatase deficiency, is another rare cause of postterm pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women at highest risk of postterm pregnancy are those with a previous postterm pregnancy. After one postterm pregnancy, the risk of a second postterm birth is increased two- to three-fold; the risk of recurrence is quadrupled after two prior postterm pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Additional, more modest risk factors (RR &lt;2) include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/11,13,14,16-21\">",
"     11,13,14,16-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nulliparity",
"     </li>",
"     <li>",
"      Male fetus",
"     </li>",
"     <li>",
"      Maternal obesity",
"     </li>",
"     <li>",
"      Older maternal age",
"     </li>",
"     <li>",
"      Maternal or paternal personal history of postterm birth",
"     </li>",
"     <li>",
"      Maternal",
"      <span class=\"nowrap\">",
"       race/ethnicity",
"      </span>",
"      (African-American women, Latina, and Asian women are at lower risk than Caucasians)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postterm pregnancy is associated with fetal, neonatal, and maternal risks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/22-26\">",
"     22-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fetal and neonatal risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postterm fetuses tend to be larger than term fetuses, with a higher incidence of macrosomia (&ge;4500 g) (2.5 to 10 percent versus 0.8 to 1 percent at term) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Complications of macrosomia include prolonged labor, cephalopelvic disproportion, and shoulder dystocia, all of which increase the risk of birth injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31337?source=see_link\">",
"     \"Fetal macrosomia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/1/16408?source=see_link\">",
"     \"Timing and route of delivery in pregnancies at risk of shoulder dystocia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, up to 20 percent of postterm fetuses have \"fetal dysmaturity (postmaturity) syndrome,\" a term used to describe infants with characteristics of chronic intrauterine malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. These fetuses are at increased risk of umbilical cord compression due to oligohydramnios, and nonreassuring antepartum or intrapartum fetal heart rate patterns due to placental insufficiency or cord compression. Meconium passage is common and may be related to physiological maturation of the gut or fetal hypoxia. Neonates have a long thin body, long nails, and are small for gestational age. Their skin is dry (vernix caseosa is decreased or absent), meconium stained, parchment-like, and peeling; it appears loose, especially over the thighs and buttocks, and has prominent creases; lanugo hair is sparse or absent, while scalp hair is increased. These",
"    <span class=\"nowrap\">",
"     fetuses/neonates",
"    </span>",
"    are at risk for the short- and long-term morbidity typically seen in intrauterine growth",
"    <span class=\"nowrap\">",
"     restriction/small",
"    </span>",
"    for gestational age infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31142?source=see_link\">",
"     \"Postterm infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link&amp;anchor=H16#H16\">",
"     \"Fetal growth restriction: Evaluation and management\", section on 'Outcome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perinatal mortality increases as pregnancy extends beyond 39 to 40 weeks of gestation due to increases in both non-anomalous stillbirths and early neonatal deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Intrauterine infection, placental insufficiency and cord compression leading to fetal hypoxia, asphyxia, and meconium aspiration are thought to contribute to the excess perinatal deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The perinatal mortality rate at &ge;42 weeks of gestation is twice the rate at term, increasing four-fold at 43 weeks, and five- to seven-fold at 44 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/25,38-41\">",
"     25,38-41",
"    </a>",
"    ]. Neonates born at &ge;41 weeks of gestation experience one-third greater neonatal mortality than term neonates born at 38 to 40 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/33\">",
"     33",
"    </a>",
"    ]. However, the absolute risk of fetal or neonatal death is low. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Expectant management'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31142?source=see_link&amp;anchor=H8#H8\">",
"     \"Postterm infant\", section on 'Perinatal mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term effects of postterm birth are unclear. Studies on long-term outcomes for children born postterm are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31142?source=see_link&amp;anchor=H10#H10\">",
"     \"Postterm infant\", section on 'Long-term outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6971073\">",
"    <span class=\"h2\">",
"     Maternal risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal risks of postterm pregnancy include an increased frequency of labor abnormalities and sequelae of labor induction and fetal macrosomia. These sequelae include failed induction, third and fourth degree perineal lacerations, and postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion refers to the singleton, cephalic fetus of an otherwise uncomplicated pregnancy that reaches 41 weeks of gestation. Multiple gestations, non-cephalic presentations, and complicated pregnancies are generally delivered before 41 weeks.",
"   </p>",
"   <p>",
"    We favor induction of well-dated postterm pregnancies at or shortly after",
"    <sup>",
"     <span class=\"nowrap\">",
"     </span>",
"    </sup>",
"    41",
"    <sup>",
"     0/7ths",
"    </sup>",
"    weeks of gestation, irrespective of cervical status. The alternative is expectant management with ongoing fetal assessment with intervention if fetal assessment is not reassuring or spontaneous labor does not occur by a predefined gestational age. Both of these approaches are associated with low complication rates in the low-risk postterm gravida [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction of postterm pregnancy rather than expectant management with fetal monitoring is supported by several lines of evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lower perinatal mortality and morbidity",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a 2012 meta-analysis of randomized trials comparing a policy of labor induction to a policy of awaiting spontaneous onset of labor at 39 to 42 weeks:",
"      <br/>",
"      <br/>",
"      Routine labor induction at &gt;41 weeks of gestation compared with expectant management resulted in lower perinatal mortality",
"      <span class=\"nowrap\">",
"       (1/2814",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       9/2785;",
"      </span>",
"      RR 0.30, 95% CI 0.09-0.99; 10 trials) and a lower rate of meconium aspiration syndrome (RR 0.61, 0.40-0.92; 5 trials, 1395 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/46\">",
"       46",
"      </a>",
"      ]. For induction at",
"      <span class=\"nowrap\">",
"       41",
"       <sup>",
"        0/7ths",
"       </sup>",
"       ,",
"      </span>",
"      the risk of perinatal mortality was also lower than with expectant management, but did not achieve statistical significance",
"      <span class=\"nowrap\">",
"       (0/501",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       2/497;",
"       <sup>",
"       </sup>",
"      </span>",
"      RR 0.",
"      33, 95% CI 0.03-3.17; 4 trials, 998 patients).",
"     </li>",
"     <li>",
"      When fetal mortality is based on the number of fetal deaths per 1000 ongoing pregnancies (rather than per 1000 deliveries), an analysis of fetal versus neonatal mortality rates concluded the rate of fetal demise was significantly higher than the rate of neonatal death at any gestational age",
"      <span class=\"nowrap\">",
"       &ge;40",
"       <sup>",
"        3/7ths",
"       </sup>",
"      </span>",
"      weeks of gestation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       No increase in or a reduction in cesarean delivery",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Meta-analyses have reported that routine induction at &gt;41 weeks results in no increase in the risk of cesarean delivery compared with expectant management (RR 0.91, 95% CI 0.82-1.00; 12 trials, 5994 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/46\">",
"       46",
"      </a>",
"      ] or a decrease in the cesarean birth rate (pooled cesarean delivery rate with induction at &ge;41 weeks: 17.5 versus 20.1 percent; P = 0.04; 8 trials, 6054 women) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patient satisfaction",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A survey of women at 41 weeks of gestation reported that 74 percent preferred induction to expectant management [",
"      <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We agree with guidelines that suggest routine induction between",
"    <span class=\"nowrap\">",
"     41",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     42",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    weeks of gestation rather than expectant management and monitoring as intervention at this time reduces perinatal mortality without increasing perinatal morbidity or cesarean delivery rates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/8,50\">",
"     8,50",
"    </a>",
"    ]. The exact timing during this week should take into account clinician and patient preferences and local circumstances. We favor induction of well-dated postterm pregnancies at or shortly after",
"    <sup>",
"     <span class=\"nowrap\">",
"     </span>",
"    </sup>",
"    41",
"    <sup>",
"     0/7ths",
"    </sup>",
"    weeks of gestation.",
"   </p>",
"   <p>",
"    However, this approach has not been universally accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/51\">",
"     51",
"    </a>",
"    ], in part because of the low absolute rates of fetal and neonatal death: at",
"    <span class=\"nowrap\">",
"     41",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    weeks, 527 inductions would be necessary to prevent one perinatal death; at 43 weeks, 195 inductions would be necessary to prevent one perinatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/52\">",
"     52",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    We utilize cervical ripening agents in women with unfavorable cervices. In women wishing to avoid pharmacologic agents for cervical ripening and induction, membrane sweeping (also called stripping) can be performed if the cervix is sufficiently dilated, and reduces the proportion of patients who remain undelivered at 42 weeks. This was illustrated in a trial that randomly assigned 742 low-risk women at 41 weeks of gestation to membrane sweeping every 48 hours or expectant management [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/53\">",
"     53",
"    </a>",
"    ]. At baseline, the Bishop score was &lt;6 in 78 percent of women in the intervention group; the expectant management group did not undergo cervical examination. Serial membrane sweeping resulted in fewer pregnancies reaching",
"    <span class=\"nowrap\">",
"     &ge;42",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    weeks (23 versus 41 percent without membrane sweeping, RR 0.57 95% CI 0.46-0.71, number needed to treat 6). The optimum time to initiate membrane sweeping and the frequency (once versus on multiple days) has not been studied. Beginning anytime after 39 weeks of gestation is reasonable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41993?source=see_link\">",
"     \"Techniques for ripening the unfavorable cervix prior to induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Expectant management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postterm pregnancy is a universally accepted indication for antenatal fetal monitoring because the risk of antepartum fetal demise increases with advancing gestational age. In large studies from the United Kingdom, the risk of antepartum fetal demise was [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      40 to 41 weeks: 0.86 to 1.08 per 1000 ongoing pregnancies",
"     </li>",
"     <li>",
"      41 to 42 weeks: 1.2 to 1.27 per 1000 ongoing pregnancies",
"     </li>",
"     <li>",
"      42 to 43 weeks: 1.3 to 1.9 per 1000 ongoing pregnancies",
"     </li>",
"     <li>",
"      &gt;43 weeks: 1.58 to 6.3 per 1000 ongoing pregnancies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the efficacy of antenatal fetal assessment for preventing unexplained fetal demise in postterm fetuses has not been validated by appropriately sized and placebo-controlled randomized trials, and probably never will be evaluated in this way because of ethical and medicolegal concerns of assigning some pregnancies to an unmonitored group. One small trial that compared two methods of fetal assessment has been performed, and did not find a difference in neonatal outcome between groups [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal type and frequency of fetal testing, and the gestational age for beginning monitoring, have not been determined. We suggest monitoring fetal well-being by the nonstress testing with amniotic fluid volume assessment or by the biophysical profile (BPP); neither method has been proven to be superior. Doppler ultrasonography of the umbilical artery has no proven benefit in monitoring the postterm fetus and is not recommended for this indication [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Case control studies support initiating antepartum fetal surveillance between",
"    <span class=\"nowrap\">",
"     41",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     42",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    weeks of gestation (287 to 294 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. We suggest twice weekly testing beginning at",
"    <span class=\"nowrap\">",
"     41",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    weeks or shortly thereafter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of fetal assessment\", section on 'Antenatal testing methods'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Induction is indicated for development of any of the usual obstetrical indications, including evidence of oligohydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Adverse pregnancy outcomes (nonreassuring fetal heart rate tracing, neonatal intensive care unit admission, low Apgar) are more likely when oligohydramnios is present [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/60-65\">",
"     60-65",
"    </a>",
"    ]. Frequent assessment is important because amniotic fluid can become severely reduced within 24 to 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16535/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=see_link\">",
"     \"Oligohydramnios\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/33/15890?source=see_link\">",
"       \"Patient information: When your baby is overdue (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/38/26209?source=see_link\">",
"       \"Patient information: Postterm pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postterm pregnancy refers to a pregnancy that is",
"      <span class=\"nowrap\">",
"       &ge;42",
"       <sup>",
"        0/7ths",
"       </sup>",
"      </span>",
"      weeks of gestation or 294 days from the first day of the last menstrual period (LMP). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In pregnancies dated by first trimester ultrasound examination, the prevalence of postterm pregnancy is about 2 percent and fewer inductions are performed for postterm pregnancy than in pregnancies dated by LMP. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After one postterm pregnancy, the risk of another such pregnancy in the subsequent birth is increased two- to three-fold; the risk of recurrence is quadrupled after two prior postterm pregnancies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risks of fetal and neonatal death increase with increasing gestational age after 40 weeks of gestation, but the absolute risk of death is low. Intrauterine infection, placental insufficiency or cord compression leading to fetal hypoxia and asphyxia, and meconium aspiration are thought to contribute to the excess perinatal deaths. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Morbidity and mortality'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Expectant management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal and neonatal morbidity in postterm pregnancy is related, in part, to complications from fetal macrosomia. Dysmaturity, which occurs in up to 20 percent of postterm fetuses, also results in short- and long-term morbidity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women",
"      <span class=\"nowrap\">",
"       &ge;41",
"       <sup>",
"        0/7ths",
"       </sup>",
"      </span>",
"      weeks of gestation, we suggest induction rather than expectant management (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Induction is associated with lower perinatal mortality than expectant management and does not increase the risk of cesarean delivery. The benefits of routine induction are modest, however, and depending on their values and preferences, some women may choose to be managed expectantly. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization. International Statistical Classification of Diseases and Related Health Problems. Geneva, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/2\">",
"      Births: Final data for 2010. Natl Vital Stat Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/3\">",
"      Zeitlin J, Blondel B, Alexander S, et al. Variation in rates of postterm birth in Europe: reality or artefact? BJOG 2007; 114:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/4\">",
"      Neilson JP. Ultrasound for fetal assessment in early pregnancy. Cochrane Database Syst Rev 2000; :CD000182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/5\">",
"      Caughey AB, Nicholson JM, Washington AE. First- vs second-trimester ultrasound: the effect on pregnancy dating and perinatal outcomes. Am J Obstet Gynecol 2008; 198:703.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/6\">",
"      Blondel B, Morin I, Platt RW, et al. Algorithms for combining menstrual and ultrasound estimates of gestational age: consequences for rates of preterm and postterm birth. BJOG 2002; 109:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/7\">",
"      Bukowski R, Saade G, Malone F, et al. A decrease in postdates pregnancies is an additional benefit of first trimester screening for aneuploidy. Am J Obstet Gynecol 2001; 185:S148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/8\">",
"      Clinical Practice Obstetrics Committee, Maternal Fetal Medicine Committee, Delaney M, et al. Guidelines for the management of pregnancy at 41+0 to 42+0 weeks. J Obstet Gynaecol Can 2008; 30:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/9\">",
"      Kramer MS, McLean FH, Boyd ME, Usher RH. The validity of gestational age estimation by menstrual dating in term, preterm, and postterm gestations. JAMA 1988; 260:3306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/10\">",
"      Bennett KA, Crane JM, O'shea P, et al. First trimester ultrasound screening is effective in reducing postterm labor induction rates: a randomized controlled trial. Am J Obstet Gynecol 2004; 190:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/11\">",
"      Oberg AS, Frisell T, Svensson AC, Iliadou AN. Maternal and fetal genetic contributions to postterm birth: familial clustering in a population-based sample of 475,429 Swedish births. Am J Epidemiol 2013; 177:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/12\">",
"      Taylor NF. Review: placental sulphatase deficiency. J Inherit Metab Dis 1982; 5:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/13\">",
"      Mogren I, Stenlund H, H&ouml;gberg U. Recurrence of prolonged pregnancy. Int J Epidemiol 1999; 28:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/14\">",
"      Olesen AW, Basso O, Olsen J. Risk of recurrence of prolonged pregnancy. BMJ 2003; 326:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/15\">",
"      Kistka ZA, Palomar L, Boslaugh SE, et al. Risk for postterm delivery after previous postterm delivery. Am J Obstet Gynecol 2007; 196:241.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/16\">",
"      Laursen M, Bille C, Olesen AW, et al. Genetic influence on prolonged gestation: a population-based Danish twin study. Am J Obstet Gynecol 2004; 190:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/17\">",
"      Morken NH, Melve KK, Skjaerven R. Recurrence of prolonged and post-term gestational age across generations: maternal and paternal contribution. BJOG 2011; 118:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/18\">",
"      Divon MY, Ferber A, Nisell H, Westgren M. Male gender predisposes to prolongation of pregnancy. Am J Obstet Gynecol 2002; 187:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/19\">",
"      Stotland NE, Washington AE, Caughey AB. Prepregnancy body mass index and the length of gestation at term. Am J Obstet Gynecol 2007; 197:378.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/20\">",
"      Caughey AB, Stotland NE, Washington AE, Escobar GJ. Who is at risk for prolonged and postterm pregnancy? Am J Obstet Gynecol 2009; 200:683.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/21\">",
"      Denison FC, Price J, Graham C, et al. Maternal obesity, length of gestation, risk of postdates pregnancy and spontaneous onset of labour at term. BJOG 2008; 115:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/22\">",
"      Knox GE, Huddleston JF, Flowers CE Jr. Management of prolonged pregnancy: results of a prospective randomized trial. Am J Obstet Gynecol 1979; 134:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/23\">",
"      Yeh SY, Read JA. Management of post-term pregnancy in a large obstetric population. Obstet Gynecol 1982; 60:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/24\">",
"      Lagrew DC, Freeman RK. Management of postdate pregnancy. Am J Obstet Gynecol 1986; 154:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/25\">",
"      Feldman GB. Prospective risk of stillbirth. Obstet Gynecol 1992; 79:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/26\">",
"      Olesen AW, Westergaard JG, Olsen J. Perinatal and maternal complications related to postterm delivery: a national register-based study, 1978-1993. Am J Obstet Gynecol 2003; 189:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/27\">",
"      Spellacy WN, Miller S, Winegar A, Peterson PQ. Macrosomia--maternal characteristics and infant complications. Obstet Gynecol 1985; 66:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/28\">",
"      Rosen MG, Dickinson JC. Management of post-term pregnancy. N Engl J Med 1992; 326:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/29\">",
"      Lu Y, Zhang J, Lu X, et al. Secular trends of macrosomia in southeast China, 1994-2005. BMC Public Health 2011; 11:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/30\">",
"      Vorherr H. Placental insufficiency in relation to postterm pregnancy and fetal postmaturity. Evaluation of fetoplacental function; management of the postterm gravida. Am J Obstet Gynecol 1975; 123:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/31\">",
"      Shime J, Librach CL, Gare DJ, Cook CJ. The influence of prolonged pregnancy on infant development at one and two years of age: a prospective controlled study. Am J Obstet Gynecol 1986; 154:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/32\">",
"      Mannino F. Neonatal complications of postterm gestation. J Reprod Med 1988; 33:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/33\">",
"      Bruckner TA, Cheng YW, Caughey AB. Increased neonatal mortality among normal-weight births beyond 41 weeks of gestation in California. Am J Obstet Gynecol 2008; 199:421.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/34\">",
"      Heuser C, Manuck T, Hossain S, et al. Non-anomalous stillbirth by gestational age: trends differ based on method of epidemiologic calculation. J Matern Fetal Neonatal Med 2010; 23:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/35\">",
"      Cotzias CS, Paterson-Brown S, Fisk NM. Prospective risk of unexplained stillbirth in singleton pregnancies at term: population based analysis. BMJ 1999; 319:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/36\">",
"      Rasmussen S, Albrechtsen S, Irgens LM, et al. Risk factors for unexplained antepartum fetal death in Norway 1967-1998. Early Hum Dev 2003; 71:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/37\">",
"      Hannah ME. Postterm pregnancy: should all women have labour induced? A review of the literature. Fetal and Maternal Medicine Review 1993; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/38\">",
"      Divon MY, Haglund B, Nisell H, et al. Fetal and neonatal mortality in the postterm pregnancy: the impact of gestational age and fetal growth restriction. Am J Obstet Gynecol 1998; 178:726.",
"     </a>",
"    </li>",
"    <li>",
"     Bakketeig, LS, Bergsjo, P. Post-term pregnancy: magnitude of the problem. In: Enkin M, Keirse MJ, Chalmers I, eds. Effective Care in Pregnancy and Childbirth. Oxford: Oxford University Press, 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/40\">",
"      Nakling J, Backe B. Pregnancy risk increases from 41 weeks of gestation. Acta Obstet Gynecol Scand 2006; 85:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/41\">",
"      De Los Santos-Garate AM, Villa-Guillen M, Villanueva-Garc&iacute;a D, et al. Perinatal morbidity and mortality in late-term and post-term pregnancy. NEOSANO perinatal network's experience in Mexico. J Perinatol 2011; 31:789.",
"     </a>",
"    </li>",
"    <li>",
"     Treger, M, Hallak, M, Silberstein, T, et al. Postterm pregnancy: Should the definition of 42 weeks be reconsidered? [Abstract no. 452] Society for Maternal-Fetal Medicine, Miami, FL, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/43\">",
"      Alexander JM, McIntire DD, Leveno KJ. Forty weeks and beyond: pregnancy outcomes by week of gestation. Obstet Gynecol 2000; 96:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/44\">",
"      Alexander JM, MCIntire DD, Leveno KJ. Prolonged pregnancy: induction of labor and cesarean births. Obstet Gynecol 2001; 97:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/45\">",
"      A clinical trial of induction of labor versus expectant management in postterm pregnancy. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 1994; 170:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/46\">",
"      G&uuml;lmezoglu AM, Crowther CA, Middleton P, et al. Induction of labour for improving birth outcomes for women at or beyond term. Cochrane Database Syst Rev 2012; :CD004945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/47\">",
"      Divon MY, Ferber A, Sanderson M, et al. A functional definition of prolonged pregnancy based on daily fetal and neonatal mortality rates. Ultrasound Obstet Gynecol 2004; 23:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/48\">",
"      Caughey AB, Sundaram V, Kaimal AJ, et al. Systematic review: elective induction of labor versus expectant management of pregnancy. Ann Intern Med 2009; 151:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/49\">",
"      Heimstad R, Romundstad PR, Hyett J, et al. Women's experiences and attitudes towards expectant management and induction of labor for post-term pregnancy. Acta Obstet Gynecol Scand 2007; 86:950.",
"     </a>",
"    </li>",
"    <li>",
"     National Collaborating Centre for Women&rsquo;s and Children&rsquo;s Health Clinical Guideline. Induction of Labour. July 2008. www.nice.org.uk/nicemedia/live/12012/41255/41255.pdf (Accessed on June 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/51\">",
"      Menticoglou SM, Hall PF. Routine induction of labour at 41 weeks gestation: nonsensus consensus. BJOG 2002; 109:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/52\">",
"      Heimstad R, Romundstad PR, Salvesen KA. Induction of labour for post-term pregnancy and risk estimates for intrauterine and perinatal death. Acta Obstet Gynecol Scand 2008; 87:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/53\">",
"      de Miranda E, van der Bom JG, Bonsel GJ, et al. Membrane sweeping and prevention of post-term pregnancy in low-risk pregnancies: a randomised controlled trial. BJOG 2006; 113:402.",
"     </a>",
"    </li>",
"    <li>",
"     Myers ER, Blumrick R, Christian AL, et al. Management of Prolonged Pregnancy. Rockville (MD): Agency for Healthcare Research and Quality (US); 2002 May. (Evidence Reports/Technology Assessments, No. 53.)",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/55\">",
"      Alfirevic Z, Walkinshaw SA. A randomised controlled trial of simple compared with complex antenatal fetal monitoring after 42 weeks of gestation. Br J Obstet Gynaecol 1995; 102:638.",
"     </a>",
"    </li>",
"    <li>",
"     Amercan College of Obstetricians and Gynecologists. Antepartum fetal surveillance. ACOG practice bulletin #9. Amercan College of Obstetricians and Gynecologists, Washington, DC 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/57\">",
"      Stokes HJ, Roberts RV, Newnham JP. Doppler flow velocity waveform analysis in postdate pregnancies. Aust N Z J Obstet Gynaecol 1991; 31:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/58\">",
"      Guidetti DA, Divon MY, Langer O. Postdate fetal surveillance: is 41 weeks too early? Am J Obstet Gynecol 1989; 161:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/59\">",
"      Bochner CJ, Williams J 3rd, Castro L, et al. The efficacy of starting postterm antenatal testing at 41 weeks as compared with 42 weeks of gestational age. Am J Obstet Gynecol 1988; 159:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/60\">",
"      Phelan JP, Platt LD, Yeh SY, et al. The role of ultrasound assessment of amniotic fluid volume in the management of the postdate pregnancy. Am J Obstet Gynecol 1985; 151:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/61\">",
"      Crowley P, O'Herlihy C, Boylan P. The value of ultrasound measurement of amniotic fluid volume in the management of prolonged pregnancies. Br J Obstet Gynaecol 1984; 91:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/62\">",
"      Oz AU, Holub B, Mendilcioglu I, et al. Renal artery Doppler investigation of the etiology of oligohydramnios in postterm pregnancy. Obstet Gynecol 2002; 100:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/63\">",
"      Tongsong T, Srisomboon J. Amniotic fluid volume as a predictor of fetal distress in postterm pregnancy. Int J Gynaecol Obstet 1993; 40:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/64\">",
"      Bochner CJ, Medearis AL, Davis J, et al. Antepartum predictors of fetal distress in postterm pregnancy. Am J Obstet Gynecol 1987; 157:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/65\">",
"      Morris JM, Thompson K, Smithey J, et al. The usefulness of ultrasound assessment of amniotic fluid in predicting adverse outcome in prolonged pregnancy: a prospective blinded observational study. BJOG 2003; 110:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16535/abstract/66\">",
"      Clement D, Schifrin BS, Kates RB. Acute oligohydramnios in postdate pregnancy. Am J Obstet Gynecol 1987; 157:884.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6749 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-EC60C7DA3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16535=[""].join("\n");
var outline_f16_9_16535=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fetal and neonatal risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6971073\">",
"      Maternal risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Induction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Expectant management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31337?source=related_link\">",
"      Fetal macrosomia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=related_link\">",
"      Oligohydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=related_link\">",
"      Overview of fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/38/26209?source=related_link\">",
"      Patient information: Postterm pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/33/15890?source=related_link\">",
"      Patient information: When your baby is overdue (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31142?source=related_link\">",
"      Postterm infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=related_link\">",
"      Small for gestational age infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41993?source=related_link\">",
"      Techniques for ripening the unfavorable cervix prior to induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/1/16408?source=related_link\">",
"      Timing and route of delivery in pregnancies at risk of shoulder dystocia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_9_16536="Norfloxacin: Drug information";
var content_f16_9_16536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Norfloxacin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/7/28789?source=see_link\">",
"    see \"Norfloxacin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6758355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Noroxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Norflox&reg;;",
"     </li>",
"     <li>",
"      CO Norfloxacin;",
"     </li>",
"     <li>",
"      Norfloxacine&reg;;",
"     </li>",
"     <li>",
"      Novo-Norfloxacin;",
"     </li>",
"     <li>",
"      PMS-Norfloxacin;",
"     </li>",
"     <li>",
"      Riva-Norfloxacin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F202604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Quinolone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F202563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dysenteric enterocolitis",
"     </b>",
"     <b>",
"      <i>",
"       (Shigella",
"      </i>",
"     </b>",
"     <b>",
"      unlabeled use):",
"     </b>",
"     Oral: 400 mg twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostatitis:",
"     </b>",
"     Oral: 400 mg every 12 hours for 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Traveler's diarrhea (unlabeled use):",
"     </b>",
"     Oral: 400 mg twice daily for 3 days, single dose may also be effective",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uncomplicated gonorrhea:",
"     </b>",
"     Oral: 800 mg as a single dose.",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of uncomplicated gonococcal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infections:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Uncomplicated due to",
"     <i>",
"      E. coli, K. pneumoniae, P. mirabilis",
"     </i>",
"     : 400 mg twice daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Uncomplicated due to other organisms: 400 mg twice daily for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Complicated: 400 mg twice daily for 10-21 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F202564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F202565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 400 mg every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F202532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Noroxin&reg;: 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F202518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM246795.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM246795.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F202536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hold antacids, sucralfate, or multivitamins/supplements containing iron, zinc, magnesium, or aluminum for 2 hours after giving norfloxacin; do not administer together. Best taken on an empty stomach with water (1 hour before or 2 hours after meals, milk, or other dairy products).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F202535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Uncomplicated and complicated urinary tract infections caused by susceptible gram-negative and gram-positive bacteria; sexually-transmitted disease (eg, uncomplicated urethral and cervical gonorrhea) caused by",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     ; prostatitis due to",
"     <i>",
"      E. coli",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of gonococcal disease.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F202611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Norfloxacin may be confused with Norflex&trade;, Noroxin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Noroxin&reg; may be confused with Neurontin&reg;, Norflex&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F202602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2% to 3%), headache (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3% to 4%), abdominal cramping (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Eosinophilia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;0.3% to 1%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperhidrosis, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorectal pain, anorexia, constipation, diarrhea, dyspepsia, flatulence, loose stools, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hematocrit/hemoglobin decreased (1%), leukopenia (1%), thrombocytopenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Proteinuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;0.3% (Limited to important or life-threatening): Acute renal failure, agranulocytosis, albuminuria, anaphylactoid reactions, anaphylaxis, angioedema, anxiety, arthralgia, arthritis, ataxia, bursitis, cholestatic jaundice, depression, diplopia, drug rash with eosinophilia and systemic symptoms (DRESS), dysgeusia, dysmenorrhea, erythema multiforme, exacerbation of myasthenia gravis, exfoliative dermatitis, GI bleeding, Guillain-Barr&eacute; syndrome, hearing loss, hematuria, hemolytic anemia (sometimes associated with G6PD deficiency), hepatic failure, hepatic necrosis, hepatitis, hyper-/hypoglycemia, hyperkalemia, hypersensitivity reactions, insomnia, interstitial nephritis, MI, myoclonus, neutropenia, nystagmus, orthostatic hypotension, pancreatitis (rare), peripheral neuropathy, photosensitivity/toxicity, pseudomembraneous colitis, pseudotumor cerebri, seizure, Stevens-Johnson syndrome, stomatitis, tendonitis, tinnitus, torsade de pointes, toxic epidermal necrolysis, triglyceridemia, vaginal candidiasis, vasculitis, ventricular arrhythmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F202539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to norfloxacin, quinolones, or any component of the formulation; history of tendonitis or tendon rupture associated with quinolone use",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F202522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Fluoroquinolones may prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval; avoid use in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, uncorrected hypokalemia, hypomagnesemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Tremor, restlessness, confusion, and very rarely hallucinations, increased intracranial pressure (including pseudotumor cerebri) or seizures may occur; use with caution in patients with known or suspected CNS disorder. Discontinue in patients who experience significant CNS adverse effects (eg, dizziness, hallucinations, suicidal ideations or actions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as s systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: The use of quinolones has been linked to peripheral neuropathy (rare); discontinue if symptoms of sensory or sensorimotor neuropathy occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions. Discontinue use if photosensitivity occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tendon inflammation/rupture:",
"     <b>",
"      [U.S. Boxed Warning]: There have been reports of tendon inflammation and/or rupture with quinolone antibiotics; risk may be increased with concurrent corticosteroids, organ transplant recipients, and in patients &gt;60 years of age.",
"     </b>",
"     Rupture of the Achilles tendon sometimes requiring surgical repair has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps) have also been reported. Strenuous physical activity may be an independent risk factor for tendonitis. Discontinue at first sign of tendon inflammation or pain. May occur even after discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis:",
"     <b>",
"      [U.S. Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis.",
"     </b>",
"     Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported; avoid use in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use caution with renal impairment; dose adjustment required. May increase risk of tendon rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in individuals at risk of seizures (CNS disorders or concurrent therapy with medications which may lower seizure threshold). Potential for seizures, although very rare, may be increased with concomitant NSAID therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syphilis: Since norfloxacin is ineffective in the treatment of syphilis and may mask symptoms, all patients should be tested for syphilis at the time of gonorrheal diagnosis and 3 months later.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Adverse effects (eg, tendon rupture, QT changes) may be increased in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Pediatrics: Safety and efficacy have not been established in children; other quinolones have caused transient arthropathy in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F202599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F202527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caffeine: Quinolone Antibiotics may decrease the metabolism of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Quinolone Antibiotics may enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Norfloxacin may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the serum concentration of Quinolone Antibiotics. Quinolone Antibiotics may decrease the serum concentration of Didanosine. Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolone antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolone Antibiotics. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Quinolone Antibiotics may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrofurantoin: May diminish the therapeutic effect of Norfloxacin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Quinolone Antibiotics. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the absorption of Quinolone Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Quinolone Antibiotics. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Quinolone Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Quinolone Antibiotics may decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Quinolone Antibiotics may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Quinolone Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F202554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Norfloxacin average peak serum concentrations may be decreased if taken with dairy products or other polyvalent cations. Norfloxacin may increase blood levels of caffeine. Management: Best taken on an empty stomach with water 1 hour before or 2 hours after meals, milk, or other dairy products. Hold antacids, sucralfate, or multivitamins/supplements containing iron, zinc, magnesium, or aluminum for 2 hours after giving norfloxacin; do not administer together. Use caution with caffeine-containing beverages/foods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Dong quai and St John's wort may cause photosensitization. Management: Avoid dong quai and St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F202529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F202542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies norfloxacin as pregnancy category C. Norfloxacin crosses the placenta, distributing to cord blood and amniotic fluid. An increased risk of teratogenic effects has not been observed in animals or humans following norfloxacin use during pregnancy; however, because of concerns of cartilage damage in immature animals, norfloxacin should only be used during pregnancy if a safer option is not available.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F202569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F202543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Norfloxacin was not detected in the milk of nursing mothers administered an oral 200 mg dose. It is not known if concentrations would be detectable after a higher dose or multiple doses. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F202544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral formulations should be administered on an empty stomach with water (1 hour before or 2 hours after meals, milk, or other dairy products). Maintain fluid intake to ensure adequate hydration and urinary output.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F202541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Noroxin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (20): $96.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15577086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor CBC, renal and hepatic function periodically if therapy is prolonged.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F202545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ambigram (CO, DO, GT, HN, PA, SV);",
"     </li>",
"     <li>",
"      Amicrobin (ES);",
"     </li>",
"     <li>",
"      Ampliron (PE);",
"     </li>",
"     <li>",
"      Anquin (IL);",
"     </li>",
"     <li>",
"      Baccidal (JP, KP, TW);",
"     </li>",
"     <li>",
"      Bexinor (SG);",
"     </li>",
"     <li>",
"      Biofloxin (IN);",
"     </li>",
"     <li>",
"      Chibroxin (AE, BH, BR, CN, CY, EG, ES, HR, IQ, IR, JO, KW, LB, LY, OM, PE, QA, SA, SY, VE, YE);",
"     </li>",
"     <li>",
"      Chibroxine (FR, UY);",
"     </li>",
"     <li>",
"      Chibroxol (LU);",
"     </li>",
"     <li>",
"      Euroflox (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Floxacin (MX);",
"     </li>",
"     <li>",
"      Fluseminal (GR);",
"     </li>",
"     <li>",
"      Gonorcin (TH);",
"     </li>",
"     <li>",
"      Grenis (PE);",
"     </li>",
"     <li>",
"      Gyrablock (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SG, SY, YE);",
"     </li>",
"     <li>",
"      Heiwin (PH);",
"     </li>",
"     <li>",
"      Janacin (HK, MY, TH);",
"     </li>",
"     <li>",
"      Lexinor (BD, CL, ID, IN, JP, PK, SE, SG, TW);",
"     </li>",
"     <li>",
"      M-Flox (TH);",
"     </li>",
"     <li>",
"      Manoflox (TH);",
"     </li>",
"     <li>",
"      Mitatonin (HK);",
"     </li>",
"     <li>",
"      Myfloxin (TH);",
"     </li>",
"     <li>",
"      Negaflox (BG);",
"     </li>",
"     <li>",
"      Niterat (CO);",
"     </li>",
"     <li>",
"      Nolicin (CZ, EE, HR, HU, PL, RU);",
"     </li>",
"     <li>",
"      Noracin (BR);",
"     </li>",
"     <li>",
"      Norbactin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Norbactin Eye Drops (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Norflogen (EC);",
"     </li>",
"     <li>",
"      Norflohexal (DE);",
"     </li>",
"     <li>",
"      Norflosal (CR, NI);",
"     </li>",
"     <li>",
"      Norflox (IN);",
"     </li>",
"     <li>",
"      Norflox Eye (IN);",
"     </li>",
"     <li>",
"      Norflox-AZU (DE);",
"     </li>",
"     <li>",
"      Norfloxbeta (DE);",
"     </li>",
"     <li>",
"      Norfloxin (MY);",
"     </li>",
"     <li>",
"      Normax Eye Ear Drops (IN);",
"     </li>",
"     <li>",
"      Noroxin (AU, BB, BF, BJ, BM, BS, BZ, CH, CI, CN, ET, FI, GH, GM, GN, GY, IT, JM, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, NL, PE, PK, PT, SC, SD, SL, SN, SR, TN, TR, TT, TZ, UG, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Noroxin Oftalmico (MX);",
"     </li>",
"     <li>",
"      Noroxine (FR);",
"     </li>",
"     <li>",
"      Norsol (AR);",
"     </li>",
"     <li>",
"      Nufloxib (AU);",
"     </li>",
"     <li>",
"      Oranor (MX);",
"     </li>",
"     <li>",
"      Orsanic (PY);",
"     </li>",
"     <li>",
"      Respexil (BR);",
"     </li>",
"     <li>",
"      Roxin (AU);",
"     </li>",
"     <li>",
"      Sefnor (TH);",
"     </li>",
"     <li>",
"      Senro (ES);",
"     </li>",
"     <li>",
"      Sofasin (GR);",
"     </li>",
"     <li>",
"      Urinex (CO, MY);",
"     </li>",
"     <li>",
"      Urobacid (MY);",
"     </li>",
"     <li>",
"      Uroctal (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Uroflox (IN);",
"     </li>",
"     <li>",
"      Uronor (UY);",
"     </li>",
"     <li>",
"      Uroseptal (EC);",
"     </li>",
"     <li>",
"      Uroxacin (AR);",
"     </li>",
"     <li>",
"      UT-in (ZA);",
"     </li>",
"     <li>",
"      Utinor (GB, PH);",
"     </li>",
"     <li>",
"      Winaflox (PH);",
"     </li>",
"     <li>",
"      Xacin (TH);",
"     </li>",
"     <li>",
"      Yeloz (CO);",
"     </li>",
"     <li>",
"      Zoroxin (AT, BE, DK, LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F202521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Norfloxacin is a DNA gyrase inhibitor. DNA gyrase is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; bactericidal",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F202538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid, up to 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 10% to 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3-4 hours; Renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute): 6.5 hours; Elderly: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (26% to 32% as unchanged drug; 5% to 8% as metabolites); feces (39%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bhattacharya SK and Sur D, &ldquo;An Evaluation of Current Shigellosis Treatment,&rdquo;",
"      <i>",
"       Expert Opin Pharmacother",
"      </i>",
"      , 2003, 4(8):1315-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/12877639/pubmed\" id=\"12877639\" target=\"_blank\">",
"        12877639",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(14):332-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/17431378/pubmed\" id=\"17431378\" target=\"_blank\">",
"        17431378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedrich LV and Dougherty R, &ldquo;Fatal Hypoglycemia Associated With Levofloxacin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(12):1807-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/15585448/pubmed\" id=\"15585448\" target=\"_blank\">",
"        15585448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frothingham R, &ldquo;Glucose Homeostasis Abnormalities Associated With Use of Gatifloxacin,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(9):1269-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/16206101/pubmed\" id=\"16206101\" target=\"_blank\">",
"        16206101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gavin JR 3rd, Kubin R, Choudhri S, et al, &ldquo;Moxifloxacin and Glucose Homeostasis: A Pooled-Analysis of the Evidence From Clinical and Postmarketing Studies,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2004, 27(9):671-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/15230648/pubmed\" id=\"15230648\" target=\"_blank\">",
"        15230648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graumlich JF, Habis S, Avelino RR, et al, &ldquo;Hypoglycemia in Inpatients After Gatifloxacin or Levofloxacin Therapy: Nested Case-Control Study,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(10):1296-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/16185172/pubmed\" id=\"16185172\" target=\"_blank\">",
"        16185172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hooper DC and Wolfson JS, &ldquo;Fluoroquinolone Antimicrobial Agents,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(6):384-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/1987461/pubmed\" id=\"1987461\" target=\"_blank\">",
"        1987461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khaliq Y and Zhanel GG, &ldquo;Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(11):1404-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/12766835/pubmed\" id=\"12766835\" target=\"_blank\">",
"        12766835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lawrence KR, Adra M, and Keir C, &ldquo;Hypoglycemia-Induced Anoxic Brain Injury Possibly Associated With Levofloxacin,&rdquo;",
"      <i>",
"       J Infect",
"      </i>",
"      , 2006, 52(6):e177-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/16269178/pubmed\" id=\"16269178\" target=\"_blank\">",
"        16269178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lo WY and Friedman JM, &ldquo;Teratogenicity of Recently Introduced Medications in Human Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2002, 100(3):465-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/12220765/pubmed\" id=\"12220765\" target=\"_blank\">",
"        12220765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loebstein R, Addis A, Ho E, et al, &ldquo;Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: A Multicenter, Prospective Controlled Study,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1998, 42(6):1336-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/9624471/pubmed\" id=\"9624471\" target=\"_blank\">",
"        9624471",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lomaestro BM and Bailie GR, &ldquo;Quinolone-Cation Interactions: A Review,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(11):1249-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/1763542/pubmed\" id=\"1763542\" target=\"_blank\">",
"        1763542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malone RS, Fish DN, Abraham E, et al, &ldquo;Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2001, 45(10):2949-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/11557500/pubmed\" id=\"11557500\" target=\"_blank\">",
"        11557500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohr JF, McKinnon PS, Peymann PJ, et al, &ldquo;A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(10):1303-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/16185173/pubmed\" id=\"16185173\" target=\"_blank\">",
"        16185173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nilsson-Ehle I and Ljungberg B, &ldquo;Quinolone Disposition in the Elderly: Practical Implications,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 1991, 1(4):279-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/1794020/pubmed\" id=\"1794020\" target=\"_blank\">",
"        1794020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Park-Wyllie LY, Juurlink DN, Kopp A, et al, &ldquo;Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(13):1352-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/16510739/pubmed\" id=\"16510739\" target=\"_blank\">",
"        16510739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stein GE, &ldquo;The 4-Quinolone Antibiotics: Past, Present, and Future,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1988, 8(6):301-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/2851772/pubmed\" id=\"2851772\" target=\"_blank\">",
"        2851772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Szarfman A, Chen M, and Blum MD, &ldquo;More on Fluoroquinolone Antibiotics and Tendon Rupture,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(3):193.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walker RC and Wright AJ, &ldquo;The Fluoroquinolones,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1991, 66(12):1249-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/1749294/pubmed\" id=\"1749294\" target=\"_blank\">",
"        1749294",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang S and Rizvi AA, &ldquo;Levofloxacin-Induced Hypoglycemia in a Nondiabetic Patient,&rdquo;",
"      <i>",
"       Am J Med Sci",
"      </i>",
"      , 2006, 331(6):334-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/16775443/pubmed\" id=\"16775443\" target=\"_blank\">",
"        16775443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Workowski KA and Berman SM, \"Centers for Disease Control and Prevention: Sexually Transmitted Diseases Treatment Guidelines,\"",
"      <i>",
"       MMWR",
"      </i>",
"      , 2006, 55(RR-11):1-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/9/16536/abstract-text/16888612/pubmed\" id=\"16888612\" target=\"_blank\">",
"        16888612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9710 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-A7B55BFC08-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16536=[""].join("\n");
var outline_f16_9_16536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6758355\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202558\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202559\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202604\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202563\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202564\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202565\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202532\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202518\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874936\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202536\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202535\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202611\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202602\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202539\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202522\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202599\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202527\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202554\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202529\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202542\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202569\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202543\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202544\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202541\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15577086\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202545\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202521\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202538\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9710\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9710|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/7/28789?source=related_link\">",
"      Norfloxacin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_9_16537="Generalized periodic epileptiform discharges";
var content_f16_9_16537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F66411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F66411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    GPEDS: generalized periodic epileptiform discharges",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 357px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chong DJ, Hirsch LJ. Which EEG patterns warrant treatment in the critically ill? Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol 2005; 22:79. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16537=[""].join("\n");
var outline_f16_9_16537=null;
var title_f16_9_16538="Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection";
var content_f16_9_16538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/9/16538/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/9/16538/contributors\">",
"     T Barry Kelleher, MD, FRCPI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/9/16538/contributors\">",
"     Nezam H Afdhal, MD, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/9/16538/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/9/16538/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/9/16538/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/9/16538/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/9/16538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects are observed in almost 80 percent of patients receiving peginterferon (PEG-IFN) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (RBV) combination therapy for chronic hepatitis C virus (HCV) infection (",
"    <a class=\"graphic graphic_figure graphicRef63602 \" href=\"UTD.htm?3/44/3790\">",
"     figure 1",
"    </a>",
"    ). Care of patients with chronic hepatitis C depends upon recognition of those at increased risk for side effects, anticipation (and prevention) of side effects, and appropriate response when they occur. Furthermore, the ability to achieve a sustained virologic response (SVR) to therapy depends in part upon the degree of compliance with therapy. Reduction of the dose of these agents (or their discontinuation) due to side effects can potentially compromise the outcome, depending upon when dose reduction occurs.",
"   </p>",
"   <p>",
"    This topic review will summarize the major side effects associated with combination therapy. A detailed discussion on combination therapy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEMATOLOGIC SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic side effects are common during treatment with peginterferon (PEG-IFN) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (RBV). One study found that they were more common in patients with a history of hypertension, a low baseline platelet count, low baseline hemoglobin, and raised serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is extremely common among patients taking",
"    <span class=\"nowrap\">",
"     PEG-IFN/RBV",
"    </span>",
"    combination therapy for chronic hepatitis C.",
"   </p>",
"   <p>",
"    In a retrospective analysis of 677 patients who were treated with non-pegylated (standard) interferon (IFN) and RBV, 56 percent experienced a decrease in hemoglobin of &ge;3",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and in approximately 10 percent the hemoglobin declined to less than 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard IFN and RBV therapy is associated with a mean maximal hemoglobin decrease within the first 12 weeks of 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/3\">",
"     3",
"    </a>",
"    ]. In more recent studies of PEG-IFN and RBV, the development of anemia and need for dose reductions were similar to those previously reported with standard IFN and RBV. The maximal decrease in hemoglobin is reported at 3.7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/4\">",
"     4",
"    </a>",
"    ] in individuals with normal renal function, with the development of a hemoglobin less than 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    ranging between 9 to 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of anemia is multifactorial and is caused by RBV-induced hemolysis and IFN suppression of the normal compensatory bone marrow response. IFN is a potent suppressor of all components of the bone marrow and inhibits erythropoiesis, as evidenced by an inadequate reticulocyte response to anemia. IFN has also been associated with autoimmune hemolytic anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H21#H21\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'AIHA after interferon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RBV is the major contributor to treatment-associated anemia. RBV-induced hemolytic anemia is dose dependent, although the exact mechanism is unclear. It resolves upon discontinuation and stabilizes with dose reduction. RBV is concentrated within erythrocytes and results in a relative deficiency of adenosine triphosphate (ATP) within red blood cells and hence increased susceptibility to oxidative damage and extravascular hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Hemolysis correlates with the concentration of RBV and its metabolites in red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]; levels reach a steady state after three to four weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/12\">",
"     12",
"    </a>",
"    ]. RBV also causes bone marrow erythroid hypoplasia in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link&amp;anchor=H5#H5\">",
"     \"Investigational therapies for hepatitis C virus infection\", section on 'Ribavirin derivatives'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Host genetic factors appear to contribute to the hemolysis seen with RBV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/15\">",
"     15",
"    </a>",
"    ]. A genome-wide association study identified polymorphisms in a region of chromosome 20 that were associated with a decreased risk of RBV-induced hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/16\">",
"     16",
"    </a>",
"    ]. The polymorphisms were associated with decreased functionality of inosine triphosphatase (ITPA). ITPA hydrolyzes inosine triphosphate (ITP) and deoxyinosine triphosphate, and defects in the enzyme lead to ITP accumulation within the cell. It is postulated that the accumulated ITP competes with the triphosphate active form of RBV in an unknown cellular processes, protecting cells from the lytic effects of RBV-triphosphate.",
"   </p>",
"   <p>",
"    The recommended manufacturers' guidelines for the treatment of",
"    <span class=\"nowrap\">",
"     PEG-IFN/RBV-induced",
"    </span>",
"    anemia center on RBV dose reduction (",
"    <a class=\"graphic graphic_table graphicRef53213 graphicRef75290 \" href=\"UTD.htm?23/60/24525\">",
"     table 1A-B",
"    </a>",
"    ). Special care needs to be taken in patients with a history of cardiac disease. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"     \"Pegylated interferon (peginterferon) alfa-2a: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     \"Ribavirin: Pediatric drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?37/5/37974?source=see_link\">",
"     \"Pegylated interferon (peginterferon) alfa-2b and ribavirin: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to emphasize that RBV is renally excreted and may accumulate to dangerously toxic levels in patients with impaired renal function. RBV should be completely avoided in patients on dialysis or with moderate to severe renal insufficiency.",
"   </p>",
"   <p>",
"    It may also be possible to prevent the development of anemia or decrease its severity. A small trial in children and young adults suggested that eicosapentaenoic acid, an omega-3 fatty acid, may decrease the reduction in hemoglobin seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    use [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/17\">",
"     17",
"    </a>",
"    ]. Additional trials are warranted to further investigate eicosapentaenoic acid's potential role in the treatment of HCV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Use of erythropoietic growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reducing the dose of PEG-IFN",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RBV to a total cumulative dose less than 80 percent of planned exposure over a 48 week period, in particular prematurely discontinuing either of these agents, is associated with a decline in sustained virologic response (SVR). One strategy to limit dose reduction and prevent the need to interrupt therapy has been the use of erythropoietic growth factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies evaluating the use of erythropoietin (EPO) in HCV patients treated with IFN and RBV have been published in final or preliminary form (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. At least two decision analyses concluded that approaches involving EPO or darbepoetin were cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, the cost-effectiveness was sensitive to rates of SVR and there is no definite evidence that use of these growth factors can increase SVR. Nevertheless, significant improvement seen in quality of life, particularly fatigue, by maintaining the hemoglobin above",
"    <span class=\"nowrap\">",
"     12g/dL",
"    </span>",
"    has led many experts to adopt the use of EPO as an adjunct to HCV therapy. Notably, EPO may not be reimbursed by all insurers, depending in part upon the hemoglobin level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H348977446#H348977446\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Medicare and Medicaid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EPO is not approved by the US Food and Drug Administration for treatment or prevention of anemia in patients undergoing treatment for HCV. Nevertheless, it is used commonly in patients with anemia during treatment of HCV in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/11\">",
"     11",
"    </a>",
"    ]. It can be administered at any time point throughout the course of therapy depending on patient preference. It has been traditional practice to maintain hemoglobin values between 11 and 12",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    However, because of concerns about increased mortality rates and increased rates of thromboembolic disease (especially with higher hemoglobin levels) associated with the use of erythropoietic stimulating agents in patients with cancer and chronic renal failure, it may be wiser to keep hemoglobin levels closer to 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. Darbepoetin (which has a much longer half life) has also been used but there is less experience [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15412?source=see_link\">",
"     \"Erythropoietin: Subcutaneous administration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Side effects associated with the use of EPO include headache and flu-like symptoms. Pure red cell aplasia with EPO use has been reported due to the development of anti-erythropoietin antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/29\">",
"     29",
"    </a>",
"    ]. One case has also been reported in a patient taking EPO while on",
"    <span class=\"nowrap\">",
"     PEG-IFN/RBV",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/30\">",
"     30",
"    </a>",
"    ]. Red cell aplasia due to EPO is considered to be rare with an estimated incidence of 0.02 per 10,000 patient-years of exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=see_link\">",
"     \"Pure red cell aplasia due to anti-erythropoietin antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following examples are illustrative of the findings in the largest reports.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an open label study, patients who had hemoglobin levels of 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or less during the first 24 weeks of combination",
"      <span class=\"nowrap\">",
"       PEG-IFN/RBV",
"      </span>",
"      therapy (n = 64) were randomly assigned to treatment with EPO (40,000 units) weekly or to standard care [",
"      <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/18\">",
"       18",
"      </a>",
"      ]. At week 16, the mean hemoglobin in the EPO group was significantly higher than those receiving standard care (13.8 versus 11.4",
"      <span class=\"nowrap\">",
"       g/dL).",
"      </span>",
"      At study end, significantly more patients who received EPO maintained a dose of RBV of at least 800",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (83 versus 54 percent). The effect on SVR was not reported.",
"     </li>",
"     <li>",
"      Another trial included 185 patients who developed anemia (hemoglobin &lt;12",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      while on combination therapy who were randomly assigned to EPO (40,000 units weekly given subcutaneously, increased to 60,000 units if hemoglobin failed to increase by 1",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/19\">",
"       19",
"      </a>",
"      ]. The RBV dose was maintained in significantly more patients randomized to EPO (88 versus 60 percent); there was a corresponding significant increase in mean hemoglobin concentration (2.2 versus 0.1",
"      <span class=\"nowrap\">",
"       g/dL).",
"       <br/>",
"       <br/>",
"       Interestingly,",
"      </span>",
"      dose reduction alone is rarely associated with an increase in hemoglobin above 12",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      This becomes important when considering changes in quality of life (QOL). In the EPO group there was an improvement in QOL in seven of the eight domains of the SF-36, but particularly in the areas of vitality and physical functioning. Maximal improvements of QOL were seen when hemoglobin levels were raised above 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third trial included 150 patients with chronic genotype 1 HCV infection who were randomly assigned to one of three groups: (a)",
"      <span class=\"nowrap\">",
"       PEG-IFN/RBV",
"      </span>",
"      with RBV 13.3",
"      <span class=\"nowrap\">",
"       mg/kg/day;",
"      </span>",
"      (b)",
"      <span class=\"nowrap\">",
"       PEG-IFN/RBV",
"      </span>",
"      with RBV 13.3",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      plus 40,000 units EPO per week; (c)",
"      <span class=\"nowrap\">",
"       PEG-IFN/RBV",
"      </span>",
"      with a higher dose of RBV (15.2",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      plus EPO 40,000 units per week [",
"      <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/20\">",
"       20",
"      </a>",
"      ]. In groups b and c, EPO was initiated at the start of therapy and titrated to maintain a hemoglobin level of between 12 and 15",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      The dose of RBV was reduced by 200 mg increments in all groups if the hemoglobin declined below 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or for management of other side effects as needed.",
"      <br/>",
"      <br/>",
"      No significant difference in end-of-treatment response was observed among the three groups. However, SVR was higher in group c (45 percent) compared with groups a and b (27 and 24 percent, respectively) because of a lower rate of relapse. The SVR overall for this study was lower than previously reported, but the lower rate was probably due to a relatively high percentage of African Americans in the study who generally have lower response rates. The authors concluded that a significant increase in SVR can be achieved in patients with genotype 1 treated with higher doses of RBV with EPO to prevent dose reduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with interferon is commonly associated with bone marrow suppression. Depressed neutrophil counts could potentially increase the risk of infection, though some studies have failed to show an association [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/32\">",
"     32",
"    </a>",
"    ]. Neutropenia is defined as an absolute neutrophil count (ANC) less than",
"    <span class=\"nowrap\">",
"     1500/microL.",
"    </span>",
"    Neutropenia can be mild (ANC of 1000 to",
"    <span class=\"nowrap\">",
"     1500/microL),",
"    </span>",
"    moderate (ANC of 1000 to",
"    <span class=\"nowrap\">",
"     500/microL),",
"    </span>",
"    or severe (ANC",
"    <span class=\"nowrap\">",
"     &lt;500/microL).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of neutropenia\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PEG-IFN has a pharmacokinetic profile associated with more profound bone marrow suppression than standard IFN. While dose reductions due to neutropenia are required in 5 to 8 percent of patients on standard interferon, dose reductions are required in 18 to 20 percent of patients on peginterferon [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Severe neutropenia developing during the course of therapy has been described in approximately 0.66 percent of patients receiving PEG-IFN compared with 0.22 percent of those taking standard IFN [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the reduction in ANC, the rate of bacterial sepsis is relatively low in HCV treated patients. A study of 119 patients with chronic hepatitis C treated with standard IFN and RBV noted an average reduction in ANC of 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/33\">",
"     33",
"    </a>",
"    ]. Documented or suspected bacterial infections developed in 22 patients (18 percent), but in no patient with neutropenia. Similar conclusions were reached in a large multicenter trial in the United States in which bacterial infections did not correlate with the duration of neutropenia or the nadir neutrophil count [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/34\">",
"     34",
"    </a>",
"    ]. In African American HCV-infected patients (who may have constitutional neutropenia), the neutrophil count does not appear to decline significantly from baseline, suggesting that such patients should not necessarily be excluded from treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for IFN dose reduction for neutropenia have been provided by the manufacturers. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"     \"Pegylated interferon (peginterferon) alfa-2a: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?37/5/37974?source=see_link\">",
"     \"Pegylated interferon (peginterferon) alfa-2b and ribavirin: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Filgrastim",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     Filgrastim",
"    </a>",
"    is a human",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) that targets late myeloid progenitors, enhancing their production and function. Filgrastim is licensed for use in chemotherapy-induced marrow suppression and bone marrow transplantation to ameliorate neutropenia and prevent and treat sepsis.",
"   </p>",
"   <p>",
"    Some clinicians have advocated use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    (300 mcg one to three times per week) to avoid IFN dose reduction during treatment of HCV. However, the efficacy of this approach is unclear. Only one small controlled trial has described the use of filgrastim in combination with IFN therapy for hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/35\">",
"     35",
"    </a>",
"    ]. A total of 30 patients with HCV and advanced histologic disease were randomly assigned to 5 million units of IFN daily alone or in combination with G-CSF (300 mcg SQ on Mondays and Thursdays). As expected, mean white blood cell (WBC) count and peak WBC counts of those receiving G-CSF were greater than those not receiving G-CSF therapy. The SVR rate was higher in those treated with filgrastim but the results were not statistically significant.",
"   </p>",
"   <p>",
"    Given the lack of evidence that neutropenia is associated with a significantly increased risk of sepsis in HCV treated patients, the expense of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    , and the potential side effects of filgrastim, we suggest it be considered only for those with ANCs of less than",
"    <span class=\"nowrap\">",
"     500/microL",
"    </span>",
"    and a higher than average risk of infection, such as those with cirrhosis,",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    co-infection, and patients posttransplantation on immunosuppressants. In such patients, it is our practice to use filgrastim 48 hours prior to the weekly PEG-IFN administration to counteract the maximal neutropenic effects of the PEG-IFN. It is important not to measure the neutrophil count within 24 hours of PEG-IFN since neutropenia is maximal at that time. The dose can be titrated from 300 mcg once weekly up to 300 mcg three times per week with a goal of maintaining the ANC greater than",
"    <span class=\"nowrap\">",
"     750/microL.",
"    </span>",
"    Filgrastim is generally extremely well tolerated; common side effects include nausea, bone pain, and flu-like illness, although these are usually masked by the symptoms associated with PEG-IFN and RBV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia is common in patients with advanced liver disease. The cause is multifactorial due in part to increased platelet sequestration in the spleen and reduced production of thrombopoietin (a cytokine that regulates megakaryocyte maturation and platelet production) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Interferon also reduces the platelet count. In patients treated with PEG-IFN alfa 2a and RBV, dose reduction is necessary in 3 to 4 percent of those treated with",
"    <span class=\"nowrap\">",
"     PEG-IFN/RBV",
"    </span>",
"    versus 1 percent in those treated with standard IFN and RBV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 321 patients with HCV, the mean platelet count dropped from",
"    <span class=\"nowrap\">",
"     191,000/microL",
"    </span>",
"    prior to treatment to",
"    <span class=\"nowrap\">",
"     113,100/microL",
"    </span>",
"    (42 percent) during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/38\">",
"     38",
"    </a>",
"    ]. A platelet count of &lt;50,000 was seen in 30 patients (9 percent) and a platelet count of",
"    <span class=\"nowrap\">",
"     &lt;25,000/microL",
"    </span>",
"    was seen in 9 patients (3 percent). Minor bleeding was more common in patients with platelet counts",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL",
"    </span>",
"    compared with patients whose counts were",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    or greater (11 versus 1 percent). The mean platelet count in patients with minor bleeding was",
"    <span class=\"nowrap\">",
"     80,800/microL",
"    </span>",
"    at the time of bleeding, compared with",
"    <span class=\"nowrap\">",
"     144,800/microL",
"    </span>",
"    at visits that were not associated with bleeding. The one case of significant bleeding (due to angiodysplasia) occurred in a patient with a platelet count of",
"    <span class=\"nowrap\">",
"     65,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Severe thrombocytopenia is usually seen only in those with established cirrhosis or in rare patients in whom IFN induces autoimmune thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/39\">",
"     39",
"    </a>",
"    ]. Platelet counts increase in patients who achieved an SVR, possibly because of a reduction in splenomegaly, improvement in hepatic fibrosis, and increased production of thrombopoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The manufacturers have provided recommendations for dose reduction in patients who develop thrombocytopenia. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"     \"Pegylated interferon (peginterferon) alfa-2a: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?37/5/37974?source=see_link\">",
"     \"Pegylated interferon (peginterferon) alfa-2b and ribavirin: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other than dose reduction, there are no approved therapies available to augment platelet count in those undergoing treatment with PEG-IFN and RBV. The development and use of platelet derived growth factors could enhance tolerability, safety, and efficacy of IFN therapy in patients with HCV. Two such agents are now available, but more data are needed before they can be recommended.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/58/34724?source=see_link\">",
"     Oprelvekin",
"    </a>",
"    (IL-11) is approved for the treatment of chemotherapy-induced thrombocytopenia; however, it is associated with significant fluid retention and arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link\">",
"     \"Clinical applications of thrombopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     Eltrombopag",
"    </a>",
"    (approved by the FDA in November 2008) is a small molecule agonist of the physiological target of thrombopoietin leading to increased activation and differentiation of megakaryocytes. In a study on patients with hepatitis C cirrhosis, it caused a dose dependent increase in platelet count thereby permitting the initiation of antiviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/42\">",
"     42",
"    </a>",
"    ]. However, an FDA Safety Alert was issued in May 2010 when the ELEVATE (ELtrombopag EVaulated for its Ability to overcome Thrombocytopenia and Enable procedures) trial was terminated due to an increased incidence of portal vein thrombosis in patients with chronic liver disease and thrombocytopenia who were receiving eltrombopag. Six patients (4 percent) of the patient in the eltrombopag group developed portal vein thromboses compared with only one patient (1 percent) in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a preliminary report of a second randomized trial, 715 patients with HCV and thrombocytopenia were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients who achieved a platelet count of 90,000 or higher (682 patients) were then assigned to peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    plus eltrombopag (450 patients) or placebo (232 patients). Patients in the eltrombopag arm had a longer interval to first antiviral dose reduction and a lower proportion of antiviral dose reductions. SVR rates were also higher in the eltrombopag arm (23 versus 14 percent). There was no significant difference between the groups with regard thromboembolic events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FLU-LIKE SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects associated with IFN therapy are flu-like symptoms (mainly muscle aches, headaches, and low-grade fevers) which are seen in over 80 percent of patients. Flu-like symptoms are most severe in the first 48 hours after IFN administration and persist beyond the third month of therapy in only 10 percent of patients. Patients should be advised to anticipate such symptoms and reassured that they tend to improve with continued therapy. We also suggest that patients take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (one gram 30 minutes before injection) and increase their fluid intake. We suggest that the total dose of acetaminophen not exceed 2 g per day. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"     \"Patient information: Hepatitis C (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NEUROPSYCHIATRIC SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With improved management of anemia and other side effects associated with treatment, neuropsychiatric reactions have come to account for a progressively larger share of the overall burden associated with treatment. Indeed, neuropsychiatric side effects are increasingly recognized as a primary cause of both treatment failure and clinical decisions not to start treatment in the first place. Their recognition and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24551?source=see_link\">",
"     \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Recognition and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1674?source=see_link\">",
"     \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Respiratory tract symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory tract symptoms including a nonproductive cough and shortness of breath are relatively common with IFN monotherapy, and occur at a similar rate in those treated with",
"    <span class=\"nowrap\">",
"     PEG-IFN/RBV",
"    </span>",
"    (24 versus 26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/6\">",
"     6",
"    </a>",
"    ]. RBV use may be associated with a persistent cough without any objective airway disease. The etiology of dyspnea is usually related to the severity of anemia; however, rarely interstitial pneumonia and bronchiolitis obliterans can occur and necessitate immediate discontinuation of",
"    <span class=\"nowrap\">",
"     PEG-IFN/RBV",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Fortunately they are rare complications of IFN therapy and have generally occurred in patients receiving high doses of intravenous IFN. Assessment of dyspnea requires immediate measurement of hemoglobin and chest x-ray. As a general rule, in the setting of anemia and a normal chest x-ray, treatment of anemia with either dose reduction or institution of erythropoietin will improve or resolve symptoms of dyspnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246677798\">",
"    <span class=\"h2\">",
"     Nausea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea has been reported in 29 to 43 percent of patients treated with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/47\">",
"     47",
"    </a>",
"    ]. Management includes the use of antiemetic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=see_link&amp;anchor=H558191836#H558191836\">",
"     \"Approach to the adult with nausea and vomiting\", section on 'Antiemetics and prokinetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ophthalmologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ophthalmologic disorders (retinal hemorrhages, cotton wool spots, loss of color vision, and rarely retinal artery or vein obstruction) can occur during IFN therapy. The most common ocular complication has been the development of a mild-to-moderate ischemic retinopathy. On fundoscopy, this appears as cotton-wool spots or hemorrhages that resemble diabetic retinopathy. The incidence of this retinopathy has varied greatly in different reports (2 to 86 percent), but most cases have not been associated with significant visual loss [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/48-55\">",
"     48-55",
"    </a>",
"    ]. The risk may be greater in patients with a history of hypertension or diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/48,55\">",
"     48,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several cases of glaucoma have also been reported in association with IFN therapy, but a causative association remains unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Case reports have also described a toxic effect of IFN on the optic nerve, in which patients presented with blurred vision similar to that seen with optic neuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/49,58\">",
"     49,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be cautioned about the possibility of visual disturbance when they are treated with IFN therapy. We suggest a baseline retinal examination performed by an ophthalmologist in patients who have diabetes or hypertension prior to treatment and then we perform regular fundoscopic examination during treatment. In addition, we refer patients for prompt ophthalmologic examination for any new ophthalmologic complaints particularly changes in visual acuity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Glucose metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have suggested an association between HCV and diabetes mellitus, although the strength of the association remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link\">",
"     \"Extrahepatic manifestations of hepatitis C virus infection\"",
"    </a>",
"    .) Patients with established type 1 diabetes mellitus may experience a worsening of glucose homeostasis (and even the development of ketoacidosis) while those with type 2 diabetes controlled with dietary measures or oral agents may develop a requirement for insulin.",
"   </p>",
"   <p>",
"    We suggest monitoring of blood glucose and hemoglobin A1C and informing patients of the disturbances that may occur in their glucose levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counseling both male and female patients about the risks of pregnancy while on",
"    <span class=\"nowrap\">",
"     PEG-IFN/RBV",
"    </span>",
"    therapy, and for six months after discontinuing treatment, is critically important. IFN (5 to 10 million units) caused abortion in pregnant rhesus monkeys, and there are no adequate and well-controlled studies in pregnant women. IFN is therefore not advisable in pregnancy.",
"   </p>",
"   <p>",
"    RBV produced significant embryonal or teratogenic effects in every animal species studied. Thus, it is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in pregnancy, and any woman that becomes pregnant on RBV should immediately notify their clinician and receive appropriate counseling about teratogenicity and the option for therapeutic abortion. In addition, women should not become pregnant during the six months after stopping RBV. The risk of birth defects in men taking RBV is unclear, but men taking RBV should be advised not to impregnate their partners while on",
"    <span class=\"nowrap\">",
"     PEG-IFN/RBV",
"    </span>",
"    or for six months after stopping the medications. We advise all patients on RBV to practice at least two forms of contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Autoimmune disease exacerbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other autoimmune diseases can develop or be exacerbated during IFN therapy, including psoriasis, vitiligo, rheumatoid arthritis, lichen planus, sarcoidosis, dermatitis herpetiformis, and type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/60-66\">",
"     60-66",
"    </a>",
"    ]. Thus, IFN should be used with caution in patients with known autoimmune disease and is contraindicated in patients with known autoimmune hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis has been described in association with HCV and with IFN therapy. In a summary of case reports that included 68 patients with HCV-associated sarcoidosis, the sarcoidosis first appeared after starting interferon-based therapy in 75 percent of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/66\">",
"     66",
"    </a>",
"    ]. Symptoms developed within the first six months in two-thirds of patients. Clinical features included predominantly pulmonary disease (76 percent) and cutaneous disease (60 percent). Compared with a control population of patients with sarcoidosis without HCV, patients with both disorders were less likely to have hilar or extrapulmonary adenopathy and had a higher prevalence of cutaneous sarcoidosis and articular involvement.",
"   </p>",
"   <p>",
"    Management was described in 42 cases. Antiviral therapy was stopped in 25 patients (60 percent) and continued or adjusted in 6 patients. In the remaining 11 patients, sarcoidosis first appeared after antiviral therapy had been discontinued. Of 46 patients with follow-up data, remission or improvement was observed in 83 percent, while stabilization occurred in an additional 11 percent. The authors note that the clinical course may be more severe in patients with preexisting sarcoidosis treated with antiviral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dermatologic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV has been associated with multiple dermatologic complications including leukocytoclastic vasculitis, porphyria cutanea tarda, lichen planus, erythema nodosum, urticaria, erythema multiforme, and polyarteritis nodosa (",
"    <a class=\"graphic graphic_table graphicRef82174 \" href=\"UTD.htm?13/12/13515\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Both IFN and RBV have been associated with rashes. The most common is a non-specific, pruritic rash associated with flaky dry skin. Although the rash has been attributed to RBV, it appears to be more common in those treated with",
"    <span class=\"nowrap\">",
"     PEG-IFN/RBV",
"    </span>",
"    combination therapy. The rash resolves over time in many patients but may require a reduction in the dose of RBV (or discontinuation) if it is severe. All patients are advised to avoid powerful skin detergents and use regular non-perfumed skin moisturizers in addition to sunblock. With persistent symptoms we also suggest a low-potency steroid cream (1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ) and non-sedating antihistamine (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    10 mg).",
"   </p>",
"   <p>",
"    Erythema and induration are almost invariable at the IFN injection site, however they may occasionally deteriorate to painful nodules and rarely ulcerate. If severe injection site reactions occur we immediately assess injection technique and avoid further injections in that region.",
"   </p>",
"   <p>",
"    Hyperpigmentation of the tongue has been described with",
"    <span class=\"nowrap\">",
"     PEG-IFN/RBV",
"    </span>",
"    combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. It primarily occurs in dark-skinned patients and typically improves or disappears slowly once treatment is complete. Associated hyperpigmentation of the gums, oral mucosa, and skin may also be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hair loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversible hair loss occurs in approximately 20 percent of patients, probably due to telogen effluvium, as a result of IFN [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/73\">",
"     73",
"    </a>",
"    ]. While it resolves upon discontinuation of therapy, it can be distressing to patients. Anecdotal experience suggests hair loss may be reduced by using",
"    <span class=\"nowrap\">",
"     silk/satin",
"    </span>",
"    pillow cases, avoiding high pressure showers, and cutting long hair. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    has also been used but its efficacy is unclear. Hair growth returns to normal within three to six months following discontinuation of treatment. Autoimmune alopecia areata has also been reported with IFN but is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Thyroid dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of thyroid dysfunction is common in patients treated with IFN. The most common interferon-alfa-associated thyroid abnormality is the development of antithyroid antibodies without clinical disease (5 to 15 percent of patients). Approximately 5 to 10 percent of patients develop one of three autoimmune thyroid diseases: Patients can develop hyperthyroidism due to Graves' disease, painless thyroiditis (a variant of Hashimoto's thyroiditis) with a triphasic course of transient hyperthyroidism followed by transient hypothyroidism with a return to euthyroidism, or hypothyroidism due to Hashimoto's thyroiditis. More rarely, patients may develop hypothyroidism that does not appear to be related to underlying autoimmunity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36505?source=see_link&amp;anchor=H5#H5\">",
"     \"Principles of interferon therapy in liver disease and the induction of autoimmunity\", section on 'Thyroid disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=see_link\">",
"     \"Painless thyroiditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients receiving IFN alfa should be monitored for thyroid disease, particularly women and patients with preexisting antithyroid antibodies. We suggest measuring TSH and antithyroid antibodies before treatment and every 12 weeks during treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IFN therapy can usually be continued while hypothyroidism is being treated.",
"     </li>",
"     <li>",
"      Asymptomatic biochemical hyperthyroidism due to Graves' disease or painless thyroiditis that is picked up on scheduled thyroid testing can be observed closely and, if symptoms are minimal, low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      can be instituted. If clinically apparent hyperthyroidism develops, we stop",
"      <span class=\"nowrap\">",
"       PEG-IFN/RBV",
"      </span>",
"      and get specialist endocrinology assistance with further management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"       \"Diagnosis of and screening for hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"       \"Diagnosis of hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following interferon withdrawal, spontaneous normalization of thyroid function can be expected in many, but not all, patients with hypothyroidism, but not in those who develop Graves' disease. Persistence of antithyroglobulin and antithyroid peroxidase antibodies after stopping interferon therapy predicts the later development of thyroid dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36505?source=see_link&amp;anchor=H5#H5\">",
"     \"Principles of interferon therapy in liver disease and the induction of autoimmunity\", section on 'Thyroid disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Migraine headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine headaches develop in fewer than 2 percent of patients receiving combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/75\">",
"     75",
"    </a>",
"    ]. They appear to be due to RBV and are reversible when RBV is discontinued or, in some cases, the dose is reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden hearing loss and tinnitus have been described with IFN and PEG-IFN IFN plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/9/16538/abstract/76\">",
"     76",
"    </a>",
"    ]. The mechanism is unclear but may be related to direct ototoxicity of IFN, autoimmunity, or hematologic changes. Hearing loss has not fully resolved in all patients after discontinuing therapy. On the other hand, continuation of therapy may not worsen symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects are observed in almost 80 percent of patients receiving peginterferon (PEG-IFN) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (RBV) combination therapy for chronic hepatitis C virus (HCV) infection (",
"    <a class=\"graphic graphic_figure graphicRef63602 \" href=\"UTD.htm?3/44/3790\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Anemia and neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    are commonly associated with anemia and neutropenia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The recommended manufacturers' guidelines for the treatment of",
"      <span class=\"nowrap\">",
"       PEG-IFN/RBV",
"      </span>",
"      induced anemia center upon RBV dose reduction (",
"      <a class=\"graphic graphic_table graphicRef53213 graphicRef75290 \" href=\"UTD.htm?23/60/24525\">",
"       table 1A-B",
"      </a>",
"      ). Special care needs to be taken in patients with a history of cardiac disease. (See",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"       \"Pegylated interferon (peginterferon) alfa-2a: Drug information\"",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"       \"Ribavirin: Pediatric drug information\"",
"      </a>",
"      and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?37/5/37974?source=see_link\">",
"       \"Pegylated interferon (peginterferon) alfa-2b and ribavirin: Patient drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who develop anemia, we suggest use of erythropoietin&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The major expected benefit is improvement in quality of life since a benefit on sustained virologic response has not been consistently demonstrated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Use of erythropoietic growth factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with interferon is commonly associated with neutropenia. Given the lack of evidence that neutropenia is associated with a significantly increased risk of sepsis in HCV treated patients, and the expense, costs, and potential side effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       filgrastim",
"      </a>",
"      , we suggest that it should be considered only for those with an absolute neutrophil count of less than",
"      <span class=\"nowrap\">",
"       500/microL",
"      </span>",
"      and a higher than average risk of infection, such as those with cirrhosis,",
"      <span class=\"nowrap\">",
"       HIV/HCV",
"      </span>",
"      co-infection, and patients posttransplantation on immunosuppressants (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Flu-like symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be advised to anticipate such symptoms and reassured that they tend to improve with continued therapy. We also suggest that patients take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (1 gram 30 minutes before injection) and increase their fluid intake (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest that the total dose of acetaminophen not exceed 2 grams per day. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Flu-like symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Neuropsychiatric side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition and management are of neuropsychiatric side effects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24551?source=see_link\">",
"     \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Recognition and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1674?source=see_link\">",
"     \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of other side effects have been described. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Other'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/1\">",
"      Nachnani JS, Rao GA, Bulchandani D, et al. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin. Ann Hematol 2010; 89:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/2\">",
"      Sulkowski MS, Wasserman R, Brooks L, et al. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/3\">",
"      Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19 Suppl 1:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/4\">",
"      Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/5\">",
"      Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/6\">",
"      Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/7\">",
"      De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/8\">",
"      Grattagliano I, Russmann S, Palmieri VO, et al. Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. Hepatology 2004; 39:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/9\">",
"      Balestrieri C, Serra G, Cauli C, et al. Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? Blood 2006; 107:3409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/10\">",
"      Lin CC, Yeh LT, Vitarella D, Hong Z. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir Chem Chemother 2003; 14:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/11\">",
"      McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int 2006; 26:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/12\">",
"      Homma M, Matsuzaki Y, Inoue Y, et al. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004; 2:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/13\">",
"      Canonico PG, Kastello MD, Spears CT, et al. Effects of ribavirin on red blood cells. Toxicol Appl Pharmacol 1984; 74:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/14\">",
"      Cosgriff TM, Hodgson LA, Canonico PG, et al. Morphological alterations in blood and bone marrow of ribavirin-treated monkeys. Acta Haematol 1984; 72:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/15\">",
"      Asselah T, Pasmant E, Lyoumi S. Unraveling the genetic predisposition of ribavirin-induced anaemia. J Hepatol 2010; 53:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/16\">",
"      Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/17\">",
"      Suzuki M, Inage E, Minowa K, et al. Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients. Pediatr Int 2012; 54:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/18\">",
"      Dieterich DT, Wasserman R, Br&auml;u N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/19\">",
"      Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/20\">",
"      Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/21\">",
"      Younossi Z, Ong J, Collantes R. Darbepoetin alfa for ribavirin-induced anemia in patients with chronic hepatitis C treated with pegylated interferon and ribavirin: a preliminary analysis. Gastroenterology 2004; 126 Suppl 2:AB83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/22\">",
"      Spiegel BM, Chen K, Chiou CF, et al. Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clin Gastroenterol Hepatol 2005; 3:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/23\">",
"      Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006; 44:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/24\">",
"      Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/25\">",
"      Henke M, Laszig R, R&uuml;be C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/26\">",
"      Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23:5960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/27\">",
"      Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/28\">",
"      Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006; 24:4708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/29\">",
"      Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/30\">",
"      Stravitz RT, Chung H, Sterling RK, et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005; 100:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/31\">",
"      Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/32\">",
"      Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 2010; 52:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/33\">",
"      Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/34\">",
"      Jacobson IM, Brown RS, Frielich B, et al. Weight-based Ribavirin dosing increases sustained virological response in patients with chronic hepatitis C: final results of the WIN-R study, a US community based trial (abstract). Hepatology 2005; 42:749A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/35\">",
"      Van Thiel DH, Faruki H, Friedlander L, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995; 42:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/36\">",
"      Kawasaki T, Takeshita A, Souda K, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999; 94:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/37\">",
"      Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of \"hypersplenic\" thrombocytopenia. J Clin Invest 1966; 45:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/38\">",
"      Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol 2010; 53:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/39\">",
"      Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002; 107:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/40\">",
"      Yagura M, Tanaka A, Tokita H, et al. Factors regarding increase of platelet counts in chronic hepatitis C patients with sustained virological response to interferon-Relation to serum thrombopoietin levels. Hepatol Res 2005; 33:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/41\">",
"      Artz AS, Ershler WB, Rustgi V. Interleukin-11 for thrombocytopenia associated with hepatitis C. J Clin Gastroenterol 2001; 33:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/42\">",
"      McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357:2227.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm211796.htm (Accessed on May 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/44\">",
"      Adfdhal N, Dusheiko G, Giannini EG, et al. Final results of ENABLE 1, a phase 3 multicenter study of eltrombopag as an adjunct for antiviral treatment of hepatitis C virus-related chronic liver disease associated with thrombocytopenia. Hepatology 2011; 54:1427A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/45\">",
"      Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 1994; 106:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/46\">",
"      Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci 2010; 55:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/47\">",
"      Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36:S237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/48\">",
"      Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996; 91:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/49\">",
"      Manesis EK, Moschos M, Brouzas D, et al. Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998; 27:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/50\">",
"      Kuga K, Hasumura S, Nagamori S, et al. Intraocular hemorrhage developing during interferon therapy. Intern Med 1996; 35:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/51\">",
"      Hayasaka S, Fujii M, Yamamoto Y, et al. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 1995; 79:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/52\">",
"      Manesis EK, Petrou C, Brouzas D, Hadziyannis S. Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol 1994; 21:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/53\">",
"      Fortin E. Neurovisual complications of interferon-alpha therapy. Hepatology 1998; 27:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/54\">",
"      Mehta N, Murthy UK, Kaul V, et al. Outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin. Dig Dis Sci 2010; 55:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/55\">",
"      Vujosevic S, Tempesta D, Noventa F, et al. Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening. Hepatology 2012; 56:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/56\">",
"      Moriarty AP. Indocyanine green enhanced diode laser photocoagulation of subretinal neovascular membranes. Br J Ophthalmol 1994; 78:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/57\">",
"      Kwon YS, Choe YH, Chin HS. Development of glaucoma in the course of interferon alpha therapy for chronic hepatitis B. Yonsei Med J 2001; 42:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/58\">",
"      Isler M, Akhan G, Bardak Y, Akkaya A. Dry cough and optic neuritis: two rare complications of interferon alpha treatment in chronic viral hepatitis. Am J Gastroenterol 2001; 96:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/59\">",
"      Noto H, Raskin P. Hepatitis C infection and diabetes. J Diabetes Complications 2006; 20:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/60\">",
"      Georgetson MJ, Yarze JC, Lalos AT, et al. Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol 1993; 88:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/61\">",
"      Simsek H, Savas C, Akkiz H, Telatar H. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatology 1996; 193:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/62\">",
"      Nagao Y, Sata M, Ide T, et al. Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C. Eur J Clin Invest 1996; 26:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/63\">",
"      Nawras A, Alsolaiman MM, Mehboob S, et al. Systemic sarcoidosis presenting as a granulomatous tattoo reaction secondary to interferon-alpha treatment for chronic hepatitis C and review of the literature. Dig Dis Sci 2002; 47:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/64\">",
"      Tahan V, Ozseker F, Guneylioglu D, et al. Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature. Dig Dis Sci 2003; 48:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/65\">",
"      Borghi-Scoazec G, Merle P, Scoazec JY, et al. Onset of dermatitis herpetiformis after treatment by interferon and ribavirin for chronic hepatitis C. J Hepatol 2004; 40:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/66\">",
"      Ramos-Casals M, Ma&ntilde;&aacute; J, Nardi N, et al. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) 2005; 84:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/67\">",
"      Daoud MS, Gibson LE, Daoud S, el-Azhary RA. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc 1995; 70:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/68\">",
"      Berk DR, Mallory SB, Keeffe EB, Ahmed A. Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. Clin Gastroenterol Hepatol 2007; 5:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/69\">",
"      Gurguta C, Kauer C, Bergholz U, et al. Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C. Am J Gastroenterol 2006; 101:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/70\">",
"      Farshidi D, Chiu MW. Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C. J Am Acad Dermatol 2010; 62:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/71\">",
"      Willems M, Munte K, Vrolijk JM, et al. Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection. Br J Dermatol 2003; 149:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/72\">",
"      Bachmeyer C, Pellen JC. Tongue hyperpigmentation during hepatitis C treatment. CMAJ 2012; 184:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/73\">",
"      Tosti A, Misciali C, Bardazzi F, et al. Telogen effluvium due to recombinant interferon alpha-2b. Dermatology 1992; 184:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/74\">",
"      Kernland KH, Hunziker T. Alopecia areata induced by interferon alpha? Dermatology 1999; 198:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/75\">",
"      Br&auml;u N, Bini EJ, Stancic S, et al. Severe migraine headaches are caused by ribavirin but not by interferon alpha-2B in combination therapy for chronic hepatitis C. J Hepatol 2003; 38:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/9/16538/abstract/76\">",
"      Formann E, Stauber R, Denk DM, et al. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol 2004; 99:873.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3651 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16538=[""].join("\n");
var outline_f16_9_16538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEMATOLOGIC SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Use of erythropoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Filgrastim",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FLU-LIKE SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NEUROPSYCHIATRIC SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Respiratory tract symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H246677798\">",
"      Nausea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ophthalmologic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Glucose metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Autoimmune disease exacerbation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dermatologic complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hair loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Migraine headaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Anemia and neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Flu-like symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Neuropsychiatric side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3651\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3651|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/44/3790\" title=\"figure 1\">",
"      Time course PEG side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3651|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/25/21916\" title=\"table 1A\">",
"      Pegintron Rebetol dose mod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/43/6844\" title=\"table 1B\">",
"      Pegasys Copegus dose mod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/12/13515\" title=\"table 2\">",
"      Skin manifestations PEG ribavir",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=related_link\">",
"      Clinical applications of thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=related_link\">",
"      Darbepoetin alfa for the management of anemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15412?source=related_link\">",
"      Erythropoietin: Subcutaneous administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=related_link\">",
"      Investigational therapies for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24551?source=related_link\">",
"      Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Recognition and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1674?source=related_link\">",
"      Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=related_link\">",
"      Painless thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2a: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/5/37974?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2b and ribavirin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36505?source=related_link\">",
"      Principles of interferon therapy in liver disease and the induction of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=related_link\">",
"      Pure red cell aplasia due to anti-erythropoietin antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=related_link\">",
"      Ribavirin: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_9_16539="Signs malnutrition HD patients";
var content_f16_9_16539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indices of malnutrition in hemodialysis patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Serum albumin concentration less than 4.0 g/dL (40",
"g/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuous decline in estimated dry weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein catabolic rate less than 0.8 g/kg per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Body weight less than 80 percent of ideal weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low serum creatinine and urea concentrations in",
"patients without residual renal function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marked reduction in anthropometric measurements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholesterol concentration less than 150 mg/dL (3.9",
"mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transferrin concentration less than 150 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin growth factor-1 concentration less than 300",
"      &micro;g/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low",
"predialysis serum potassium (and possibly phosphorous) concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low serum prealbumin concentration (less than 30 mg/dL)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16539=[""].join("\n");
var outline_f16_9_16539=null;
var title_f16_9_16540="Histological classification of panniculitis";
var content_f16_9_16540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of panniculitis based upon histology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Predominantly septal panniculitis, without vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema nodosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema nodosum migrans/subacute nodular migratory panniculitis/chronic erythema nodosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deep morphea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Necrobiosis lipoidica diabeticorum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid nodule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subcutaneous granuloma annulare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Predominantly septal panniculitis, with vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyarteritis nodosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Superficial migratory thrombophlebitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Predominantly lobular panniculitis, without vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infectious panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traumatic panniculitis (cold, injections, post-irradiation, blunt trauma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enzymatic destruction (pancreatic panniculitis, alpha-1 antitrypsin deficiency*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deposition (gout, calciphylaxis, hyperoxaluria)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipodermatosclerosis/sclerosing panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lupus panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Panniculitis of dermatomyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Connective tissue disease panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-steroid panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subcutaneous sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Predominantly lobular panniculitis with vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema induratum/nodular vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema nodosum leprosum",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Alpha-1 antitrypsin deficiency panniculitis has been variably described as predominantly septal and predominantly lobular.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16540=[""].join("\n");
var outline_f16_9_16540=null;
var title_f16_9_16541="PTHrp changes across gestation";
var content_f16_9_16541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Changes in serum concentrations of PTHrP in non-pregnant (NP) and pregnant women (P1: first trimester; P2: second trimester; P3: third trimester), at term and 6 weeks postpartum (PP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 238px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Points shown represent means &plusmn; SD. The shaded area represents the reference range obtained in non-pregnant women (n= 280).",
"    <div class=\"footnotes\">",
"     * Denotes statistical significance as described in the text.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ardawi MS, Nasrat HA, BA'Aqueel HS. Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum: a longitudinal study. Eur J Endocrinol 1997; 137:402. Copyright &copy; 1997 Society for the European Journal of Endocrinology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16541=[""].join("\n");
var outline_f16_9_16541=null;
var title_f16_9_16542="LH response to pulsatile GnRH";
var content_f16_9_16542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    LH response to pulsatile GnRH in GnRH deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 210px; height: 374px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effect of bolus injections of GnRH (25 ng/kg every two hours) in a GnRH-deficient man on chronic pulsatile GnRH therapy. There is a normal increase in the serum concentrations of luteinizing hormone and the free alpha subunit (FAS) of luteinizing hormone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Snyder PJ, Rudenstein RS, Gardner DF, et al, J Clin Endocrinol 1979; 48:864.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16542=[""].join("\n");
var outline_f16_9_16542=null;
var title_f16_9_16543="Insertion of circular stapler into colon";
var content_f16_9_16543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insertion of circular stapler into colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 413px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGdAWsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiijpQAUVUF7E7YiO73HSplkJ7UrlcrW5LRTQ3qKdTJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorIvNctLeQxoXnkHBEQBwfQnOPwzWe+v3hP7q0iUf7TFj/IVLmkbww9SWqR0xIAyeBXJ6hqcmo3RhtWItF4LD/lp7/T+dRanql5eWjW7RxxBzh3UnJX0xjik0qIKuF7dTWcp82iOmjh/ZpznubWnoEUDvWtGBtrn0mMbgNWxbzhlBBq4swrQe5bwKKYHFBkUdTVXOezH0U1WB6U6mIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiis7UtUt7BcSNvmIysS8sff6e9Ju244xcnaK1LV1cR2sLTTttRe9crqF7c6o5jBMNrn/AFanBYf7R/p0+tQahqFxqEiGZUjiTlUUk89Mk/8A1qu2cQCD6Vk5c2iPRpUFRXNPcit7RI1CquAOw4FWhAoFWFwgx3qMtk0WsDm5O5A0A7DiokJikyv4irmapysNxpMuLb0LkmJItw+oNMhnMaHJxg1QguW+ZQMjPAqaO2lmOT8q+p6UnNIOS2ki4dRIGAaltpZJjk8D1qssMEGN3zsemeBmr9sB1P4U4ycjKfKl7qLseVAqYP61CjVIp/KtkcbRKGBpahJweKkRgwpkNWHUUUUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopjuqIWcgKBkk8YrmtR1iW7LQ2RMcJ4MvRm+noPfr9KUpJGlKlKq7I09a1IWFsRGQ1y/yovXB9T7VzFrbtK7FmLuxyzMclqVbHYC6KgJ5Jxyfqe9WLV2tnzInynqR2rCT5nqenSpxpRag7sl+xqBjGTUYme3lCMPlrUjZHAZWBBqHUYkkgJPDLyDTatsRGpd2kAYMgYHrULTKrYzn2rPFyVTbnioTc9z1PQdz+FLmNVR11L8s/vUBYvyThfWoiHRd8w2k9EPUD1PpUSs87YjOAOp/wrNzbdkVFLoXEmhgIUD5j2HJNW/tMoTcsRx23HFVbO3WJskZPc1ohweCOKcafVmdRpPuUzm8YEHZKn8J6Yq9bTFDtbgjgiqlzEUcSR8MvIP8ASmzX0RRXPDDr/hWiViWudWWxvwsHGanDY61mWF1G8f3hVzzFYcMK0TOKcbOzJXkHalgf58etQGkV8NgdfWi4nHQ0qKzbnWtMsv8Aj91KygI7Szqp/Imsmfx54bhBxqSSkdoY3k/9BU1ZgdRRXES/EfSh/wAe9nqdwf8AYgCj/wAeYVa0Lxg2r3vkLpNzbp13zOufyGaLAdbRSKSRkjFLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFYvia5aGw8qMkSTt5YI/hGMk/l/Ok3ZXKhBzkorqZeq37ajcGOBs2qHGB/Ge5Pt6fn6VNbWoRQW6+lV9NgAUNjAHQfyrVjUH8KyWurPSm1BckQVOOnHpVG7QId2PlNadZupXCKpQjOactjOndyKRJibzEOB3AqC5u2YHLYFMa7AjZSCT0Bp9tahCHuVDN1WI9vdv8KxlKx2O0NZEMNtJcDezeVD/fYct/uj+tWgYLUZiUI2Pvvy5/z7USvJK3yHLHqx6D6UtvYknc/J6kmp5XLchty1m7Io3EjSsAuQp6lupq5aII4wAKnm+zRjbIyc9iefyrmfEHim00SN49++UDKk8AemfeqsoK7NIfvFyQR05YKPmYL9SBShxtyrBgO4Oa8ijtfFPi6UyQPJaWbHhiCWYew7V1Xh/wCHmq2pLNqd7lhhiZiP0GKuClLW1kc9apRp6KV35f5nV3t9HBCWuJ44l7F2ArjrrW7QOwWYykngRKX/AFA/rXVW3gG0Vg95IHfuXOT+dbNvoOkWmPkRiPbNa+zT3ZzrGOPwo4Sx1+7VdtppdzKexkIQfpn+VX0vfFN3/qLW2tlPcqzkfjkfyruBLYW4xHEnHrio5Nahj4XYv0xVKKRzzrTm7s5JNC8T3nN1q10qnqsREYH/AHyB/Opv+ECNx/yELua49pZmf+ZNbFx4jiXOZQPxrLuPFlumf3uaozuyza+BNItv4Ih9AK0YvDujw/8ALNDj2rk5/GUQzgk1Qm8ZE52Ami4j0RLLSofuwJx7AVLHNZQsDHEin1rymXxXcv8AdQ/rVSTxFet320Ae7xSLIgZTkGn15t4D8UNM/wBlu5Bu/hOa9HjcOoYdDSAdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWbquqRWCYI8yZh8sank+59B70N2KjFydkaVcj4luFm1KONGDLDGc4OcMx6f+O1BPPd324zyNsP/LNMhQP6/jVCVVt43fZhFUtgfTNYzndWR6GHw/s5c0nqa9nKAoHarf2uKM4aRAfTPP5VxZuJCiSI7kA/MNxwfXj0rVtvNaJWVgqMMjaAOKFpuOaUtjaudSVV/do5J7t8o/x/SsS7uGkJYsAO+Mn9f/rVbjtTMdsSF27n/E9qnSzitvmcrJMOc/wJ9Pf3qZSQ4NU99yjbw+Rtmm5lxuVW6KPU+/8AKo2uGmk2r90nnuTVq5Ik5U5UMGJ/vc8/hVu2tUjlLsODyBUxhfVlOdveluVI2kRgrLgHocf/AF6sNbSzIczOR6A4FWbhkKEjGV5qtI/lgsjfL3FaLQyvzGdqUcWm6fNcHBdRxn1rzHw1Yf8ACR64dSv8vAspWCM9ODyx/lXVfEjUmXw5OIT85yB9cECuS0XVf7Lihgtxu8qMLnvnHWpjHmnr0Na0/ZYe0d5fkj2+2vbbT7ZYoUjUAdaq3XiNEBzIAPrXlE+tX0/O/YD6nFZ0t8XbbLdbnP8ACpyfyroPJPTbzxbCmf3gJ9qxLvxkTkRjJrkYLW8uf+PewupB/eddg/NsVu6d4O1W7UNLLa2iHsMyMPwwB+tQ61NacxapzfQjn8TXsv3FwPWs+bVbuTO+bb7A122mfDu1kcG8vLy4A6hMRr+gz+tdXY+CPD9uozpcEpHebMp/8eJojVUthSg47niRuzLJsEzyOf4U5P5VftND1i9I+zaRfuD0LxmMfm2BXvtraW1ogS1t4oEHAEaBR+lWK0uSeJWvgHxHNgm0tbbP/PacZH/fIatW3+GWpvj7TqlrEO4jjaT+ZWvWKKQHnMXwutyP9I1a5Y/9M41X+eatwfDDRU/11xfzn/alVR/46oru6KAOYsPA3h+xlWWGzcyLyGeeQ8/99YrpI41jQIg2qOwp9FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGfq9+tha78bpWO1F9T/hXLwRvPI0szF3Y5JPepdama61eTnMcP7tB2zxk/nx+FWraHCgelYyfMz0qMFSp36sekI21V1O3zYzjHJjP8jWh0qC8kCQndyDxjufahpIFJtnJWts0qokQ3MR0/ma6XSYoLW0ZLsKxQ7huAPHoKh0m3GmwSNOB5vIbPYdhWddzPLc/MSEbjaPz5/Kk9SVebstkal1qzzDZbqIoh09T+FZ9zdOQqMdyDngY596gJVOc49qrSXAzg801T6sbnGOkTVt5gY8H+Ic1LJdNsQZ6A5/L/wCtWNDcPnCjNXbWN5pRjBJznPQD1NaWSMXJyYG9LHaATniqct7hFTeWYjgLya2vsKZ5kfHcLgA0s6xwwkIqIMcAAColJG0KbPPPG8EtzoNwsUbhlIkAbjIByRivOLMa/fN5tlZ+TCTgPKQM167rc4j2YUOxbaVPQj0NRWOnxFlZ0+Xsg4GK46td07tM9F0aXIvaK9jE8NeGTPHHNqxNww5KkkIT9M8j612Vnpltbf8AHnBFECOdqAD+VW7ZQNyIvUYGB2q7ZWUrMBJ8oFcE6sqr95nPLli7xSRHa2WTj7x/SugsNOJA38KO1T2NqiABRz61pooUYFd+Hopq/Q4K1Z7ISONY1woxT6KK9BKxyBRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqlf6jbWCbriTDYyEUZZvoKG7DUXJ2Rx0J3zGRuSzkn65NbET8D0rHtJFlmldUZI2dmUOADjJxxn3rRRtv0rnievNXL2QRmobSP7TfF2GYoenoW9fwqFpztxHyzYCj37VoS7NN0499q8nuxok9DBpx06sytVPm3zMn+qTAI7Fvesi9yroowrueMkdADk/rW1ZDMWJPmZsls9zUyWdsJA/koXHQsMkfT0qoOy1Ccbe6jnEsnkwcu+f+ealv1qxHpEhGfKRPeRsn8h/jXSU1hVubMlBdTGj08J/rJXOOoQBB/j+tTRLHECkYCjrU1y2xvrWZdS7VZuw6ms5SOunBM0GkAGSazL6cEHnp0FZsmpRoDl+apPPLeOEhBAY4z3P0FYzqJI66dCzuNEJ1DUo1XlYzkntmuqtrFPlDKAB0+lR6NpQtYSzYMh49cD0z/WtlIflA715dWbqyutjKvWTdl0Eit0UhlUDFXolBAOOaZbQl+D0FaEMPI9BW9Gg5a2OCpUSJbdAie5qaiivYjFRVkcTd3cKKKKoQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVDWL4WNm0gAMh+VFPdu34Um7DjFydkVNb1Y2h8i2Aa4IySeiD1Pr9K56K3aRmklYs7cszclqdaRtI7SSsWcnLMerH1rViQAcisW3JnqRjGgrLczGhdVAXt0NCzFfllUg+orUkRdpqkkBurgQoMAcs/90f40mrFxqJrUk0tRcagpXlYhuJ9+wpfEMpkeOFTkFxn+f8ASrd3cx2MIihHz4wAOtZDRNMwaYuW68HjNRqyIe9LnexYtwUXBqyrZqsilRxz7UokwcHhvStEOSuXQxxzQzACqvn8cdahluCPvcU7kKm2yPUJgHGenesu+mUWzgHJIpl7cGWQgHiqk43RkevFYykd9OlypFS1sRdyFz8ihipIXk+4JrpdOtYbaLbFGNxGGc5Jb8abpsJW2RcDkbsH3Of61qW1uGGNpU14cpznJq+hFWr0HwA96uLGcCkhtSCK0I4sAZrsw9GT3OCpUXQbaIF+93q+BgcVCqgjpUw6V6tGPKrHFN3dwooorcgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5bxVIXvreL+GNC2Pcnj9Afzrqa5HxED/AG0+e8aEfTJqKmx1YRXqDrKMeWPzq5t44qlbMdgHQ1cR88GoR01LtkV1II4S3U9AB1J6AVNCo07Ty8vMrctju3oP5VFEgub9V/hiG8n37f1NGov5t7HEPuxDcR79qiWrJte0fmyl5bySlm5Y8sfT2FWkgwualSMdfXrUoFUkVKZUK4NMkAYYYfQ9x9KtSqOtQOOKBpmdcOyNtz9D6/Ws+6uiQUJ6dauar+7UNn8KypQHIfrkVnI7aKTVxigk5/KkYeZPHCv3iRn2/wAjmorm6WBcKN0h6CrXh6Frifz2OQB8vue5+nauetUUIs2m7LmOgijJXKjgcAVr6ajNwyn69qqwRHhR0FbNsAqAVyYSkpTuzya89NCUKAOKUKTTh7U4DFewo9jhbFUYpaKK1SsQFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqt/dxWNs085wo4wOSx9B70DSbdkSXE8dvEZJ3VEHVmOBXnvirUNQvtb06bQ47d7NT5d2bgFG254ZPcc8EDrVm7ln1S4824bCg/Ig6KPT3PvVqC1KphRhawlJy0Wx6VGgqXvSepSj1vTzqTaeblI7xcYjkypfIBG0n734VqGYqKo3GnI8kcjQxSNE26MuoJQ+oPY1jWVnq9tqFwsV3LfWkgdhbSqDIjdgr5HHbngVLdjeyep3OmqIdP85/vS5c/TsKx4ZzLczSHqzkD6Dgfyptt4ltL62ktvJubO5twolguYyhQHpg9COOx5qvYTRCMbshsnJIx3pX1MqUG1KTW5tI/FSKwNU0cEZU5FSqwP1rRMlxJzg1DJgA0jTBRjNVLi5VFLE8ChsIwbM7W2AjC5rmprjbgBwrkkDL4H8verWtX5ckjp2qnozPJdqdhcqpJAGTgkf4Vw4qq4QcluepSjyR1LVlbxCUNdr5zsu4RAgfmO4/Sum02BZZPN8nyz0yMDiqS2FpdTIv2EM2cgvGBiuisbSC1wkcEYkxnAA4HrXk03KrO8mc2Iqq2l7l6CJEUY5PpmrtupB6cVBEv/16txmvZoRV9DyKjuTYFFFFegjAKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXF63dHUdTKI2YICVUdi3Qn+n/666TXLo2elXEqHD7dqH/aJwK5TTIBs4HHSsqj6HbhIJXqMu2EALDI4FaexcYxUMKFMEDirGRSSLqSbZBLGByOlJpoWKOaeRtsYYkk9MAY/pRdSgJheWPAHqfSs7W7jZHDYRnjAMhHf2/rUTKjFzXL3M3W4I/EaTQXkZNm3ATJBPPBz696y303U9F0pU0oPqZSUsUu5cP5ePuq2Ov1rrLCAbQSOB0FX2RSMYpqJo6vL7q2OPtdUQfZVn/0S6nTcttMQH64IxnmtVLjcBng03xDoun6pBtv7WOXb91iMMnurdR+Fc1fLq9pqkb2slvcaa5VGgkG1oh0LK3f1wal6G0bVEdUzDaTWFqt0RkBvlrHk8RQPdyWVrcYnRipikBVuO4B6jvkVDM08zfvDtz/AHjiolPQ6KVO2pFcOZ5cfwjqfaui8PWjxwm4CgFvXjAxxWRp1mZJAuwvzyO7H39BXYWkTALGPmI6t2B9B614+MrqfuRKrTsrFu1V4xvALyHoBwPx9BWraQlF+Y5Y8sfU1WhUIUUdWPP5VpRDiqw0Dyas7kqjAqWM4PNQBsnCc+p7VPEgByeT6169JHJInooorsMgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA57xkxFnbKOhmBP0Ck1Q0wARqDV7xkP9GtD280j/AMdP+FZUDlEGPSsJ/EenQjeikbwxikkA2mqUF0QAG5FSTXA8st2Ap3I5GnYSBPMutx+5GCxPvXOiQ3d+8vXe5I+mcD9K3dTkNloFw68SyDaPqeP61g6UoDIffisb3Z1UV7rn8joojsUD0FTeaKrqwx1pC4FbXMHG7INSlG3ArDvpP3Rx17VfvpdzYrHvmrKTudtCNkjntWijmgkYxqZ1UlZCBle+Ae1aWjQTzJGUgiZiAWKscDjvxWbfsdsijnPyge/Suw0OC5is441iQgAZYMR+mP615OOSlJJnVUnyQJ7O0YEqSgJ6hByfxrXijESgAfQCq8KyIBkBWJwoBySfr2FaEMewcncx6muSMO55dWd9xqJI0ikALt9eT+VXkjJH7xsj0HAqFGAPvVqM5HNd+HSWhyzkSIAMAcAVLHy1RDJ4FPDAMI15J5PsK9Kmc7LFFA6UV1mYUUUUAFFFFABRRRQAUUUUgCiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFV724W1tZZ5MlY1LEDqaBpNuyMnxa8X9mhHcCberIvUnnnA+hNYIcADjtUayvczPcXJ3TOc+wHYD2q0qgryK55Pmdz16VP2UeVjEkHY1cs1NzOkf8ACPmY+3aqUsK7SQSCPStDw6xJlUnIXqe9Q3YdV2g2hni45tbeJRwJASPwNZVrtiCnvjpVjxFcma8EA+6uGPuewpI7ISRqWXBI60o6u5dL3KSUiUXS496ilu8ggVDNYEcxyEexqIq0CYnXevqtVdlRjB6oV2DDJNYmqXQTODz2q/dXNukRw5+nOa5HV9S2XMaJHtaQHyy/3fcn86ynNQV29DrpQcnoi7awm8vooBkYG9iOo9P8a7uzsTFGkbXl1JgDIZwB+gFcZoEU8Lf6rzQX3PKGw7n1x/Su28yUW7skDJhc5cgdvYmvFq1XUm5LYxxTd+VFrT0DF5QWIJKpuYnjuRzV7OKq6fGYrSFD1VAD9cVbjUu1OOp5k3qwReatxD1qIELwOtJLPsVQo3SOcKP6n2rqpe6zKWpZaTHyIMsfyHuaW3ADMevOM9yaqs4t4Ou6RiAD/eY8VZi+VFXOcDk13QqIzcbLQuKaWq6Pg1MrBhwc12QmpIxasOooorQQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXO+MpyLOC3U/66TLfRef57a6KuS8Vtv1W1j7JGWx9T/8AY1FR+6dGFjeqijBBwCauJCxXgcU63UEj0rVjUBRiskjuqVbMxJIiAQan0E7Irtu4wP0q7dxgoTjms/TARbX2Pb+RqJqwc/PTfy/MybQfabwu/Jd8n866lIUCgYrlbJvLcMOzZro1voggLMB9TVU7WLxUZXViO7hCnIrG1DIcAAla07i+iY4DA1TuZUeM4GSKJWHR5o2ujn76EuD0Fcnq9q8gJ6+SwkB746EY+hrs5gWJJFc/eD/TVXHDZU/TFctWHPFx7nrUpWRp+GrxbmJEt4nmccOY1JGfduma7FFnki2MiICCDk5OK5TwbM8FiyqcfNtP4Cu0gkURq0jAZ/U+1eNRjeCPMxjtN2RNDzHkdKnRsJwMD1qKJXyWUbVPOG6/X2qaMb13NwOwrphGx58hqsScKM/5709Ygshkb5nIxn0HpTwQvA4FV5pjI3kwnB/iYfwj/GtFZIWr2EX99clyfkiyqj1Pc/0qzvwMk4A6ms23klQNHCI3ii4DMSPz4/WmwpLdgyXJzAfuouQCPU+v41PPYtw77FpLk3b4iyIB1fpu9h7e9adrKCWUdFIX9B/jWeDjOOAOAKjtZxEJmkO0GTgnjsK2o4nllqZyhzLQ3gc0VSjmZv8AVpIw9cYH61Zi3YO+vXhPmRzONiSiiitCQooooAKKKKACiiigAozRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyPiQH+3Yz2MK/wDoTV11ct4uQpfWU38LBoyffII/TdUVPhOnCP8AeW9RIOlX4WJSs+3YEVchcAYqEdNREkvKMD3FZmi4W4urdjncMj6VoysNpFZUJ8vWo8fxgg/kf8KmoOmrxkjGvoZbS68mP7rH5T7Z4q3bWbn5Wyzdyas6yuJYpMcK+Pwzmr1kyZ5xuNZ01c6pVnyJlMaYSc8U82oVSCK2SQBnoKo3Dq2SpBHtWrikc6rSk7M5+9g8tSw6Vzl3AXvY2HqT+ldLqMu47OwrCusjDDqpzWEtz1KLbWpQ0y7uLS6NrAiOXYsXc4C8mvQNEUGPe7eZJjlzx+AHYV58ky6fqjzMu+ORNwGCT68DHWuk0y4u7s7nD2tscYT+Nx7nsPYc14qtCUovo2Z4unzK60Oz80OGSMbmxgkdB9TStN5SqGQk9AFwcn25qnNcLp9kgCbpDwka9Scf55q1aROQHkO6Q9T6ew9q3T6HkOKSv0Gs0swIQGIHjJwT+AqvqEy6bZ+XGPmbOCTkk+pq7dTrAgxyRwAOrH0rmdcMjXUSyMGmbkgdEHQD9TUzaimzSjDnlrsXwC1hDBu2+e4T3x1P8iPxrUuXWJI4wQBkZHoK5291DYYEgXeUjOSMfK2QB3+tV7lr/UGVnkjhAAGI1JP1yT/SohTq1I2gvmbui5Wbdkb0upWiRFjcRA54BYA59Kn0bySv2y6kiDSH93uIAA6ZH5Vyi6OnWUSSk9S7cH8Bx+lWotOSJQkcKIvQBVAH8q7sNhp0589SzFOhFxspHdx3EMhxHNGx/wBlganrz9tPQ8NEh+oBp0a3Ftzb3NxCB0COdo/4CeP0r01UfVHM8EvsyO+orjo9a1KJAN8E+O8iFSfxU4/SpH8TX0cDM1haFgMgC6bB/wDIdP2kTF4Sr0/M6vcN23I3Yzj2p1eGeOL/AFSWHTL/AE64lstQnJu53gkKuIiTiPPG4DCjBGCccV7NpV9BqWnwXdpJ5sMqhlbGM/h2q+ZXsYunJR5mtC7RRRTICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKx/E9qbnSJSilpYcSoAMkkdR+WRWxRSaurFQk4SUl0PPtO1GN1XDA+hrZSVCu7cAPWub8UaW+j6j50K/6FO3yY/gY9V+ncfl2qWxt5bhVedzs7KOlcybi+VnuOnCpBVIvRmzLfQpwG3H0Xms/7UDqEUhyoB4J4HTvV6OFIxhVApLqGKWImXjaODTknJGceWOgXe24ikUfeIyAex6j9a8+j8XEXEsNwpS4hYoQucZBxXUW10iztCHyq9P/AK1cBqVuLHxBqt211FE1wxZBJgYO3r7cjrXDOc6clZnfhKEZc0ZfI7G38US3dmwV4SyjDAkg/wA6zD4uMJb90QVPKhutcbZ24tbWKG0KNdXEhM0rPkE9d3qB3ya3tM0ZdU0+4kjubZ7i1crMm4gKv/PQHuvfpWkKk5I6KuGo0teheuNeid/NVjkjO00kWoGZcsCVPcDpXMl4Rq7DzY2tY0AVgchznGQe4q/oy3V1fSvwlurYHXJ57Uvaa27g4KC0NO7mR4YygffESAQO3Wr9rrMklugWKQbSCXVSf0xW7FZARh0VAxHUAZqL+zJuSvGefSsquCVSXPezOaVaEtGiHSfEMct3dXOqymJ9wSFZAVCxjGSMjqTz+VddeakkFgZYSJWOAoVh8xPbP6/SuRksZcESDK9w3INVltzazQyWxKLG+4wZ+Qn1Hof0qamFlFXgznnRp1Gmv+AdXezDS9La9uzvnP3R23HgAfyrnIFuJnZ5m3zOctzwv1Pf+VO8VarDqd3pdvC2BGWmkTurAAAH/vo1atiFjUA9smtMPQja7CnFwhzSWrLljaKiAsNzDp6D6VpW8IY8jp2qrZuGXBrRiUjkV6CSOWpJ31JkiRRzgAUx2jGQMZ7GoJ3+YgnkVUaRQeXp3sZxhctuVJAqVoojHywHpWaJUPR6TzQTjdmlcvkfc0IrCKX+MVi67Ci2dxHuK+YBECOuWIUfzrVspRzntWTeutxrenW7H5RIbmT2VRgA/wDfWfwppJtETnKCk2zg/iNdFdQlgiOBHstQB24BcD3GzP417H4OsG0zwvptpIu2RIQzr6M3zMPzJrxOOM6v4v0lZfmN1ePcuD/daQL/AOgivoelS96cpBjP3dGnS+YUUUVueaFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc545kVNAlhYAm5kSEZ7ZOSfrgEj3rFtJgsCgDkVofELP2PTD2+2DP/AH7ese3P7sVzVH7x7OEgvYL1NGGRpMk8KKGt3uVIlO1DwFB/nTbPLHZ2zV3VVMFrFIh5B5HrQtVdjk+WXKjk5TbWGrrHdxt5eDgr16da5fxDaJe6XeQ3MMkhlIKSLJgIoOeV7nAq74w1SR7q1XyQ7Kdu5euCcc0gV2UR8SMwOWPRRjODXLJxm2ux6dOMqaUnu/0OFl0uGC+LRiQsECoXJBx6D1rrNLtphbSMg8pShDsrEMQeCrD0470zS0e1vluLyH7S6bsIoAxnpkHtXVaVdXN2kjm0SNcgBHOVYc5B9etZuTWyf3F1ptLY810PSLW/1m9aWSQ28DAIg4GPb24rv9G0wTzrHCNiKAAB0ArppvD9mLXzLG3ii3DdIsYHXufep9CtUtmYYwxHBralBdTkrYz2kW0XrWySGML1IHU0k0YVuO9XGIAqv99s112PMUm3co3KfJyKxbi3O4kV1DoCORms27t9xwo5qJROilUtocnfWazOsg+S5QYWQDkj0PqKjsNQYSm3uV2TL1HY+4PcVu3lq6xliOlYOpWpuYg8WBcR8oemfUH2rFprY74OM1Zm7a3ZjOc1oprKIhBGW7VxlpdGSAMxIYcEHr+NSPeBeRyapTsRLDRk9TZuNRkeVmJwD2qq94SfvVkNcO5y7hE9TwK0NJ0681WFpbG2uJIlON5AQE+g3EZqee7t1LcIU1eWiJRckng1Il0VbJPB602TRtUg5ksroY/ux7//AEEmqc6TwrmZGjGcDzFMZz9GAp3a3EnTls0blneEvtByGqCGUTXWuXu7CwW/2dD2zggn/vpyPwrIS5e1PmyHaigsSemO9OuHe2+G9xMBtuL6TOG65bLn/wAeNbUXuzzswjbliupk+BkN18TLCPbhLa3TA9P3ZP8AMV75Xivwkg8/x9rNxj5IUKqfyA/RjXtVPDr3bmOZv98l2SCiiitzzgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDnfHFsZ/Ds0ijL2zrcY9lOW/wDHd1cvaMDCjA5BGQa9HkVZEZHAZWGCD3Feam2/su5nsJW4gbMZJ5aM/dJ/l9RXPWVnzHq5fUvB0+q1NO0mEbfNwPWnX1693tRBiNOnqT61SjOEDHkt0HtVvT4wW3HpUK+x1yjFPne6M5NFNxcrMypgdCa1f7JgIG7JPfGADWgBgU2RgiEmqUUjCVac+pSns7WOPaIgPYcc1VVAowowPQVO7GV/r0FatppqFA0nJPaizkDmqa94y7ad4H3L07j1rQQR3HzwcMOqdPyqa7sI0TKistleBwyHBFTKDWqJ5o1dY7l4sTwScjqDwRT4iMfSmQTx3ceJB+8X06j6GoZneFCw+ZR1PcfUU4z6MizbsW3cAVEoz8x79KoRXaz98c9KtiUAVaaYODjoyO9A8iQnpg1xpbDke/BrotWusoUU8Y5rl3YmTHrWNR6no4SDUW2Vb1IodQAllSJJ13DOeT0IA/I/jT4baSdS1lbSOq5zLKCAB6hep/HFWLlQ9/YbxwUfP0yv+FdjbwCO1jtoAPMkHzH09fw5rgr1pqbpw08x1a7p2OR0XQZNS1WOEvvVcNLJ/dHBwOOPw9q9dtbeK2t0hgQJEg2qo6AVn6DYRWcBaJcb+AT1I9fxOTWtXZl+F9lFzm7yl1PFxmJdaVuiCmsodSrAFTwQec06ivQOM87+Jeh6bb+H5p4IjbXE8iW4EB2K+9gGyvT7u45xnjrXO/EO5gsNI8P2Ux2iWRDgD7zFgwHt8sbV0vxIlN3r2g6WvKhnunHvwifo0n5Vw3xPA1X4g6BoqsCQj4TPIOwRqfznP5UuRWdupoqsrpt3t3PQvhhoEuk2N1e3K7Jb4q6ocZVMEjPuSxz+FdxSKoVQAMADGKWlGKirIKtWVWbnLdhRRRVGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxvxHsY5dMivVJSeGaJCy/xI0gBU+3P+c12VY/iq1N54fvYkG6QIJFHqyEOB+a1M1eLRvhp8laMvM43zR5hX04xWxaLtjBrBhAeYupyrYYH2rdt2+QVzRPar6JIubhjJqncyFzgdBVk8p9KpspDYqmzmgluWdMg3y7mHAreXAFZ+nKFT3NXHbaua0itDlrPmkQXsoPyj8apPGHXFSOdzk+tOUHFJ6lxXKtDHnje3l3xkgj0q0ky3MJK4DgfMvr70+/UbM1kK7wy+Yv3c8isZo6or2iv1ILoG1lLR/dPIFMbU5Nu3ofWtG7VJ496/dbt6GueuYZUdvlLAHGQKi7Oqkoz+LcS5uC+ST9aq2yGacAdOp+lL5Er5LLsReSz8ACpbRjcRtHpnzAHa9yw+UHuF9T+lZymormlsdUmoRsi1Ywrd6s8h+aO3QIAOec5P9K7SytygijIy8rAOfQdcVmeHtKW0ijTnJJdieST6k+vSujtADeqP7qEn8+P61zU4urUUn1Z4uKrXdl0NMAAYHApaKK9w8oKKKKAPO7tBf8AxQuHB3fZYYoCOwIBf/2rXIR6fH4i+MukyMCfsNxLfb0OCFRSuM+hZ48jvipfClwb34heJtbLuYbeOXbhjgnI2EjP9wqPwrU+D1r9p8Sa7qbDKxRx2sbe7MXcfkIqYHrVFFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPNru3NjqVxaEYEbZT0KHpj+X1FWrWfBwTXQeJ9MN5ALm3XNzADwOrr3X69x/9euPVj94VyyXKz3aFRYiF3v1OgRsineWWIPas61myBzWlC4xg007kTi47F2L5VGKWaQkYqFWI6UE5qzmtrcci5OTUtNQjFJI4UUA9WVL8gjFZbL8pyPrV65bP41VmwsRPtWcjrpaKxQjmKPsOduayNV1GdtQe3s3CKgHmPjJzjOBVx5S06BP7wrH3RprF8GZB+8DckegrJndCCvdouQWD3OHuPNnxzl24/Lp+latnmCVVVcDupAH5VBZajGnyZRh/skGtNWinXsfbvUToQqrXcxqSlezWh0FpIhKuDwVIx79f6Vd03m7nJ67QR+v+FcpFM9vKodiYjxnuK6TSpQ10rd5I8HHqOf8AGpguSrFM8uvTcUzaooor1Dzwqjrd2bDSL27GN0ELyAHuQpIFXq5D4n3Rj8NfYogxn1CZLZNvUZOSfphTQB5n4OhOn+C9avM/PdyRwgHqBgyD/wAddB+FehfB6xFr4Sa4Iw97dSzsPoREv/jsan8a4PWWGlaNNpd0PJu0uJLiSLIP7vhUYEcH5FXjqMgHHFexeGbRrHw7pdrIgSSG2jR1HZgoz+uabEjTooopDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4XxRCINf3BQEuIQ3AxllJBP1wVruq57xjZtPp63EQzJbNvIHUoR8w/kfwqKivE6cJU5Kqv10OWQlGyOlaNvMCAM1kxvn3HY1MpK8qa5ke1KPNubsc3Y/nUocHvWNHdEcMKmF0PXFXzHPKjqaZkA6VE7+pql9pHrTWnzRzCVKxLIwzk1majcfuyoPWnzzgA85rIuJGkf+QrOTOulT1uwgYK7SOcJGCxNeieGtOWx02PfEq3EmZJWwM5Y5wfpnH4Vxvh+w+3anDbHmKPE059gflX8T+gNel1tRj1ODM612qaKd7p9peoVureKQHuy8j8a5+88NyQEvp8rOOvlueQPQH/H866yitXFS3PPp150/hehwAYtuSQFXBwQRgg+hFXtKn8i6ijc9GBU+q5/+vWn4msPNga7gX99GMsB/Ev+I61zBlJCP12ncMdxjkflXHiKba03WqPSpyVeB6LRVXT5fPs4ZCckqMn1NWq7ISU4qS6nkNWdmFcn4h23ninTYJMeTZRPdyk9Mk4X/wBBeusrz3XL3yrLXtSxuaeU2sQHdVGCB9drfnVCOMsY38Q+PZriX54mlSEqfR2V2H4Iiivda8i+E9mxvYZpOZCZbhz2zjH/ALUr12gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoIBGDRRQBwWvaWdNuy0KkWkhyhHRD3U+g9Py7VmhiK9KuIY54XimQPGwwVPQiuK1nQ57ItLAplthzkcsg9x3+tc86dtUevhcWprknv8AmZZl9qTzwvJ4A65qpcuFiz1JwAB3NZ03mPbMHXIUgKBnkYycj8KxbPSjFM6BbuLA55PT/GmyXK7c7sjtisVo3dCm05J5PTPTge3NP+ztIMTNlOPkXpRdi9nEsSXSyybEOTwcDnjn/CpIond0jijMk7nCIOpP9B79ql0vTZ7yQx2MOcH5nPCKfc/0HNd3omjQaXEWH7y5cfPKw5PsB2HtVwpuRz4nFwoKy1fYXw9pSaVZbCQ9xId00g/ib/AdBWvRRXUkkrI8GUnNuUt2FFFFMkCM8HpXn+p2p0/UJIWG2MktF2BX0/DpXoFQXNvDcx7LiJJU9HAIqJx5jfD1/Yyv0KHhoMNGg3dDkr9M1rUxEWNQqABQAAB0Ap9OEeWKiZTlzycu5V1OdrbT7iZBl0jJUerY4/WuG1+1EekNZ5ytnYvKfeVxtTPvzmu11RPOEEP8LSBm+i8/zxXN63EW0O+nYfNeXCKP91DkD/x01RJF8N7URR3EmPlVFRfzO7+S129c/wCDIfJ0p+MZkz/46v8AXNdBQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGLqPh+xvSWMZhlJyWjwMn3GMfjjNY1x4PlDE214hB7OhB/MH+ldnRUOnF9Dop4qrT0Ujhl8IXpOHurdV9QGJ/pWlaeErWMhruaSfHVR8in+v6109FJUooqWNrS0uRQQxW8KxwRrHGvAVRgCpaKK0OXcKKKKACiiigAooooAKKKKAKlwNxlYddvlr9TVDXrdWsreBeitwPoP/AK9avl8r6Alj7miaBJipft0oAr6PEIdPiUdCS35kn+tXaaihEVV6AACnUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_9_16543=[""].join("\n");
var outline_f16_9_16543=null;
